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Abstract 
 
 
Introduction – Due to spatial separation from the native vascular bed, solid tumours 
develop regions with limited access to nutrients essential for growth and survival. The 
promotion of a process known as macroautophagy may facilitate in the maintenance of 
intracellular amino acid levels, through breakdown of cytoplasmic proteins, so that they 
remain available for macromolecular biosynthesis and ATP production. Several studies point 
to the potential ability of some cancers to temporarily increase autophagy and thereby prolong 
cell survival during metabolic stress. The validity of these claims is assessed when a 
commonly used breast cancer cell line and an epithelial breast cell line are starved of amino 
acids in this study. Furthermore, we go on to hypothesize that acute amino acid deprivation 
during treatment will result in an elevated sensitivity of MDAMB231 cells to doxorubicin 
toxicity but limit its cytotoxic side-effects in MCF12A cells. 
 
Methods and study design- Human breast cancer cells (MDAMB231) and breast 
epithelial cells (MCF12A) cultured in complete growth medium were compared to those 
incubated in medium containing no amino acids. Steady state autophagy levels were 
monitored using classical protein markers of autophagy (LC3-II and beclin-1) and the acidic 
compartmentalization in cells (Lysotracker™ red dye) in conjunction with autophagy 
inhibition (bafilomycin A1 and ATG5 siRNA). Cell viability was monitored using several 
techniques, including caspase 3/7 activity. ATP levels were assessed using a bioluminescent 
assay, while mass spectrometry based proteomics was used to quantify cellular amino acid 
levels. Similar techniques were used to monitor autophagy during doxorubicin treatment, 
while cellular doxorubicin localization was monitored using immunofluorescence 
microscopy. Finally, a completely novel GFP-LC3 mouse tumour model was designed to 
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assess autophagy and caspase activity within tumours in vivo, during protein limitation and 
doxorubicin treatment. 
  
Results - Amino acid deprivation resulted in a transient increase in autophagy at 
approximately 6 hours of amino acid starvation in MDAMB231 cells. The amino acid content 
was preserved within these cells in an autophagy-dependent manner, a phenomenon that 
correlated with the maintenance of ATP levels. Inhibition of autophagy during these 
conditions resulted in decreased amino acid and ATP levels and increased signs of cell death.  
MCF12A cells displayed a greater tolerance to amino acid starvation during 24 hours of 
amino acid starvation. Evidence indicated that autophagy was important for the maintenance 
of amino acid and ATP levels in these cells and helped prevent starvation-induced cell death. 
Furthermore, data showed that concomitant amino acid withdrawal resulted in decreased 
cellular acidity in MDAMB231 cells, and increased acidity in MCF12A cells, during 
doxorubicin treatment. These changes correlated with evidence of increased cell death in 
MDAMB231 cells, but a relative protection in MCF12A cells. A novel model was used to 
apply these techniques in vivo, and although mice fed on a low protein diet during high dose 
doxorubicin treatment had increased mean survival and smaller tumour sizes, evidence 
suggested that autophagy is protecting a population of cells within these tumours. 
 
Conclusions - This novel approach to tumour sensitization could have several 
implications in the context of cancer therapy, and given the delicate relationship that 
autophagy has with the cancer microenvironment, efforts to determine the mechanisms 
involved in autophagy and sensitization could lead to new and innovative treatment 
opportunities for cancer management. 
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Opsomming 
Inleiding – As gevolg van hul skeiding van die oorpronklike vaskulêre netwerk, ontwikkel 
soliede gewasse areas met beperkte toegang tot noodsaaklike voedingstowwe. Die 
bevordering van „n proses wat as makro-autofagie bekend staan, kan die handhawing van 
intrasellulêre aminosuur vlakke fasiliteer. Voorafgenoemde proses word waarskynlik deur die 
afbreek van sitoplasmiese proteïene teweegebring om sodoende vir makro-molekulêre 
biosintese en ATP produksie beskikbaar te kan wees. Verskeie studies dui daarop dat 
sommige kankersoorte die vermoë het om autofagie tydelik te verhoog, en daarby sel 
oorlewing gedurende metaboliese stress te verleng. Die geldigheid van hierdie eise word 
evalueer wanneer „n algemeen beskikbare borskanker sellyn, en „n borsepiteelsellyn in hierdie 
studie van aminosure verhonger word. Verder, veronderstel ons dat akute aminosuur 
ontneming gedurende behandeling „n verhoogde sensitiwiteit van MDAMB231 selle tot 
doxorubicin toksisiteit tot gevolg sal hê, maar terselfdetyd die middel se sitotoksiese newe-
effekte in MCF12A selle sal beperk. 
 
Metodes en studie ontwerp – Menslike borskanker- (MDAMB231) en bors epiteel 
selle (MCF12A) wat in volledige groeimedium gekweek is, is vergelyk met selle wat in 
aminosuur vrye medium gekweek is.  Basislyn autofagie-vlakke is gemonitor deur die gebruik 
van klassieke autofagie proteïen merkers (LC3-II en beclin-1) en die asidiese 
kompartementalisering in selle (Lysotracker™ rooi kleurstof) saam met autofagie inhibisie 
(bafilomycin A1 and ATG5 siRNA). Sellewensvatbaarheid is deur die gebruik van verskeie 
tegnieke, insluitend caspase 3/7 aktiwiteit,  gemonitor.  ATP-vlakke is deur die gebruik van „n 
bioluminiserende tegniek gemeet, terwyl massa-spektrometrie-gebaseerde “proteomics” 
gebruik is om sel aminosuur vlakke te kwantifiseer. Soortgelyke tegnieke is gebruik om 
autofagie gedurende doxorubicin behandeling waar te neem, terwyl sellulêre doxorubicin 
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lokalisasie deur die gebruik van immunofluoresensie mikroskopie gemonitor is. Ten slotte, is 
„n unieke GFP-LC3 muismodel in hierdie studie ontwikkel. Hierdie model is gebruik om 
autofagie en caspase aktiwiteit in gewasse in vivo te bestudeer tydens proteïen beperking en 
doxorubicin behandeling. 
 
Resultate – Aminosuur ontneming het tot „n tydelike verhoging in autofagie na ongeveer 6 
ure van aminosuur verhongering in MDAMB231 selle gelei. Die aminosuur inhoud van 
hierdie selle het op „n autofagie-afhanklike manier behoue gebly. Hierdie verskynsel het met 
die handhawing van ATP-vlakke gekorreleer.  Autofagie inhibisie gedurende hierdie 
kondisies het „n verlaging in aminosuur en ATP-vlakke teweeggebring, sowel as 
vermeerderde tekens van seldood tot gevolg gehad. MCF12A selle het „n groter toleransie tot 
aminosuur verhongering tydens die 24 uur aminosuur verhongeringsperiode getoon. Getuienis 
het aangedui dat autofagie belangrik vir die handhawing van aminosuur en ATP-vlakke in 
hierdie selle was, en gehelp het om verhongerings-geïnduseerde seldood te voorkom. Verder 
het data gewys dat aminosuur ontrekking tot verminderde sellulêre asiditeit in MDAMB231 
selle, en verhoogde asiditeit in MCF12A selle gedurende doxorubicin behandeling gelei het. 
Hierdie veranderinge stem ooreen met getuienis van toenemende seldood in MDAMB231 
selle, maar „n relatiewe beskerming in MCF12A selle. „n Unieke model was gebruik om 
hierdie tegnieke in vivo toe te pas. Alhoewel verhoogde oorlewing en kleiner gewasse in 
muise op „n lae proteïen dieet gedurende hoë dosis doxorubicin behandeling opgemerk is, het 
bewyse voorgestel dat autofagie „n populasie selle binne die gewasse beskerm. 
 
Gevolgtrekkings – Hierdie unieke benadering tot tumor sensitisering kan verskeie 
implikasies in die konteks van kanker behandeling hê. Gegewe die delikate verhouding van 
autofagie met die kanker mikro-omgewing, kan pogings om die meganismes betrokke in 
autofagie en sensitisering te bepaal, tot nuwe en innoverende behandelings vir kanker lei. 
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Preamble  
 
 
It seems a strange concept to me to have to justify my choice of research topic with statistics. 
Almost everyone of a certain age will be confronted with the spectre of cancer in one of its 
nefarious guises at some point, either indirectly or, less happily, personally. For women, this 
will most likely take its form as a breast cancer. Despite many well-intentioned efforts, the 
number of breast cancer sufferers worldwide appears to be increasing, and breast cancer is 
now the most prevalent form of cancer in woman today. Cancer is an inevitable corollary to 
the medical advances that now permit human life-spans to surpass their evolutionarily 
programmed limits. Women in the United States have a 1 in 8 chance of developing breast 
cancer at some point in their lifetime, and 1.3 million diagnosed cases of this form of cancer 
were reported worldwide in 2010 (Breastcancer.org, September 2010). In South Africa, breast 
cancer has also now taken the lead in the race to be the most prevalent cancer variety, and 
population forecasts estimate that the incidence of breast cancer in the South African 
population will have increased by 15.8% in 2015 (UN, World Population prospects, 2008). 
These statistics are alarming and finding practical solutions to improve breast cancer 
treatment is imperative. 
 
The studies contained within this thesis are presented in separate chapters, each a product, and 
contingent on the findings, of the last. Therefore, the layout of this manuscript more or less 
follows the sequence in which the experimental work (and hence these studies) were 
performed.  
 
The concept for the first chapter presented here was conceived in the tradition of hypothesis-
driven research, which is to say essentially at random, in conjunction with a pragmatic 
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awareness of the limitations of our laboratory and the resources at our disposal. This initial 
work characterizes the impact of complete amino acid starvation on a commonly used human 
breast cancer cell line in comparison to a non-tumourogenic human breast epithelial cell line. 
Based on the findings from this study, a second study (presented in chapter 2) was undertaken 
to determine the role of a proteolytic process known as autophagy during these conditions. As 
increased autophagy is often described (but never directly shown) to preserve amino acid and 
ATP levels in cancer cells during circumstances of nutrient depletion, a third study (presented 
in chapter 3) was performed in an attempt to directly demonstrate these phenomena in the 
context of amino acid deprivation, and thereby pose a mechanism for the autophagy-
dependent protection that was revealed in the previous two studies.    
 
Unfortunately, cancer is an actual disease (or more accurately, a cluster of genetic diseases 
with similar phenotypes), and studies such as those presented in the first three chapters, while 
scientifically significant, appeal more to those unfortunate enough to have decided to combine 
their curious nature with more academic interests than those hoping to find real and effective 
means to combat cancer. With this important reality in mind, and armed with data from our 
first three studies, our amino acid deprivation protocol was applied in combination with the 
administration of a chemotherapy drug (doxorubicin) to cancer cells and non-cancer cells. 
Finally, a novel in vivo model was developed (described in chapter 5) and utilized to apply 
certain aspects of our in vitro findings into a living animal with a tumour (described in chapter 
6). 
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1  
 
The comparative impact of acute amino acid starvation on 
growth and survival of a metastatic breast cancer cell line 
(MDAMB231) and a non-tumourogenic breast cancer cell 
line (MCF12A) 
 
 The genetic diversity of tumour forming cancers is proving to be far greater 
than first believed, and research investigating approaches that target 
phenotypic characteristics common to a wide range of cancers could prove 
beneficial when developing therapeutic regimes aimed at a broader range of 
malignancies. The safety and apparent effectiveness of strategies employing 
controlled amino acid starvation of cancer patients has exposed a 
potentially feasible and reproducible therapeutic intervention approach. The 
effects of a short term cessation of the external amino acid supply in a 
tumourogenic and a non-tumourogenic cell culture model are assessed in 
this chapter. Data presented here demonstrates that a fast growing, 
metastatic cancer cell line is more sensitive to a dearth of amino acids than 
a non-tumourogenic line and that short term deprivation of amino acids 
results in increased cell death and proliferation arrest in these cells. 
 
1 Introduction 
 
Cancer is a cluster of genetic diseases with a phenotype manifesting in unbridled cellular 
growth, but of the purported hallmarks of cancer, only the metastatic potential of cancerous 
neoplasms can be used to differentiate malignant from benign tumours. All cancer tumours 
contain several mutations of low frequency, and recent evidence continues to demonstrate 
huge variation in number and frequency of cancer mutations (Wadman, 2011) which suggests 
a need for further development in the field of phenotypic screening to complement the 
enormous investment placed in targeted drug approaches. Not only is this tactic unconstrained 
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to prior knowledge of biological mechanisms and pathways directing the processes behind 
cancer, but it has the potential to uncover previously unknown treatment perspectives.  
 
1.2 Targeting breast cancer 
 
Fortunately, advances in early detection using screening and mammography have resulted in 
significant reductions in mortality rates in breast cancer patients. Despite this progress the 
lifetime risk of developing breast cancer for western women is approximately one in eight, 
with approximately 1.3 million newly diagnosed breast cancer cases expected in 2010 
(Breastcancer.org, September 2010). Breast cancer is now the most prevalent form of cancer 
among women, and in the South African context, cancer of the breast is the leading cancer in 
females in terms of both incidence and mortality. Alarmingly, this trend is set to continue 
with population forecasts indicating that the future burden of breast cancer in the South 
African population, in terms of incidence, will have grown by 15.8% in 2015 (extracted from 
the United Nations, World Population prospects, the 2008 revision).  
 
1.3 Targeting cancer 
 
Current desires to implement personalized medicine for cancer sufferers are hindered by a 
lack of useful cancer biomarkers. In fact, no new major cancer biomarkers have been 
validated for clinical use in over two decades (Diamandis, 2010). Technological advances and 
reduction in the costs associated with genotyping have allowed genome-wide association 
studies to identify several polymorphisms associated with cancer risk (Hicks et al., 2011). 
However, while these avenues promise to impact considerabley impact on the future of cancer 
treatment, the inevitable accumulation of mutations during progression to advanced tumour 
status confer a level of uniqueness to heterogeneous cancer populations. Unfortunately, it is 
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this unique nature of tumour genetic profiles that renders personalized approaches to cancer 
therapy a mere prospective solution at present (Schreiber et al., 2011). Therefore, finding 
practical solutions to rapidly facilitate improvement of current cancer treatments is 
imperative. Despite their genetic variability, environmental constraints imposed on fast 
growing cancers result in characteristic tumour microenvironments and hence analogous 
features in many tumours. Strategies that focus on these common attributes of solid tumours, 
and aim at improving our understanding of how cancer tumours manage to maintain 
exponential growth during times of metabolic stress, could be used to exploit the cancer 
metabolome and be directed at a broader range of genetically dissimilar cases (Gatenby and 
Gillies, 2004). 
 
1.3 Amino acid manipulation in the management of tumour progression 
 
Regulation of protein intake is seen as essential both during all stages of cancer progression 
and following successful treatment (Doyle et al., 2006). This is reflected in the nutritional 
recommendations from the American Cancer Society which stipulate that those with cancer 
be placed on diets high in protein content, both during and after treatment, in order to 
maintain healthy amino acid precursor pools (Lee and Longo, 2011). Indeed, cancer patients 
are known to present with abnormal plasma free amino acid profiles that appear to vary 
depending on cancer type (Cascino et al., 1995, Lai et al., 2005). Unfortunately, attempts to 
characterize the profiles of these amino acid imbalances in order to discriminate between the 
variants of cancer have not been altogether successful (Maeda et al., 2010). 
 
Biosynthesis of proteins requires that they be constructed in the precise arrangement of amino 
acids necessary to dictate their folding into functioning molecules. As peptides and proteins 
represent the major functional and structural proportion of cells, a continuous assimilation of 
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amino acids from the external environment is necessary for mammalian cells to continue this 
synthesis. Furthermore, tumour expansion  also depends on proteins (and therefore on amino 
acids) for the production of tumour structural elements and growth factors needed for 
angiogenesis (Holm et al., 1995). One might therefore consider that the rapid growth of 
cancerous tumours imposes a need for a precursor pool of amino acids large enough to satisfy 
their needs during this protein and DNA assemblage.  
 
Conventional therapies for victims of malignant tumours typically involve some combination 
of ionizing radiation, chemotherapy and surgery, all of which are associated with negative 
side effects. Utilization of amino acids in a clinical context could provide a safe alternative or 
adjuvant for the management of cancer metastasis and progression. 
 
1.3.1 Amino acid supplementation in the management of cancer 
progression 
 
It is evident that fast growing cell populations require a high amino acid supply in order to 
continue proliferating, and therefore many studies have attempted to starve cancers of amino 
acids as a potential therapeutic strategy (discussed in the next section). It seems 
counterintuitive to suggest that maintaining or complementing the amino acid pool of cancer 
patients by means of supplementation would have a negative impact on amino acid hungry 
tumours, but several studies have demonstrated that augmenting the levels of specific amino 
acids do in fact have negative consequences in some cancers. For instance, derivatives of the 
amino acid L-cysteine are known to impact angiogenesis and tumour invasion (Morini et al., 
1999). N-Acetyl cysteine (NAC) causes a decrease in proliferation in several colorectal 
adenocarcinoma cell lines that is associated with decreased cell surface expression of type one 
IGF-R, which is important in proliferation and prevention of apoptosis (Kelly et al., 2002). 
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NAC supplementation also affects cellular mechanisms that are important in contributing to 
the metastatic potential of melanoma (Tosetti et al., 2002) and bladder cancer cells 
(Kawakami et al., 2001). NAC has further been shown to reduce tumour size and the presence 
of angiogenic markers (Albini et al., 2001) and induce apoptosis/necrosis and vascular 
collapse (Agarwal et al., 2004) in mouse sarcoma and breast tumour xenografts, respectively.  
 
Glutamine is the most abundant amino acid in the body, and it is essential for cellular growth 
in tumours (Souba, 1993). In fact, some cancers can be described as “glutamine traps” 
(Souba, 1993) due to the net mobilization of glutamine toward tumour regions (Carrascosa et 
al., 1984). Therefore, despite the obvious nutritional benefit provided to the host, it might be 
expected that dietary glutamine supplementation would aid in tumour progression. However, 
glutamine has been demonstrated to retard tumour growth in breast cancer xenografts 
(Klimberg et al., 1996), a phenomenon linked to a positive correlation between glutamine 
levels and glutathione and a negative correlation with the pro-inflammatory prostaglandin 
PGE2 (Klimberg et al., 1996). An increased consumption of glutamine by tumours depletes 
circulating glutamine levels and leads to the impaired activity of natural killer cells. Increased 
dietary glutamine is believed to restore this function and impede further tumour growth 
(Yoshida et al., 1995). 
 
Supplementation with certain other amino acids might also be beneficial to some cancer 
patients. The amino acid arginine is an important precursor of nitric oxide (NO) (Cooke and 
Dzau, 1997), and increased NO production has been strongly associated with increased 
apoptosis in many breast cancer cell lines (Simeone et al., 2002) as well as in a head and neck 
cancer xenographt model (Kawakami et al., 2004). Isoleucine has purported anti-angiogenesis 
effects in some colon cancers and may prevent liver metastasis and decrease tumour growth 
through the impairment of vascular endothelial growth factor (Murata and Moriyama, 2007). 
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Some indirect observations have also provided insight. Cancer patients have relatively 
increased levels of hydroxyproline in their urine (Okazaki et al., 1992) and reduced levels in 
cancer tissue (Okazaki et al., 1992). This could result in a proline deficiency in people with 
cancer. Indeed, supplementation with lysine and proline correlated with decreased migration 
of breast and ovarian cancer cells and reduced growth of various tumour xenografts (Roomi et 
al., 2006, Roomi et al., 2005). 
 
1.3.3 Amino acid deprivation in the management of tumour progression 
 
Among their other requirements, cells demand amino acids for cell division and the synthesis 
of adequate quantities of material necessary to duplicate proteins, peptides and DNA during 
cell doubling. The process of proliferation in fast dividing cancer cells seems to require 
increased levels of amino acids to support the protein biosynthesis during these periods of 
growth (Medina et al., 1992). This is reflected by the observation that the amino acid 
transporters ASCT2, LAT1 and SLC6A14 exhibit elevated levels of expression in many 
cancer types. This increased expression has been suggested to play an important role in 
proliferation and survival of tumour cells (Fuchs and Bode, 2005, Gupta et al., 2006). Indeed, 
experimental down-regulation of amino acid transporters has been employed to successfully 
impair cancer cell growth by starving cancer cells of amino acids (Kim et al., 2006a). 
Moreover, the effectivness of anticancer agents such the compound E7070 has been linked to 
its ability to inhibit amino acid transport (Tsukahara et al., 2001). This outlines the 
importance of amino acid redistribution and supply in carcinogenesis and provides an avenue 
for novel intervention options for patients resistant to other therapies.  
 
Due to the important functions of amino acids in cancer growth, experiments investigating 
their exclusion or deprivation as treatment for cancer were common as early as the first half of 
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the last century. These studies took the form of amino acid restriction diets in laboratory 
animals with cancer. However, these initial investigations failed to establish a link between 
dietary restriction of amino acids and alterations in tumour growth patterns (Drummond, 
1917). In addition, experiments omitting single amino acids such as lysine or cysteine 
demonstrated few therapeutic benefits. For example, it was observed that the growth rates of 
spontaneous mammary carcinomas in mice could be curbed for only short periods following 
omission of lysine from the diet, but that normal rapid growth resumed following prolonged 
diets free in lysine (Kocher, 1944). 
 
Expectations were rekindled in the latter half of the century when a multitude of studies 
generated findings showing that amino acid restriction diets could in fact slow tumour 
development. The first of the studies demonstrating this beneficial property of amino acid 
starvation treatment in cancer utilized diets deprived only in methionine, valine or isoleucine 
(Sugimura et al., 1959). Thereafter, it was established that diets deficient in the amino acid 
phenylalanine could cause reduction in tumour sizes (Lorincz and Kuttner, 1965). Since then 
it has been demonstrated that limiting tyrosine in addition to phenylalanine leads to 
impairment in the chemotactic ability and invasiveness (Pelayo et al., 1999) as well as focal 
adhesion kinase dependent apoptosis in melanomas (Fu et al., 1999), and that tyrosine and 
phenylalanine restriction also results in metabolically linked cell death of prostate cancer cells 
(Fu et al., 2010). 
 
As complete and prolonged amino acid restriction was deemed too dangerous to have real 
clinical relevance, most research expounded on the principle that depleting the circulating 
levels of single amino acids thought to be critical to tumour growth and development could 
curb their progression. The enzyme asparaginase catalyzes hydrolysis of asparagine and is 
used as a treatment for acute lymphoblastic leukaemia based on the premise that these cancers 
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are unable to synthesize asparagine (Appel et al., 2007), whereas deprivation of the essential 
amino acid leucine increases sensitivity of melanoma cells with mutations in the RAS/MEK 
signalling pathway to caspase dependent cell death and inhibits their growth (Sheen et al., 
2011). Likewise, valine depletion of tumour bearing rats results in growth inhibition of 
hepatoma and mammary tumours (Nishihira et al., 1988, Tassa et al., 2003). It has also been 
demonstrated that selectively restricting amino acids has negative survival implications for 
prostate cancer cells, and that restricting these cells of phenylalanine/tyrosine, glutamine or 
methionine caused mitochondrial DNA damage and impacted on mitochondrial function and 
ATP synthesis (Liu et al., 2011c). 
 
Indirectly depriving cancer cells of amino acids may also prove to be a useful tool. Histidinol 
(an antagonist to histidine) leads to the functional deprivation of histidine,  thereby 
interrupting the biosynthesis of nucleic acids in a leukaemia cell line (Dehlinger et al., 1977). 
L-aspartic acid is an essential component of purine and pyramidine ring formation (Ahluwalia 
et al., 1990). Analogues of this non-essential amino acid interrupt this process, contributing to 
their well reported antitumour effects (Jayaram et al., 1979, Tyagi and Cooney, 1984). 
Buthionine sulfoximine, an inhibitor of glutathione synthesis, causes growth inhibition in 
certain leukaemia, breast and colon carcinoma cell lines (Dorr et al., 1986). 
 
Despite these promising amino acid deprivation studies contradictory observations provide 
valid cause for caution. Glutamine is a vitally important amino acid for tumour growth, yet 
some studies have shown that glutamine supplementation is able to repress growth of breast 
cancer (Klimberg et al., 1996). Conversely, selective restriction of glutamine in prostate 
cancer results in increased glucose consumption and cell death. Cell death was shown to be 
partly reversible if cells were also supplemented with pyruvate (Fu et al., 2010). Through 
duplication of physiological activity of L-glutamine, compounds structurally related to this 
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amino acid have been shown to interfere with its function and result in antitumour activity of 
a number of different cancers (Ahluwalia et al., 1990). 
 
Some of the most promising research into amino acid restriction involves deprivation of the 
essential amino acid methionine. The absence of methionine has repeatedly been shown to 
correlate with decreased growth of cancer cells without having negative effects on non-cancer 
cells (Poirson-Bichat et al., 1997, Guo et al., 1993, Epner, 2001), and catabolism of 
methionine through administration of methioninase inhibits cancer cell and tumour growth 
(Tan et al., 1999, Yoshioka et al., 1998). This effectiveness could be due to its nature as a 
methyl donor for methylation events in fast dividing cancer DNA. A hypothesis that is 
strengthened by evidence indicating that methyl depletion can lead to an increased 
susceptibility to genomic DNA  damage (Pogribny et al., 1995), and that histone 
methyltransferases might act as effective tumour suppressors (Huang, 2002). Furthermore, 
clinical studies have demonstrated that dietary methionine restriction is both safe and has 
potential as an antitumour agent (Epner, 2001). 
 
1.4 Short term dietary restriction and cancer 
 
Long term dietary restriction has been known to correlate positively with a decrease in cancer 
growth. It has also been shown to significantly extend the lifespan of some species (Heilbronn 
and Ravussin, 2005) and protect against both spontaneous and induced cancers (Kritchevsky, 
2003). These chronic restriction diets typically diminish caloric intake by at least 30%, but the 
negative implications of associated decreases in weight loss may lessen its attractiveness as a 
realistic treatment modality for human patients (Raffaghello et al., 2010). The recent 
discovery that so-called short term starvation (STS) regimes protect healthy cells from various 
toxins and drug induced toxicities through induction of a differential stress response where 
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cancer cells seem unable to enjoy the same protection (Lee and Longo, 2011). These 
restricted diets were demonstrated to be effective if the starvation periods remained relatively 
brief (approximately 48 hours) and were then followed directly by the toxic insult (Russo and 
Rizzo, 2008). This protective effect induced by STS has now also been confirmed in human 
based trials (Safdie et al., 2009). 
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2 Research problem and experimental aims 
 
2.1 Research problem  
 
 
Despite decades of research into amino acid starvation therapies, there are few studies that 
analyse the effect of short term, complete amino acid starvation in cancer. Up to now, most 
research has investigated the potential of longer term malnourishment of single amino acids, 
due to predicted side effects of complete depletion regimes. There is also an absence of 
studies investigating amino acid deprivation in the context of breast cancer. This along with 
recent interest and success of short term starvation strategies as therapy in the cancer setting 
has presented a need to investigate the effects of acute deprivation on breast cancer cells.  
 
2.2 Research aims  
 
1.  Establish the sensitivity of MDAMB231 cells to acute amino acid deprivation. 
2. Determine the time frame at which these cells begin to respond to amino acid 
deprivation. 
3. Confirm the relative contributions of cell death and proliferation (if any) to the 
responses observed in relation to aims (1) and (2). 
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3 Methods and materials 
 
Complete step-by step protocols are provided in the appendix. 
3.1 Study design 
 
 
 
3.2 Cell culture 
 
Experiments were performed using the human metastatic mammary carcinoma cell line 
(MDAMB231) and a human non-tumourogenic breast epithelial cell line (MCF12A). 
MDAMB231 cells were obtained from American Type Culture Collection (Rockville, MD, 
USA) and MCF12A cells were obtained from the University of Cape Town. During routine 
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maintenance, cells were grown as monolayers in Glutamax-DMEM (Celtic Molecular 
Diagnostics, Cape Town, South Africa) supplemented with 10% foetal bovine serum (Sigma 
Chemical Co., St Louis, MO, USA) at 37°C in a humidified atmosphere of 95% air plus 5% 
CO2. MCF12A growth medium was complemented with Ham‟s F12 medium (1:1) (Sigma 
Chemical Co., St Louis, MO, USA), 0.5 µg/ml hydrocortisone (Sigma Chemical Co., St 
Louis, MO, USA), 10 µg/ml insulin (Sigma Chemical Co., St Louis, MO, USA) and 20 ng/ml 
EGF (Sigma Chemical Co., St Louis, MO, USA). Cells were first allowed to proliferate in 
T75 flasks (75cm2 flasks, Greiner Bio One, Germany) until they reached 80% confluence 
before being split into appropriate treatment plates or dishes. Splitting was accomplished by 
washing the cell monolayer with warm phosphate buffered saline (PBS) followed by 
incubation with 4 ml trypsin/EDTA (Sigma Chemical Co., St Louis, MO, USA) at 37°C, with 
occasional agitation, until cells loosened completely or for a maximum of four minutes. All 
experiments were performed using exponentially growing cells.  
 
3.2.1 Note on cell confluence 
 
Sub-confluent cell populations were used for all experiments. Plating densities were 
previously determined for each cell line so that equivalent (sub-confluent) cell populations 
were always present at the time of treatment.  
 
3.3 MTT assay 
 
The 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoliumbromide (MTT) cell activity assay 
was used to indicate the percentage of metabolically viable cells post intervention. Absorption 
measurements were taken to correlate directly with the ability of vital reduction enzymes in 
the mitochondria of healthy cells to reduce MTT. 10 000 MDAMB231 cells or 15 000 
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MCF12A cells were plated 48 hours before being treated in 96-well plates using 100 µl of 
culture medium. Subsequent to treatments, supernatants were discarded and 150 µl of warm 
PBS and 50 μl of MTT (Sigma Chemical Co., St Louis, MO, USA) solution (0.01 g MTT/ml 
PBS) was added to each well containing the cell monolayer. The plate was then incubated for 
2 hours at 37ºC in a humidified 5% CO2 atmosphere. Following incubation, supernatants were 
discarded and 100 µl of isopropanol-HCl/Triton-X-100 (50:1) was added to each well and 
vigorously agitated for 5 minutes at 300-500 rpm in order to dissolve formazan crystals that 
had been generated in healthy cells. The suspension was then centrifuged for 2 minutes at 
1400 rpm and the supernatant analysed using a plate reader to determine absorbance at a 
wavelength of 540 nm versus a blank. Groups were analysed in triplicate in at least three 
separate experiments and absorbance values calculated as a percentage versus untreated 
controls.  
 
3.4 Caspase 3/7 activity assay 
 
Caspase-3/7 activity was measured using the Caspase-Glo® 3/7 assay (Promega, Madison, 
WI, USA). 10 000 MDAMB231 cells or 15 000 MCF12A cells were plated 48 hours before 
being treated in white-walled 96-well plates using 100 µl of culture medium. In experiments 
where transfection was necessary, cells were reverse transfected during plating. Sub-confluent 
cells populations were used for all experiments. Tthe Caspase-Glo® 3/7 working buffer 
reagent was prepared and equilibrated at room temperature and mixed with the lyophilized 
substrate before the reconstituted buffer was stored at -20°C. Following treatment the working 
buffer reagent was equilibrated at room temperature for 30 minutes and the 96-well culture 
plate for 10 minutes prior to assay. 100 µl (1:1) of working reagent was then added to each 
well containing cells, and the plates mixed at 500 rpm for 30 seconds. The plate was then 
incubated at 22ºC for 1 hour in the dark. The luminescence was measure in a luminometer. 
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3.5 Trypan blue assay 
 
Trypan blue cell viability was assessed using the Countess™ Automated Cell Counter 
(Invitrogen, USA). 100 000 MCF12A cells or 80 000 MDAMB231 cells were plated into 60 
mm culture dishes 48 hours prior to treatment. Following treatment cells were trypsinized and 
pelleted. 10 μl cell suspension was mixed with 10 μl 0.4% trypan blue and 10 μl loaded into a 
Countess™ chamber slide. The slide was then inserted into the instrument and trypan blue 
positivity calculated automatically and expressed as the total number of trypan blue positive 
cells, total number of trypan blue negative cells and absolute total cell number. 
 
3.6 Cell proliferation assay 
 
Cells were harvested from sub-confluent plates and were re-suspended in complete media and 
plated in 24-well plates at a density of 10 000 cells per well. After 24 h, cells were harvested 
from the first plate and counted on a hemocytometer. 
 
3.7 Analysis of cell cycle progression 
 
Flow cytometric analysis of the cell cycle was performed using the CycleTEST™ PLUS 
DNA Reagent kit (Becton Dickinson, California, USA). 200 000 MCF12A cells or 150 000 
MDAMB231 cells were plated in T25 culture flasks 48 hours prior to treatment. Prior to 
analysis, cells were trypsinzed and the cell suspensions centrifuged at 400 x g for 5 minutes at 
room temperature. Cells were then washed once in PBS. 250 µl of trypsin buffer was added to 
each tube and allowed to react for 10 minutes at room temperature. Thereafter, 200 µl of 
trypsin inhibitor and RNase buffer was added to each tube. This solution was again incubated 
at room temperature for 10 minutes. Finally, 200 µl of ice cold propidium iodide stain 
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solution was added to each tube, which was incubated on ice in the dark for a further 10 
minutes. Samples were filtered through a 50 µm nylon mesh into 12x75 mm tubes. Sample 
fluorescence was acquired using flow cytometry within 30 minutes. Results were obtained by 
using the CycleTEST™ PLUS DNA Reagent kit and ModFit LT software (Verity software 
house, Inc., ME, USA.) on BD FACSAria I. At least 30 000 list-mode data events were 
acquired for each sample. A 585/42 bandpass filter was used to analyse light emitted between 
564 and 606 nm by stained cells. 
A. B.
  
 
ModFit LT software was used to determine the percentage of cells in the g0/g1, s and g2/m 
phases. The location of these populations, after gating was used to exclude aggregates, is 
indicated in image 1.2. Mean percentages from three independent experiments were used to 
perform statistical comparisons.  
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Peripheral blood mononuclear cells (PBMCs) were isolated from human blood and used as a 
reference point for determining the location of the g0/g1 peak. An example of such a peak is 
reproduced in image 1.3. 
 
3.7 PARP Western blots 
 
3.7.1 Protein extraction and quantification 
Following treatment, cells immediately had their supernatants discarded and placed on ice. 
Cell monolayers were then rinsed three times in 5 ml of a pre-lysis buffer (20 mM Tris-HCl, 
pH 7.4, 137 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 and 0.1 mM sodium orthovanadate). Total 
cell protein was extracted by incubating cells on ice for 10 minutes in 1 ml of a modified 
radioimmunoprecipitation (RIPA) buffer, pH 7.4, containing: Tris–HCl 2.5 mM, EDTA 1 
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mM, NaF 50 mM, NaPPi 50 mM, dithiothreitol 1 mM, phenylmethylsulfonyl fluoride 
(PMSF) 0.1 mM, benzamidine 1 mM, 4 mg/ml SBTI, 10 mg/ml leupeptin, 1% NP40, 0.1% 
SDS and 0.5% Na deoxycholate. Adherent cells were then harvested from culture dishes by 
scraping. Whole cell lysates were sonicated in order to disrupt the cell membranes to release 
their contents before being centrifuged at 4°C and 8000 rpm for 10 minutes. Lysates were 
then stored at -80°C or had their protein content determined immediately. Protein content was 
quantified using the Bradford protein determination method (Bradford, 1976), directly before 
the preparation of cell lysates. 
 
3.7.2 Sample preparation (cell lysates) 
Following protein quantification, aliquots diluted in Laemmli sample buffer were prepared for 
all samples, each containing 40 μg of protein. Aliquots were then stored at -80°C for future 
analysis by Western blotting. 
  
3.7.3 SDS-PAGE and Western blot analysis 
Whole cell lysates were separated on 10% polyacrylamide gels by sodium dodecyl sulphate 
polyacrylamide gel electrophoresis (SDS-PAGE). A pre-stained protein marker ladder 
(peqGOLD, PEQLAB Biotechnologie GMBH, Germany) was loaded in the left most well on 
each gel for orientation and electrophoretic determination of molecular weights of specific 
bands. Previously prepared protein samples were boiled for 5 minutes and 40 μg of protein 
(sample preparation described above) was loaded per lane. Gels were run for 60 minutes at 
130 V (constant) and 400 mA (Mini Protean System, Bio-Rad, USA). Following SDS-PAGE, 
proteins were transferred to polyvinylidine fluoride (PVDF) membranes (Immobilon, 
Millipore, USA) using a semi-dry electrotransfer system (Bio-Rad, USA) for 60 minutes at 15 
V and limit 0.5 A. In order to prevent non-specific binding, membranes were blocked in 5% 
(w/v) fat-free milk in 0.1% Tris Buffered Saline-Tween20 (TBS-T) for 2 hours at room 
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temperature with gentle agitation. Membranes were then incubated with PARP primary 
antibody (Cell Signalling, MA, USA) diluted in 5% (w/v) fat-free milk in 0.1% TBS-T 
(1:1000), overnight at 4°C. The following day, membranes were washed in copious volumes 
of TBS-T (3X5 minutes) before being incubated in anti-rabbit (Amersham Biosciences, UK, 
and Dako Cytomation, Denmark) horseradish peroxidase-conjugated secondary antibody for 1 
hour at room temperature with gentle agitation. Following the incubation period, membranes 
were washed a further three times in TBS-T (3x5 minutes), followed by a final 10 minute 
wash in TBS. Antibodies were detected with the LumiGLO Reserve™ chemiluminescent 
substrate kit (KPL, Inc., USA) as per the manufacturer‟s instructions, and bands were exposed 
to autoradiography film (Hyperfilm, Amersham Biosciences, UK). Exposed bands were 
visualised and then quantified by densitometry using the UNSCAN-IT© densitometry 
software (Silk Scientific Corporation, Utah, USA). All bands were expressed as optical 
density readings relative to a control present on the same blot. 
 
3.8 Amino acid deprived medium 
 
Cells that were incubated without amino acids were incubated in the usual manner except in 
growth medium that contained no amino acids. Culture medium was designed and prepared to 
be identical in every way to typical growth medium, apart from the fact that it contained no 
detectable amino acids. Amino acid free culture medium was prepared by Highveld 
Biological (Pty) Ltd in association with Dr Elke Bey. Furthermore, dialyzed foetal bovine 
serum (#A15-107; PAA Laboratories GmbH, Austria) was used in the preparation of this 
media.  
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3.9 Statistical analysis 
 
All values are presented as the mean ± standard error of the mean (SEM). Differences 
between time points and treatment groups were analysed using analysis of variance 
(ANOVA).  The unpaired student‟s t-test was used when comparisons were made between 
only two groups. Significant changes were further assessed by means of the Bonferroni post 
hoc analysis where appropriate. All statistical analyses were performed using Graphpad Prism 
version 5.01 (Graphpad Software, Inc, CA, USA). The minimum level of significance 
accepted was p < 0.05.  
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4 Results 
4.1 MDAMB231 cancer cells are more sensitive than MCF12A epithelial 
cells to acute amino acid starvation 
 
Custom culture medium, designed to be free of amino acids and complemented with dialyzed 
foetal bovine serum was analyzed for amino acid content using mass spectroscopy based 
proteomics and found to contain no traces of amino acids (data not shown).  
 
Initial experiments designed to assess the sensitivity of the cell lines in this study to amino 
acid deprivation made use of the MTT assay and utilized varying dilutions of growth medium 
comprised of appropriate ratios of fully complemented growth medium and amino acid free 
medium. The capacity of the non-tumourogenic (MCF12A) breast epithelial cell line to 
reduce MTT to formazan was not diminished following a 24 hour incubation in growth 
medium deficient in amino acids (Fig 1.1). However, 48 hours after converting to amino acid 
free medium, the MTT reducing capacity of these cells had decreased more than 50%. 
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The capacity of the metastatic cancer cell line (MDAMB231) to reduce the MTT to formazan 
was significantly diminished following a 24 hours incubation in amino acid free medium (Fig 
1.2). A significant decrease was observed even when the culture medium was not completely 
deficient in amino acids. A more pronounced decrease in reductive capacity appeared after 48 
hours of amino acid deprivation. 
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When analyzed over time, the non-cancer cell line showed no change in reductive capacity 
over a 24 hour period of amino acid deprivation (Fig 1.3). 
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A rapid decrease in reductive capacity occurred after only 12 hours, but not before 6 hours, of 
amino acid deprivation in MDAMB231 cells, during 24 hour period of amino acid deprivation 
(Fig 1.4). 
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4.2 MDAMB231 cells (but not MCF12A cells) show increased signs of 
apoptosis activation during short term amino acid starvation 
 
 
 
 
 
Next, it was determined if programmed cell death was involved in the changes induced by 
complete amino acid deprivation. Results from a caspase 3/7 activity assay showed that 
MCF12A cells displayed no significant changes in caspase 3/7 activity in response to amino 
acid starvation (Fig 1.5). 
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MDAMB231 cells had a significant increase in caspase 3/7 activity at 12 and 24 hours 
following amino acid deprivation (Fig 1.6).  
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PARP, an enzyme involved in DNA damage repair, can be cleaved by both caspase 3 and 
caspase 7. PARP cleavage is a sensitive indicator of apoptotic cell death, downstream of 
caspase activity. Western blots displayed detectable PARP fragments at 89 kDa subsequent to 
24 or 48 hours of amino acid depletion in the MDA-MB-231 cells but not MCF12A cells (Fig 
1.7). 
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The trypan blue vital stain is able to traverse only those cell membranes with compromised 
integrity, and therefore functions as a marker of necrotic and late stage apoptotic cell death 
and can be used as an indicator of actual cellular impairment following an intervention. 
MCF12A cells excluded trypan blue dye during a 24 hour period of amino acid deprivation 
(Fig 1.8).  
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A significant percentage of trypan blue positive MDAMB231 cells appeared after 12 hours of 
amino acid deprivation (Fig 1.9). 
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4.3 Analysis of cell proliferation 
 
A. B.
 
 
 
Removal of amino acids from culture medium for 24 hours results in diminished cell numbers 
in both the cancer and non-cancer cell lines (Fig 1.10).  
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4.4 Analysis of the cell cycle 
 
 
A.
B.
 
 
The MDAMB231 cell line exhibited no obvious alterations in cell cycle progression at 6 
hours or at 12 hours of amino acid starvation (Fig 1.11). Mean percentages from three 
independent experiments were used to perform statistical comparisons between the same cell 
cycle phase for the different treatment groups. 
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A.
B.
 
 
After 24 hours incubation in amino acid free medium, MDAMB231 cells displayed a 
significantly increased percentage of cells in the g0/g1 phase of the cell cycle and a 
significantly decreased percentage of cells in the s phase (Fig 1.12).  
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A.
B.
 
 
MCF12A cells displayed a pattern of g0/g1 arrest after 12 hours of starvation (Fig 1.13). 
While a significantly greater percentage of cells were in the g0/g1 phase after amino acid 
starvation, significantly fewer cells were present in the g2/m and s phases.  
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A.
B.
 
 
 
The MCF12A cell lines had a significantly decreased percentage of cells in g2/m and s phases 
after 24 hours of amino acid starvation (Fig 1.14). A significantly higher percentage of cells 
were present in the g0/g1 phase of the cell cycle after 24 hours of amino acid starvation. 
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5 Discussion 
 
Breast cancer is the most common neoplasm in women worldwide. Owing to the fact that 
amino acids are vital to cancer growth, the effects of amino acid deprivation regimens on 
cancer progression have been investigated for decades, but most research in this area had 
focused primarily on decreasing or omitting particular amino acids from the 
microenvironments of cancer cells. Although experimental protocols and outcomes have 
varied, it is clear that deprivation of specific amino acids can result in decreased invasiveness 
(Pelayo et al., 1999) and proliferation (Epner, 2001) and increased levels of cell death (Fu et 
al., 2010) in several cancer cell and xenograft models. Still, there is scant evidence that short-
term, total amino acid starvation will produce analogous results. Recent clinical and pre-
clinical studies investigating short term starvation protocols during cancer treatment have 
shown promise (Safdie et al., 2009), indicating that further studies are needed in this area. 
 
The purpose of this observational study was to establish the sensitivity of a commonly used 
metastatic breast cancer cell line (MDAMB231) to a short term bout of complete amino acid 
starvation. The MTT cell activity assay assesses the fraction of metabolically viable cells, 
based on the principle that absorption measurements have been shown to correlate directly 
with the ability of vital reduction enzymes in the mitochondria of healthy cells to reduce the 
MTT compound. The MTT assay is utilized as a clonogenic and proliferation (Verma et al., 
2010) or cell death assay (Qi et al., 2011) depending on study aims, and despite its lack of 
specificity is an excellent and useful assay with which to evaluate sensitivity of cultured cells 
to experimental interventions (by assessing cell viability). Our results indicate that fast 
growing metastatic MDAMB231 cells are highly sensitive to amino acid deprivation in an in 
vitro experimental model, and that these cells are significantly more sensitive to short periods 
of amino acid deprivation than a non-tumourogenic breast epithelial line (MCF12A) (Fig 1.1 
and Fig 1.2). This is exemplified by an attenuation of MTT reducing capacity even in cultures 
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only partially deprived of amino acids for 24 hours (Fig 1.2). Cancer cells are known to 
require amino acids for growth and survival and the rapid proliferation rates of many cancers 
may depend on high levels of amino acids for protein and DNA synthesis to occur. 
MDAMB231 cells are highly glycolytic and fast growing (Robey et al., 2005) and may 
require access to greater concentrations of amino acids in a shorter period of time than slower 
growing non-cancer cells. Our observation that MTT reduction decreased subsequent to only 
12 hours of amino acid depletion in the MDAMB231 cells seems to add credence to that 
suggestion (Fig 1.4). 
 
It cannot be inferred from MTT reduction data whether changes occur due to alterations in 
proliferation patterns or simply due to loss of cells through cell death. So, next we wished to 
establish if decreased MTT activity correlated with cell death. A decrease in amino acid 
availability might not only impact the progression of biosynthesis pathways but also on 
metabolic systems in the cell (Bui and Thompson, 2006). Additionally, the pervasiveness 
throughout the cell and vital significance of amino acids to almost all cellular functions could 
be a reason why their absence has been shown to trigger programmed cell death mechanisms 
in some cancers (Fu et al., 1999). We present evidence here that a complete lack of amino 
acids results in the initiation of cell death mechanisms in the form of increased caspase 3/7 
activity in MDAMB231 cells (Fig 1.6), a phenomenon that does not appear in MCF12A cells 
in our experimental model (Fig 1.5). We also show that caspase cleavage affects the 
downstream target PARP (Fig 1.7), a protein which undergoes distinct cleavage during 
caspase dependent apoptosis (Soldani and Scovassi, 2002). Further investigation 
demonstrated that these molecular changes were accompanied by disruption in membrane 
integrity in the MDAMB231 cells after only 12 hours of amino acids starvation (Fig 1.9). 
Together, these data suggest that the high cell turnover and metabolic capacity of the cancer 
cell line is vitally dependent on amino acids, so much so that their deficiency triggers a cell 
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death response. The rapid initiation of cell death after only 12 hours in the cancer cells 
suggests that complete exhaustion of the remaining amino acid pool causes cell death. 
 
Uncontrolled cell proliferation is inherently linked to cancer and is managed by the cell cycle 
machinery (Collins et al., 1997). Chemotherapeutic agents leading to growth inhibition of 
MDAMB231 cells act in some instances by eliciting a g0/g1 phase accumulation of these 
cells (El-Sherbiny et al., 2001, Yan et al., 2006). A g0/g1 arrest in MDAMB231 cells after 24 
hours of amino acid deprivation (Fig 1.12) indicates that these cells require the availability of 
amino acids for growth and proliferation and resort to arrest of these proliferative processes in 
their absence. A lack of molecular and mechanistic data limits formation of absolute 
conclusions; here observational evidence showed that a lack of amino acid availability 
resulted in a decrease in the ability of these cells to proliferate efficiently. Interestingly, while 
the non-tumourogenic cell line showed no lethal response to acute amino acid deficiency, they 
had a pronounced g0/g1 cell cycle arrest and a decreased s phase after only 12 hours without 
externally available amino acids (Fig 1.13). While these slower growing cells did not respond 
by initiation of immediate cell death like the cancer cells, lower amino acid levels still 
resulted in a profile of cell cycle arrest. Notably, the changes in the cell cycle were not 
reflected by the MTT assay. 
 
5.1 Conclusion 
 
Here we present evidence demonstrating that a fast growing metastatic cancer cell line is 
more sensitive to a dearth of amino acids than a non-tumourogenic line and that short term 
deprivation of amino acids results in increased initiation of cell death and evidence of 
proliferation arrest. Slower growing non-cancer cells showed no cell death response and 
instead appear to exit the cell cycle and arrest growth, presumably in an attempt to conserve 
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amino acids and ATP and prolong survival in the event that amino acid levels return to 
normal. 
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Autophagy is vital for the prevention of cell death and 
growth arrest during the first hours of amino acid 
starvation in MDAMB231 and MCF12A cells 
 
Mammalian cells have a remarkable ability to circumvent the deleterious 
consequences of short term nutrient starvation. Among the most important 
mechanisms conferring this protection is the ability of cells to generate free 
amino acids through degradation of intracellular proteins and organelles 
through the autophagosomal-lysosomal pathway. Some cancer cells have 
high levels of basal autophagy and may therefore have the capacity to evade 
some negative consequences of amino acid starvation in an acute setting. 
This chapter presents evidence that autophagy inhibition using bafilomycin 
A1 decreases cell survival and reduces proliferation levels during acute 
amino acid starvation in the K-ras mutant MDAMB231 breast cancer cell 
line, and then speculates that autophagy is crucial for this tolerance to acute 
amino starvation. 
 
1 Introduction 
 
Mammalian cells have evolved adaptive and complementary systems of mechanisms to 
manage fluctuations in cell nutrient levels. These mechanisms are not only vitally important 
when contending with typical instabilities in nutrient levels but also provide the cell with a 
way to evade negative consequences in instances of atypical extreme spells of  nutrient 
depletion. These sophisticated systems have developed in such a way as to create a buffer 
zone in which temporary variations in availability of certain nutrients have little if any effect 
on cellular function. 
  
Mammalian survival is not normally reliant on constant external energy intake as a 
considerable fraction of imbibed foodstuffs will be internally stored in well-nourished 
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individuals. As such, the whole organism is well adapted for rapid mobilization of glucose 
and fat stores during starvation conditions. Much of this is achieved through hormonal 
regulation, and it is now well established that induced decreases in insulin levels during 
periods of starvation lead to increased blood glucose levels (Johnston et al., 1982). 
Furthermore, low levels of insulin are known to stimulate lipid breakdown, while increased 
levels of circulating glucagon increase gluconeogenesis in the liver (Mortimore and Poso, 
1987). At the same time, elevated cortisol secretion stimulates both gluconeogenesis and 
increases action on fat breakdown (Douyon and Schteingart, 2002). 
 
Amino acids, on the other hand, can‟t be stored as such, and are effectively stockpiled as 
functional proteins, especially in the liver and muscle tissue. There exists a rapid equilibrium 
between the cellular amino acid pool in the tissue and the systemic amino acid pool of plasma 
protein which can be utilized to yield free amino acids for maintenance of homeostasis. A cell 
is therefore able to acquire amino acids from the plasma as required for processes such as 
protein synthesis, and the plasma amino acid pool can then be replenished by the degradation 
of proteins elsewhere in the body, such as the liver or muscle. This degradation is achieved 
through hormonal control of protein catabolism stimulated by increased glucagon (Mortimore 
and Poso, 1987) and cortisol levels (Douyon and Schteingart, 2002) and by depleted levels of 
insulin (Johnston et al., 1982). A complementary decrease in protein synthesis in the absence 
of insulin stimulation prevents biosynthesis of non-vital proteins and aids preservation of 
intracellular amino acid levels (Dice, 1988). 
 
During a bout of short term starvation cells utilize two broadly defined mechanisms that 
function together to extract amino acids from intracellular proteins; a non-lysosomal 
proteolytic pathway by means of the multi-enzymatic proteosome system or degradation 
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pathways characterized by lysosomal proteases typified by the autophagosomal-lysosmal 
system. 
 
1.1 Proteolytic responses to short-term amino acid starvation 
 
Amongst the tumultuous rhythm and microscopic fervour of the cytosol reside the functional 
units of the cell, the proteins. Proteins measure in their tens of thousands by variety in any 
given cell, and of this assortment, approximately a thousand occur in great abundance and 
comprises the majority of a cell‟s operational contents. These complex structures are the 
molecular products of a predetermined assemblage of amino acids, strung together in a 
genetically pre-programmed order. In times of short term amino acid supply-drought cells 
must acquire these fundamental components for certain vital processes and functions. It 
accomplishes this feat through an act of self-sufficiency when it catabolises resident proteins 
and recycles the building blocks for use in vital functions elsewhere in the cell. The two 
principal mechanisms whereby a cell is able to do this are described below. 
 
1.1.1 Degradation by the ubiquitin proteasome system (UPS) 
 
During starvation mammalian cells activate proteolytic systems that are able to enzymatically 
liberate amino acids for use in protein biosynthesis or energy production. Proteins destined for 
degradation by this system must first undergo several rounds of covalent tagging on their 
lysine residues with small peptides called ubiqutin, literally marking them for destruction. 
They are then shuttled into the central cavity of a cylindrical complex known as the 26S 
proteasome. Here the tagged proteins are unfolded before proteolytic enzymes located on the 
luminal wall of the proteasome reduce them to oligopeptides that are eventually broken down 
to amino acids following further enzyme action (Tisdale, 2005). This ATP dependent system 
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is accountable for most of the amino acids liberated from skeletal muscle during starvation 
and is known to be induced during short term amino acid depletion (Mitch and Goldberg, 
1996). Amino acids liberated from skeletal muscle in this way are then available for use as 
energy substrates or for conversion to glucose in the liver. In this way, the amino acid and 
nitrogen needs of cells are partially met through proteosomal degradation during the first 
hours of starvation (Finn and Dice, 2006). The ubiquitin-proteasome pathway is also activated 
in a number of disease states, and is thought to be crucial for survival during short term amino 
acid starvation in some cancers, including breast cancer (Mizrachy-Schwartz et al., 2010). 
Furthermore, increased proteasome function is known to occur in skeletal muscle during 
cancer cachexia (Lecker et al., 1999). 
 
1.1.2 Degradation by the autophagosomal-lysosomal system 
 
Autophagy broadly describes the genetically controlled transference and delivery of bulk 
cytoplasmic materials to endosomal and lysosomal compartments for degradation. Autophagy 
has been classed into three distinct ATP dependent types that differ in some functioning and 
mechanistic activation (Mizushima, 2007). Macroautophagy (referred to simply as autophagy 
henceforth) is the most well described of these, the other less understood forms designated as 
microautophagy and chaperone-mediated autophagy. Almost all eukaryotic cells possess low 
levels of autophagy at resting state (Mizushima et al., 2004). The function of this basal 
autophagy pertains mainly to the bulk ingestion of cell cytoplasm which results in the removal 
of cellular „junk‟ in the form of redundant organelles and macromolecules. In fact, autophagy 
is the only known eukaryotic system able to degrade intracellular materials that are too large 
to be broken down by the proteasome. This property of organelle and protein quality control 
is crucial to cellular homeostasis and autophagy deficiency produced though genetically 
engineered ATG5 or ATG7 knock-outs results in pathological neurodegeneration or prenatal 
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death (Cataldo et al., 1996, Kuma et al., 2004). Although described as a bulk degradation 
process, autophagy can behave selectively under some circumstances (Yu et al., 2008). This 
selective autophagy is supervised by specific protein regulators such as parkin (Mizushima 
and Levine, 2010) and substrates selectively degraded in this way are known to influence cell 
survival and death dynamics (Onodera and Ohsumi, 2004). 
 
Autophagy, first described in the 1960‟s (Stromhaug and Klionsky, 2001), is characterised by 
the development of specialized double membrane autophagosomes that engulf organelles and 
other cellular components such as proteins before attaining their lytic enzymes through fusion 
with lysosomes or endosomes. It is this union that confers the ability for mass catabolism and 
proteolysis of ingested materials (Lockshin and Zakeri, 2004). Exactly how the 
autophagosome forms and develops is only partly understood, but the discovery that these 
processes are regulated by over thirty autophagy related genes (ATG) has played a significant 
role in furthering understanding (Nakatogawa et al., 2009). It has become clear that formation 
of the autophagosome relies on the endoplasmic reticulum (ER) (Yla-Anttila et al., 2009), and 
that amino acid starvation results in recruitment of the mammalian target of rapamycin 
(mTOR) to regions located proximal to or perhaps even physically on the ER (Hayashi-
Nishino et al., 2009). Other membrane sites have now also been implicated as potential 
autophagosome precursors (Webber and Tooze, 2010). Recruitment of mTOR is followed by 
conscription of a complex of class III phosphatidylinositol-3-OH kinase (PI3K) which 
includes Beclin-1 and ATG14, proteins coded for by the ATG (Matsunaga et al., 2009). 
Subsequent to the recruitment and oligomerization of additional proteins, structures known as 
omegasomes are ultimately formed, and it is from these structures that development of 
bilayered isolation membranes, precursors of autophagosomes, is founded (Axe et al., 2008). 
Isolation membranes lengthen and surround intracellular cargo before the ends of the 
membrane meet and encapsulate the material now destined to become contents of the 
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autophagosome. The major protein complexes responsible for this series of events are coded 
for by ATG; these enzymatically catalyse reactions producing the conjugate ATG12-ATG5 
(Fujita et al., 2008) and the solubilisation and conjugation of LC3 to 
phosphatidylethanolamine (PE) to yield the lipidated variant of LC3 (ATG8), an important 
component of the autophagosome (Weidberg et al., 2010). Finally, autophagosomes fuse with 
lysosomes generating autolysosomes (or autophagolysosomes if endosomal fusion predated 
fusion with a lysosome). Finally, the inner membrane of the autophagosome, along with the 
cargo contained within it, becomes degraded by lysosomal hydrolases. 
 
 
Autophagy is believed to have evolved in response to cellular stress, primarily nutrient 
starvation, hypoxia, ATP depletion and signals prompting cellular remodelling where it has 
been demonstrated to have signalling pathway overlap (Meijer and Codogno, 2004). Although 
often described as programmed cell death type II in the past (Lockshin and Zakeri, 2004), 
contemporary models depict autophagy more accurately as a cell survival mechanism that acts 
alongside cell death in many instances (Tsujimoto and Shimizu, 2005). The relationship 
between apoptosis and autophagy is complex and many of the same mechanisms responsible 
for activation of apoptosis are also known to activate autophagy. As both systems are 
important during a stress response it is plausible that coevolution has lead to a degree of 
pathway overlap. 
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The most well defined function of autophagy is during starvation, particularly amino acid 
deprivation, and it is well known that autophagy is transiently activated during the first twenty 
four hours following a starvation incident (Mizushima et al., 2004). Leucine deficiency 
appears to be the most potent trigger for autophagy induction, but in order for autophagy to 
become fully activated many other amino acids including tyrosine, phenylalanine, glutamine, 
alanine, proline and  methionine must be lacking as well (Finn and Dice, 2006). Interestingly, 
although it has been shown that the amino acid that must be lacking in order for protein 
degradation to occur depends on tissue type, leucine shortage is necessary in all cases 
(Tischler et al., 1982). The end-products of lysosomal degradation following autophagy are 
not precisely known, but it is assumed that the basic building blocks of proteins and 
organelles (amino and fatty acids) are among them. This system also represents an important 
quality control mechanism whereby proteins are metabolised and recycled (Klionsky, 2007). 
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Hydrolysis of peptide bonds by lysosomal proteases yields protein degradation products in the 
form of peptides and amino acids which are then released into the cytosol by way of dedicated 
transport systems. Although the exact fate of these digestion products is not completely 
understood, it is most likely the case that the resulting amino acids enter back into the 
ribosomal system immediately to form new proteins, buffer the intracellular free amino acid 
pool, enter the blood and move to other tissues and organs or are eventually lost into the 
urine. 
 
1.3 Amino acid signalling in the control of autophagy 
 
It is essential that cellular growth and proliferation be coordinated with signals informing the 
cell factory of the nutrient availability status. This is vital to ensure that important energy 
consuming processes such as protein synthesis and maintenance remain in equilibrium with 
the nutrient supply. In addition to their critical function in metabolism and as compositional 
elements in cellular material, amino acids can also function as signalling molecules. The 
predominant signalling assignment of amino acids (leucine in particular (Blommaart et al., 
1997) is their ability to control signal transduction pathway activity that is integral to 
autophagy regulation. Autophagy has been conclusively demonstrated to occur in vivo in 
almost all tissues following nutrient starvation (Mizushima et al., 2004), and one perspective 
is that accessibility to sufficient levels of amino acids results in the inhibition of autophagy.  
 
It has been known for over thirty years that amino acids are able to inhibit autophagosome 
formation (Mortimore and Schworer, 1977). Inhibition of autophagy by amino acids was 
shown to be accompanied by increased stimulation of protein synthesis and an associated 
increase in the phosphorylation of a ribosomal protein designated S6 (Blommaart et al., 
1995). S6 is partly responsible for ribosomal recruitment to mRNA (Meyuhas, 2000) and is an 
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important component for cellular growth (Mamane et al., 2004). Positioned directly upstream 
of this phosphorylation event is a serine/threonine protein kinase, mTOR, which is at the 
centre of an important signalling network that moderates the rate and type of protein synthesis 
occurring in response to signals informing it of the cellular nutrient status. By balancing 
nutrient input with its usage, mTOR prevents cellular energy expenditure from outstripping 
the cell‟s capacity for nutrient acquisition and energy production (Shintani and Klionsky, 
2004).  
 
1.3.2 mTOR 
 
mTOR is controlled by a complex interplay of growth factor and nutrient signals acting at 
various levels of the mTOR pathway (Wullschleger et al., 2006). It is negatively regulated by 
a heterodimer consisting of the tubular sclerosis proteins (TSC1 and TSC2), which decrease 
mTOR signalling, by acting through a small GTP-binding protein (Rheb), during 
circumstances of diminished nutrients (Inoki et al., 2005). Insulin and growth factors act 
through PI3K/Akt and Ras, where increased growth factor signalling is converted into 
pleiotropic effects of growth and mitogenesis (Plas and Thompson, 2005). In this way, 
pathway communications during typical conditions result in phosphorylation of the 
TSC1/TSC2 complex and relief of inhibition downstream on mTOR allowing protein 
synthesis (and energy consumption) to continue unabated (Tee et al., 2002). However, mTOR 
has been shown to sense nutrient accessibility independently of these upstream mitogenic and 
growth factor signals and respond directly to alterations in amino acid, oxygen and ATP 
levels (Hay and Sonenberg, 2004). It has been proposed that hypoxia (Brugarolas et al., 2004) 
and increasing AMP/ATP ratios (Inoki et al., 2003) act at mTOR or TSC1/TSC2 to diminish 
pathway activity during times of stress. 
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1.3.3 mTOR, amino acid sensing and autophagy 
 
mTOR is extremely sensitive to changes in nutrients, and in particular to decreased 
concentrations of amino acids (Gu et al., 2006). The antifungal compound rapamycin inhibits 
mTOR directly and was shown to be able to reverse the amino acid deprivation induced 
phosphorylation of S6 (Shintani and Klionsky, 2004). This finding contributed to the 
hypothesis that amino acid dependent signalling and control of protein synthesis both acted 
through the mTOR pathway. Furthermore, amino acids stimulate mTOR signalling even in 
the absence of upstream signals from PI3K/Akt (Blommaart et al., 1995), indicating a 
potential for the presence of a devoted sensing mechanism. Current evidence indicates that an 
intracellular amino acid receptor (Beugnet et al., 2003) regulates Rheb binding to mTOR 
(Long et al., 2005), but it remains inconclusive whether mTOR itself is acting as the amino 
acids senor or if a third party inhibitor is involved in some way. Inhibition of mTOR 
signalling preserves homeostasis not only by regulating protein synthesis levels but also by 
stimulating rapid protein breakdown through concomitant autophagy regulation. It is believed 
that increasing autophagy during periods of amino acid depletion allows cells to utilize the 
break-down products of autophagic degradation as energy sources and for synthesis of 
survival proteins. How mTOR activation influences the intensity of cellular autophagy is 
unknown, but experiments involving yeast have given some insight. TOR is important during 
the starvation or rapamycin treatment of yeast cells when the dephosphorylation of the 
autophagy protein ATG1 enhances its kinase activity (Kamada et al., 2000), which is thought 
to be important for autophagosome development. TOR is also thought to be important in 
increasing phosphorylation of ATG13 in the presence of amino acids, resulting in decreased 
binding with ATG1 (Kabeya et al., 2005), a conjugation step necessary for ATG1 activity. 
Importantly, it is also now known that amino acid deprivation increases class III PI3K-
Beclin1 complex formation and therefore autophagy (Tassa et al., 2003), which provides an 
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additional indirect mechanism whereby a decreased concentration of amino acids can alter 
mTOR activity. Finally, activation of S6 might regulate a negative feedback interaction 
upstream of mTOR, possibly to prevent autophagy overstimulation (Klionsky et al., 2005). 
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1.4 Autophagy and tumourogenesis 
 
Many cancers are able to avoid apoptosis in the stressful cancer microenvironment. Cell death 
through autophagy has been suggested as a primary mechanism of tumour suppression in 
cancer cells lacking apoptosis machinery (Liang et al., 1999, Jin and White, 2008), but 
whether autophagy leads to tumour formation or suppression is still a matter of controversy 
(Eisenberg-Lerner and Kimchi, 2009). Growing tumours develop regions with limited access 
to nutrients, due to spatial separation from the native vascular bed. The manner in which 
tumour cells obtain nutrients in these scenarios is still under intense investigation (Sato et al., 
2007).  
 
As the understanding of autophagy mechanisms has developed, and its intimate relationship 
with maintenance of cellular homeostasis (through the attenuation of metabolic stress) slowly 
appreciated, interest in the role of autophagy in development of pathogenesis has emerged. 
Following from this, a large body of data supporting the links between the cancer 
microenvironment and autophagy has developed and the literature is now replete with studies 
investigating ties between cancer and autophagy. Through these studies a paradox has 
emerged, and autophagy is now often described as a double-edged sword in the literature 
(Shintani and Klionsky, 2004) due to its ability both to act as a tumour suppressor and to be 
vital to tumour progression (Eisenberg-Lerner and Kimchi, 2009). 
 
1.4.1 Autophagy as cancer suppressor 
 
Disruption of autophagy can promote cancer development, potentially through loss of 
prevention of DNA damage and instability, through removal of protein aggregates and 
damaged organelles and perhaps even by limiting cell growth (Mathew et al., 2009). Beclin1 
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(the mammalian homologue of yeast ATG6) is a component of the PI3K VPS34 complex 
required for autophagy and its importance to a functional autophagy response has been 
demonstrated in many species including humans (Furuya et al., 2005). Beclin1 was first 
identified as a Bcl2 interacting protein (Liang et al., 1998), an interaction that leads to the 
inhibition of autophagy, which is diminished during starvation (Liang et al., 1999). Some 
cancer cells have been shown to have lower levels of Beclin1 than epithelial cells derived 
from the same origin, and the characterization of Beclin1 as a haploinsufficient tumour 
suppressor leads to the first substantial association between autophagy and cancer (Liang et 
al., 1999). The allelic deletion of Beclin1 has now been strongly tied with cancer progression 
and much of the research linking autophagy and tumourogenesis deals with this association. 
Beclin1 expression levels were found to be decreased in 18 of 32 tested breast cancers and 
have also been implicated in development of other human cancers including those of the 
prostate, brain, colon and ovaries (Liang et al., 1999, Aita et al., 1999, Miracco et al., 2007). 
Furthermore, conditional ATG7 deletion in the liver of mice results in tumour formation 
(Takamura et al., 2011). It is clear from this evidence that autophagy dysfunction is associated 
with the development of cancer under some circumstances. Indeed, the monoallelic deletion 
of Beclin1 leads to spontaneous lymphomas as well as lung, breast and liver cancers in mice 
(Yue et al., 2003, Qu et al., 2003), while the over-expression of Beclin1 in culture inhibits 
cancer progression (Liang et al., 1999). The subsequent discovery that regulators of 
autophagy proteins are important in cancer development and progression also emphasizes the 
role of autophagy as a tumour suppressor. UVRAG, which interacts with the Beclin1 PI3K 
complex, is essential for autophagosame formation (Liang et al., 2006), while Bif-1 interacts 
with Beclin1 through UVRAG (Takahashi et al., 2007). Both have been implicated in 
tumourogenesis (Liang et al., 2006, Lee et al., 2006). Furthermore, well known tumour 
suppressor genes such as PTEN and TSC are known to repress mTOR activity and thereby 
induce autophagy (Arico et al., 2001, Feng et al., 2005). Additionally, oft recurring mutations 
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in cancer such as p53 (Feng et al., 2005) and DAPk (Inbal et al., 2002) have both been 
described to have roles in the induction of autophagy in some circumstances. 
 
1.4.1 Autophagy in cancer progression 
 
Despite the large body of data demonstrating a role for autophagy in tumour suppression, 
autophagy also appears to be vital for tumour survival during times of metabolic stress. 
Indeed, several cancers have been shown to have high basal autophagy activity (White and 
DiPaola, 2009, Guo et al., 2011, Yang et al., 2011), and numerous studies have demonstrated 
that autophagy inhibition can result in the activation of a programmed cell death response in 
certain cancers (Mathew et al., 2009). Furthermore, autophagy has been directly linked to the 
tolerance that some cancer cells display in response to nutrient deprivation (Sato et al., 2007). 
Also, certain genes that are frequently mutated in many cancers are known to influence 
autophagy activity. For example, Akt and class I PI3K are known to stimulate mTOR activity 
and thereby inhibit autophagy (Lum et al., 2005), while cytoplasmic p53 is now also thought 
to obstruct autophagy activation (Tasdemir et al., 2008). However, mutant p53 has not yet 
been shown to alter autophagy activity in human cancer. Together the evidence seems to 
indicate that autophagy has dual roles in cancer progression and development depending on 
the context (White and DiPaola, 2009).  
 
Although a detectable level of autophagy occurs in vivo in many tissues, almost all cells have 
the capacity to increase autophagy in response to nutrient starvation, although the degree to 
which it becomes elevated during these circumstances appears to be tissue type specific 
(Mizushima et al., 2004). Interestingly, increased autophagy is prominent in poorly 
vascularised regions of tumours but not those regions that have adequate access to the host 
blood supply (Karantza-Wadsworth et al., 2007, Degenhardt et al., 2006). Therefore, 
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autophagy as a response to nutrient deficiency in these tumour microenvironments could be 
essential for survival of some cancers (Mathew et al., 2009). Pancreatic cancer cells and 
primary tumour samples, having especially pronounced levels of basal autophagy, were 
confirmed to require autophagy for survival during periods of deprivation of essential 
nutrients (Yang et al., 2011). Furthermore, inhibition of autophagy with chloroquine reduced 
tumour size and lengthened survival. Failure to adapt to episodes of nutrient starvation would 
result in a metabolic catastrophe and therapeutic starvation regimes being used to target the 
cancer metabolome are proving insightful. Indications are that autophagy may protect cancer 
cells during nutrient depletion, and therapeutic starvation models mimicking glucose 
deprivation have shown a Beclin1-dependent increased autophagy in prostate cancer (DiPaola 
et al., 2008). Autophagy inhibition during nutrient starvation leads to cell death in cervical 
cancer (Boya et al., 2005) as well as lymphocytes from patients with chronic lymphocytic 
leukaemia. Liver, gastric and pancreatic cancer cell lines are able to withstand removal of 
glucose, serum or amino acids from culture medium for substantially longer periods than 
normal human fibroblasts (Izuishi et al., 2000). This tolerance to amino acid deprivation by 
cancer cells was linked to protective autophagy by the same authors in a colorectal cancer 
culture model (Sato et al., 2007). A possible reason for the conflicting roles for autophagy 
could be linked to the recently revealed mechanism by which colon cancers are able to resist 
the negative effects of prolonged nutrient starvation due to the presence of p53 and its role in 
autophagy regulation (Scherz-Shouval et al., 2010). 
 
High levels of basal autophagy may also be required for cancer survival in nutrient rich 
conditions, and several tumour lines are now known to be dependent on autophagy for normal 
growth. Human cancers with mutations in H-ras or K-ras may require autophagy for tumour 
survival (Guo et al., 2011), and data from recent studies suggest that pancreatic (Yang et al., 
2011) and other Ras-driven tumours (Lock et al., 2011) require autophagy for sustained 
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growth. This recently reported autophagy-addiction of some tumours could represent an 
avenue of autophagy inhibition as an effective anticancer strategy in this setting. 
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2 Hypothesis and experimental aims 
 
2.1 Research problem 
 
Autophagy is essential for cell survival during times of metabolic stress, and is known to 
become activated during times of amino acid starvation. However, whether autophagy leads 
to cancer progression or suppression is still a matter of controversy. While most evidence 
indicates that autophagy acts as a tumour suppressor, many cancer cell lines display high 
levels of basal autophagy activity. However, it is unclear whether these cancers have a 
survival advantage during times of amino acid deprivation. Few studies have investigated the 
effects of short term amino acid deprivation in this context and studies investigating a 
protective role for autophagy under these conditions in breast cancer are completely absent. 
 
2.2 Study rationale 
 
Observations from previous experiments (outlined in the previous chapter) demonstrated that 
the non-tumourogenic breast epithelial cell line MCF12A showed few detrimental effects 
after being incubated in culture medium bereft of any amino acids for 24 hours. On the other 
hand, the commonly utilized metastatic breast adenocarcinoma cell line MDAMB231 showed 
greater sensitivity to amino acid exclusion from culture media and displayed a sudden 
increase in cell death and a profile of cell cycle arrest after only twelve hours of amino acid 
starvation. As these cells are known to have high ras activation and high basal autophagy 
levels, and autophagy is thought to be an important factor in tolerance to nutrient deprivation, 
the aim of this study was to investigate whether autophagy is in fact an important survival 
mechanism during short term amino acid starvation in these cells.  
 
Stellenbosch University  http://scholar.sun.ac.za
63 
 
2.3 Hypothesis 
 
The ras mutant MDAMB231 cell line relies on a pre-existing high basal autophagy for 
survival and tolerance during the first hours of amino acid starvation but not thereafter. 
 
2.4 Experimental aims 
 
 
1. Use the lysomotropic reagent bafilomycin A1 as an autophagy inhibitor to determine 
if autophagy is necessary for survival and cell cycle maintenance during the first hours 
of amino acid starvation in MDAMB231 cells and compare this to non-tumourogenic 
MCF12A cells. 
2. Determine if any observed changes during amino acid starvation are associated with 
alterations in lysosomal acidity or markers of autophagy. 
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3 Methods and materials 
 
Complete step-by step protocols are provided in the appendix. 
 
3.1 Study design 
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3.2 Cell culture 
 
Experiments were performed using the human metastatic mammary carcinoma cell line 
MDAMB231 which were obtained from American Type Culture Collection (Rockville, MD, 
USA) and the human non-tumourogenic breast epithelial cell line MCF12A that was obtained 
from the University of Cape Town. The MCF7 cell line, also used in some experiments, was a 
donation from the University of the Western Cape.  During routine maintenance, cells were 
grown as monolayers in Glutamax-DMEM (Celtic Molecular Diagnostics, Cape Town, South 
Africa supplemented with 10% foetal bovine serum (Sigma Chemical Co., St Louis, MO, 
USA) at 37°C in a humidified atmosphere of 95% air plus 5% CO2. MCF12A growth medium 
was complemented with Ham‟s F12 medium (1:1) (Sigma Chemical Co., St Louis, MO, 
USA), 0.5 µg/ml hydrocortisone (Sigma Chemical Co., St Louis, MO, USA), 10 µg/ml 
insulin (Sigma Chemical Co., St Louis, MO, USA) and 20 ng/ml EGF (Sigma Chemical Co., 
St Louis, MO, USA). Cells were first allowed to proliferate in T75 flasks (75cm2 flasks, 
Greiner Bio One, Germany) until they reached 80% confluence before being split into 
appropriate treatment plates or dishes. Splitting was accomplished by washing the cell 
monolayer with warm phosphate buffered saline (PBS) followed by incubation with 4 ml 
trypsin/EDTA (Sigma Chemical Co., St Louis, MO, USA) at 37°C, with occasional agitation, 
until cells loosened completely or for a maximum of four minutes. All experiments were 
performed using exponentially growing cells. Bafilomycin A1 from Streptomyces griseus 
(B1793, Sigma Chemical Co., St Louis, MO, USA) was dissolved in DMSO in ready to use 
aliquots to avoid freeze-thaw cycles, and was stored at -20°C. Rapamycin from Streptomyces 
hygroscopicus (R0395, Sigma Chemical Co., St Louis, MO, USA) was dissolved in DMSO in 
ready to use aliquots to avoid freeze thaw cycles, and was stored at -20°C. 
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3.3 MTT assay 
 
The protocol for the MTT assay performed in this study is described in the materials and 
methods section in the previous chapter. 10 000 MCF7 cells were plated 48 hours before 
being treated in 96-well plates using 100 µl of culture medium.  
 
3.4 Caspase 3/7 activity assay 
  
The protocol for the Caspase-3/7 activity assay (Caspase-Glo® 3/7 assay) performed in this 
study is described in the materials and methods section in the previous chapter. 
 
3.5 Trypan blue assay 
 
The protocol for the trypan blue assay performed in this study is described in the materials 
and methods section in the previous chapter. 80 000 MCF7 cells were plated into 60 mm 
culture dishes 48 hours prior to treatment.  
 
3.6 Analysis of cell cycle progression 
 
The protocol for the flow cytometric analysis of the cell cycle performed in this study 
(CycleTEST™ PLUS DNA Reagent kit) is described in the materials and methods section in 
the previous chapter. 50 000 MCF7 cells were plated into T25 culture flasks 48 hours prior to 
treatment.  
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3.7 LC3 and Beclin-1 Western blots 
 
3.7.1 Protein extraction and quantification 
Following treatment, cells immediately had their supernatants discarded and were placed on 
ice. Cell monolayers were then rinsed three times in 5 ml of a pre-lysis buffer (20 mM Tris-
HCl, pH 7.4, 137 mM NaCl, 1 mM CaCl2, 1 mM MgCl2 and 0.1 mM sodium orthovanadate). 
Total cell protein was extracted by incubating cells on ice for 10 minutes in 1 ml of a 
modified radioimmunoprecipitation (RIPA) buffer, pH 7.4, containing: Tris–HCl 2.5 mM, 
EDTA 1 mM, NaF 50 mM, NaPPi 50 mM, dithiothreitol 1 mM, phenylmethylsulfonyl 
fluoride (PMSF) 0.1 mM, benzamidine 1 mM, 4 mg/ml SBTI, 10 mg/ml leupeptin, 1% NP40, 
0.1% SDS and 0.5% Na deoxycholate. Adherent cells were then harvested from culture dishes 
by scraping. Whole cell lysates were sonicated in order to disrupt the cell membranes to 
release their contents before they were centrifuged at 4°C and 8000 rpm for 10 minutes. 
Lysates were then stored at -80°C or had their protein content determined immediately. 
Protein content was quantified using the Bradford protein determination method (Bradford, 
1976), directly before the preparation of cell lysates 
 
3.7.2 Sample preparation (cell lysates) 
 
Following protein quantification, aliquots diluted in Laemmli sample buffer were prepared for 
all samples, each containing 40 μg of protein. Aliquots were then stored at -80°C for future 
analysis by western blotting. 
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3.7.3 SDS-PAGE and Western blot analysis 
 
Whole cell lysates were separated on 12% polyacrylamide gels for LC3 II and 10% 
polyacrylamide gels for beclin 1 by sodium dodecyl sulphate polyacrylamide gel 
electrophoresis (SDS-PAGE). A pre-stained protein marker ladder (peqGOLD, Austria) was 
loaded in the left most well on each gel for orientation and electrophoretic determination of 
molecular weights of specific bands. Previously prepared protein samples were boiled for 5 
minutes and 40 μg of protein (sample preparation described above) was loaded per lane. Gels 
were run for 60 minutes at 130 V (constant) and 400 mA (Mini Protean System, Bio-Rad, 
USA). Following SDS-PAGE, proteins were transferred to polyvinylidine fluoride (PVDF) 
membranes (Immobilon, Millipore, USA) using a semi-dry electrotransfer system (Bio-Rad, 
USA) for 60 minutes at 15 V and limit 0.5 A. In order to prevent non-specific binding, 
membranes were blocked in 5% (w/v) fat-free milk in 0.1% Tris Buffered Saline-Tween20 
(TBS-T) for 2 hours at room temperature with gentle agitation. Membranes were then 
incubated with LC3B primary antibody (Cell Signalling, MA, USA) or beclin 1 primary 
antibody (Cell Signalling, MA, USA) diluted in 0.1% TBS-T (1:1000), overnight at 4°C. The 
following day, membranes were washed in copious volumes of TBS-T (3X5 minutes) before 
being incubated in anti-rabbit (Amersham Biosciences, UK, and Dako Cytomation, Denmark) 
horseradish peroxidase-conjugated secondary antibody for 1 hour at room temperature with 
gentle agitation. Following the incubation period, membranes were washed a further three 
times in TBS-T (3x5 minutes), followed by a final 10 minute wash in TBS. Antibodies were 
detected with the LumiGLO Reserve™ chemiluminescent substrate kit (KPL, Inc., USA) as 
per the manufacturer‟s instructions, and bands were exposed to autoradiography film 
(Hyperfilm, Amersham Biosciences, UK). Exposed bands were visualised and then quantified 
by densitometry using the UNSCAN-IT© densitometry software (Silk Scientific Corporation, 
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Utah, USA). All bands were expressed as optical density readings relative to a control present 
on the same blot. 
 
3.8 Assessment of acidic compartmentalization 
3.8.1 Lysotracker™ and Hoechst staining (imaging) 
 
100 000 MCF12A cells or 80 000 MDAMB231 or MCF7 cells were plated into 60 mm 
culture dishes containing pre-autoclaved coverslips, 48 hours prior to treatment. Cell 
monolayers were rinsed three times with sterile PBS and incubated in 1:10000 
Lysotracker™/PBS solution for 10 minutes at room temperature. Cell monolayers were then 
rinsed three times with sterile PBS and fixed and permeabilised with an ice-cold 1:1 
methanol/acetone mixture for 10 minutes at 4ºC. After being left to air dry for 20 minutes in 
the dark, cells were, once more, washed three times in sterile PBS and enough Hoechst 3342 
(10 mg/ml in a 1:200 dilution) was then added to cover the entire cell monolayer. This was 
left to incubate for 10 minutes at 4ºC. Thereafter, cells were washed five times in sterile PBS 
and images were immediately acquired with an Olympus IX81 microscope fitted with CellR® 
software. A minimum of three randomly chosen fields, of at least 3 independent experiments 
per experimental condition were prepared.  
 
3.8.2 Lysotracker™ (flow cytometry) 
 
200 000 MCF12A cells or 150 000 MDAMB231 or MCF7 cells were plated into T25 culture 
flasks 48 hours prior to treatment. Prior to analysis, cells were trypsinzed and the cell 
suspensions centrifuged at 400 x g for 5 minutes at room temperature. Cells were then washed 
once in PBS. Lysotracker™ (Invitrogen™, USA) was prepared in PBS (1:10 000) 
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immediately before use. Cell suspensions were centrifuged at 400 x g for 5 minutes at room 
temperature and the pellets re-suspended in 250 µl fresh Lysotracker™/PBS and incubated for 
10 minutes at room temperature before analysis using flow cytometry (BD FACSAria I). At 
least 10 000 cells were collected using a 488 nm laser and 610LP, 616/23BP emission filters. 
 
3.9 ATG5 siRNA transfections 
 
Cells were transfected using a reverse transcription protocol into 60 mm petri dishes. 20 pmol 
of ATG5 siRNA duplex (Cell Signalling, MA, USA, lSilence® Atg5 siRNA I #6345) was 
diluted into 250 µl of transfection medium (containing no antibiotics or serum). 2 µl of 
Lipofectamine™ RNAiMAX (13778075; Invitrogen™, USA) was gently mixed and added to 
this. 250 µl of this suspension was then added to each petri dish and allowed to incubate for 
20 minutes. 100 000 MCF12A cells or 80 000 MDAMB231 cells were then plated into the 
culture dishes containing the RNAi duplex-Lipofectamine RNAiMAX complexes to have a 
final volume of 2 ml and gently mixed. Cells were incubated at 37°C until ready to treat (24-
48 hours later). Stealth RNAi (STEALTH RNAI NEG CTL MED GC, 12935300; 
Invitrogen™, USA) was used as a negative control, as suggested by the manufacturer. Cells 
were treated 48 hours later. 
 
3.9.1 RNA extraction, cDNA synthesis and RTPCR 
 
Total RNA was extracted and purified using the PureLink™ RNA Mini Kit (12183018A; 
Invitrogen™, USA) as per the manufacturer‟s instructions. RNaseOUT™ Recombinant 
Ribonuclease Inhibitor (10777019; Invitrogen™, USA) was then added to samples before 
they were stored at -40°C. cDNA was then synthesised using the SuperScript® III First-
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Strand Synthesis SuperMix (18080051; Invitrogen™,USA) as per the manufacturer‟s 
instructions. Gene expression was analyzed using realtime-PCR that was performed using the 
96-well cycler StepOnePlus™ Real-Time PCR System and SYBR® Green dye. Analysis was 
performed by the Central Analytical Facility of Stellenbosch University, DNA Sequencing 
Facility located in the Department of Genetics under the supervision of Dr Ruhan Slabbert. 
The following primers were selected and purchased through the Central Analytical Facility 
with the assistance of Dr Ruhan Slabbert.: 
 
ATG5 autophagy 5-like [Homo sapiens]. PrimerBank ID 4757798a1. Amplicon size 171. 
Primer sequence (5'  3'). Forward primer (TTGACGTTGGTAACTGACAAAGT), reverse 
primer (TGTGATGTTCCAAGGAAGAGC). Heat-shock 90kD protein-1, beta [Homo 
sapiens]. PrimerBank ID 2014949594a1. Amplicon size 247. Primer sequence (5'  3'). 
Forward primer (TGGTGTGGTTGACTCTGAGGA), reverse primer 
(GGAGGTATGATAGCGCAGCA). NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex. PrimerBank ID 4758770a1. Amplicon size 102. Primer sequence (5'  3'). 
Forward primer (GGACTGGCTACTGCGTACATC), reverse primer 
(GCGCCTATCTCTTTCCATCAGA). β-cytoskeletal actin [Homo sapiens]. PrimerBank ID 
4501885a1. Amplicon size 250. Primer sequence (5'  3'). Forward primer 
(CATGTACGTTGCTATCCAGGC), reverse primer (CTCCTTAATGTCACGCACGAT). 
 
 
3.10 Statistical analysis 
 
All values are presented as the mean ± standard error of the mean (SEM). Differences 
between time points and treatment groups were analysed using one or two way analysis of 
variance (ANOVA). Significant changes were further assessed by means of the Bonferroni 
post hoc analysis where appropriate. All statistical analyses were performed using Graphpad 
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Prism version 5.01 (Graphpad Software, Inc, CA, USA). The minimum level of significance 
accepted was p < 0.05. 
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4 Results 
4.1 Bafilomycin A1 (10 nM) decreases cell viability during acute amino 
acid starvation in MDAMB231 cells and to a lesser degree in MCF12A cells 
but not in MCF7 cells. 
 
 
 
 
 
 
 
 
MCF12A cells were incubated in culture medium completely depleted of amino acids for a 
period of 24 hours, with or without 10 nM of bafilomycin A1 (Fig 2.1). Bafilomycin A1 
inhibits acidification inside lysosomes and thereby prevents autophagosome-lysosome fusion, 
effectively inhibiting autophagy progression. The capacity for MCF12A cells to reduce MTT 
to formazan was significantly diminished at all time points tested if bafilomycin A1 (10 nM) 
was added to culture medium 6 hours prior to analysis (Fig 2.1). This is a strong indication 
that the metabolic viability of these cells is impaired. 
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MDAMB231 cells displayed a significant decrease in their ability to reduce MTT only after 
12 hours of incubation in amino acid free medium. However, if this medium was 
supplemented with bafilomycin A1 (10 nM) then their reductive capacity was significantly 
lower at 6 and 12 hours (Fig 2.2). Interestingly, bafilomycin did not alter MTT reducing 
capacity at 24 hours of amino acid deprivation.  
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The MCF7 breast cancer cell line is beclin 1 haploinsufficient and therefore partially 
autophagy incompetent. Amino acid deprivation lead to an approximately 40% lower MTT 
reducing capacity after 24 hours when compared to 0 hours (cell incubated in amino acid 
complete medium) (Fig 2.3), indicating that these cells are sensitive to amino acid 
deprivation. The presence of bafilomycin A1 (10 nM) did not alter the ability of these cells to 
reduce MTT. 
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The antifungal compound rapamycin inhibits mTOR directly and is thereby able promote the 
induction of autophagy. By including rapamycin (1 µM) in culture medium we were able to 
ameliorate the drop in MTT reductive capacity observed during a 24 hour period of starvation 
in MDAMB231 cells (Fig 2.4). The slight increase in MTT reducing capacity seen in 
MDAMB231 cells was not detected when MCF12A cells were subjected to a similar protocol 
of amino acid starvation in the presence of rapamycin (1 µM). 
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Incubation of MDAMB231 cells with bafilomycin A1 (10 nM) for 6 hours in amino acid 
complete medium did not result in any detectable changes in caspase 3/7 activity (Fig 2.5a). 
However, the presence of bafilomycin A1 (10 nM) during amino acid starvation resulted in 
significant increases in caspase 3/7 activity in cells starved for 6 and 12 hours (Fig 2.5, b + c). 
No difference in caspase 3/7 activity was observed in MDAMB231 cells that were amino acid 
starved for 24 hours, either with or without bafilomycin (10 nM). 
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Incubation of MCF12A cells with bafilomycin A1 (10 nM) for 6 hours in amino acid 
complete medium did not result in any detectable changes in caspase 3/7 activity (Fig 2.6). 
Furthermore, the presence of bafilomycin A1 (10 nM), in amino acid free medium, did not 
result in significant increases in caspase 3/7 activity in cells starved for 6 and 12 hours either. 
However, a significant increase in caspase 3/7 activity was observed if MCF12A cells were 
amino acid starved for 24 hours in the presence of bafilomycin A1 (10 nM).  
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The trypan blue vital stain is able to traverse only those cell membranes with compromised 
integrity, and therefore functions as a marker of necrotic and late stage apoptotic cell death 
and can be used as an indicator of actual cellular impairment following an intervention. 
MDAMB231 cells excluded trypan blue dye in the presence of bafilomycin A1 (10 nM) in 
amino acid complete medium (Fig 2.7). However, MDAMB231 cells became trypan blue 
positive to significant levels after 6 hours of deprivation in amino acid free medium only if 
supplemented with bafilomycin A1 (10 nM). Bafilomycin A1 (10 nM) did not exacerbate 
trypan blue positive staining at 12 or 24 hours of amino acid deprivation. 
Stellenbosch University  http://scholar.sun.ac.za
80 
 
 
 
 
 
 
MCF12A cells excluded trypan blue dye in the presence of bafilomycin A1 (10 nM), in amino 
acid complete medium (Fig 2.8). These cells did not become trypan blue positive to 
significant levels after 6 or 12 hours of deprivation in amino acid free medium. Membrane 
integrity was not significantly compromised if medium was supplemented with bafilomycin 
A1 (10 nM). However, significantly greater numbers of trypan blue positive cells (cells with 
impaired membrane integrity) were detectable in MCF12A cells starved of amino acids for 24 
hours with bafilomycin A1 (10 nM). This indicates that the presence of bafilomycin caused 
increased membrane permeability in MCF12A cells only at 24 hours of amino acid starvation. 
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4.2 Short term amino acid deprivation causes comparatively differential 
shifts in the lysosomal acidity in MCF12A, MDAMB231 and MCF7 cells. 
 
Con
6 hr
24 hr
A. B.
C.
 
 
The use of dyes to monitor the activity of lysosomes is sometimes utilized as a measure of 
autophagy. Although controversial, they can be used in combination with other techniques as 
an indicator of autophagy flux. In the MDAMB231 cell line, with high basal autophagy, 
lysosomal acidic compartmentalization increased and peaked at 6 hours after amino acid 
starvation (Fig 2.9a). Thereafter, lysosomal acidity decreased back to baseline levels after 24 
hours. These findings were confirmed qualitatively by means of imaging with Lysotracker™ 
dye, or quantitatively with flow cytometry in conjunction with Lysotracker™. 
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In the MCF12A cell line, lysosomal acidic compartmentalization was shown to display a 
sustained increase after six hours of amino acid starvation that was maintained up to 24 hours 
thereafter (Fig 2.10). These findings were confirmed visually by means of imaging and with 
flow cytometry in conjunction with the Lysotracker™ dye. 
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In the MCF7 cell line, lysosomal acidic compartmentalization was observed to increase 
during amino acid starvation. This increase became statistically significant after 24 hours of 
amino acid starvation (Fig 2.10). These findings were confirmed visually by means of 
imaging and with flow cytometry in conjunction with the Lysotracker™ dye. 
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4.3 MDAMB231 cells have a higher basal autophagy than MCF12A cells 
and display a higher autophagic flux than MCF7 cells when starved of 
amino acids. 
 
 
 
LC3 II is the most common marker for the measurement of autophagy activity. However, LC3 
II is degraded by autophagy itself, and therefore high autophagy levels can lead to decreased 
LC3 II in some circumstances of high autophagy flux. If cells are incubated with an agent that 
impairs lysosomal acidification (such as bafilomycin A1) then the accumulation of LC3 II can 
be used to determine the true level of autophagy. Blocking autophagosome degradation in this 
way can be used to distinguish between these possibilities and assess autophagy levels by the 
„amount‟ of LC3 II protein that accumulates as a result. MDAMB231 cells have a much 
higher basal level of autophagy than corresponding MCF12A cells (Fig 2.12). However, 
whereas 24 hours of amino acid starvation lead to increased levels of LC3 II in MCF12A 
cells, a similar increase was not observed in MDAMB231 cells incubated in similar 
conditions. Furthermore, inhibition of autophagosome degradation using bafilomycin A1 (10 
nM) resulted in high autophagic flux in both cell lines during starvation, but again did not 
demonstrate a relative increase in autophagy in MDAMB231 cells compared to cells 
incubated in amino acid complete medium. 
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A.
C.
B.
 
  
Induction of autophagy generates a lipidated variant of LC3 (namely LC3 II) that is 
commonly used to gauge the level of autophagy within a cell. Amino acid starvation caused 
an increase in the protein level of LC3 II in MCF12A cells that corresponded with increasing 
time spent in amino acid deprived medium (Fig 2.13a). The autophagy protein beclin 1 is vital 
for autophagy induction, but no significant change in the protein levels of this marker were 
detected in MCF12A cells incubated in amino acid free medium. 
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MDAMB231 cells were demonstrated to have increased levels of LC3 II within the first 8 
hours of amino acid starvation (Fig 2.14a). These findings (as well as those for MCF12A 
cells) corresponded with the level of acidic compartmentalization in cells treated in a similar 
manner. LC3 II levels decreased and were no different than control levels after 24 hours of 
amino acid starvation. Beclin 1 levels did not change significantly either. 
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A.
C.
B.
 
  
MCF7 cells were demonstrated to increase levels of LC3 II within the first 6 hours of amino 
acid starvation (Fig 2.15a), similar to those observed for the MDAMB231 cell line. However, 
these findings did not correspond with levels of lysosomal acidity. LC3 II protein levels 
decreased and were no different than control levels after 24 hours of amino acid starvation. 
Beclin 1 levels were shown to decrease significantly by 24 hours of amino acid starvation. 
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Autophagy flux measurements are a good indication of autophagy levels at any given time. 
To assess autophagy flux, cells were treated and then supplemented with 10 nM of 
bafilomycin A1 6 hours prior to harvesting for analysis. Values for flux were calculated from 
LC3 II protein levels obtained from western blot analysis. LC3 II levels in the presence of 
bafilomycin were divided by LC3 II levels from cells starved for the same time period 
without bafilomycin A1 (10 nM). In this way, it was determined that autophagy flux increased 
in MDAMB231 cells from 6 to 24 hours of amino acid starvation (Fig 2.16). 
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Even though MCF7 cells are known to be autophagy haploinsufficient, amino acid starvation 
appeared to increase autophagy flux when cells were starved from 6 to 24 hours by omitting 
amino acid from the culture medium (Fig 2.17). Importantly, some measures of autophagy 
flux only take treatments with blocked autophagy into account and by that measure MCF7 
cells have decreasing autophagy flux while MDAMB231 cells still have increasing flux. 
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4.4 Autophagy is important for the maintenance of normal cell cycle 
progression during amino acid starvation in MDAMB231 cells but not in 
MCF12A cells. 
 
A.
B.
 
 
 
MCF12A cells displayed no change in cell cycle progression after 6 hours of amino acid 
starvation, either with or without bafilomycin (10 nM) (Fig 2.18). 
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Although, MCF12A cells displayed a pronounced pattern g0/g1 arrest after 12 hours of 
starvation, bafilomycin A1 did not alter cell cycle progression in response to amino acid 
starvation (Fig 2.19). 
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Bafilomycin A1 did not alter cell cycle progression in response to 24 hours of amino acid 
starvation in MCF12A cells (Fig 2.20), or MCF7 cells (data not shown). 
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As in MCF12A cells, MDAMB231 cells exhibited no obvious alterations in cell cycle 
progression after 6 hours of amino acid starvation (Fig 2.21). Interestingly, inhibition of 
autophagy with bafilomycin A1 (10 nM) resulted in a significant g2/m arrest and an 
associated decrease in s-phase. 
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Inhibition of autophagy with bafilomycin A1 (10 nM) resulted in a significant g0/g1 and g2/m 
arrest and an associated decrease in s-phase in MDAMB231 cells after 12 hours of amino acid 
starvation (Fig 2.22). 
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Inhibition of autophagy with bafilomycin A1 (10 nM) resulted in a significant g0/g1 arrest 
and an associated decrease in s-phase in MDAMB231 cells after 24 hours of amino acid 
starvation (Fig 2.23). 
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4.5 Autophagy inhibition with ATG5 siRNA during 24 hours of amino 
acid deprivation leads to increased caspase 3/7 activity in MDAMB231 cells 
and MCF12A cells  
 
 
 
 
Direct inhibition of autophagy using ATG5 siRNA resulted in increased caspase 3/7 cleavage 
in MDAMB231 cells incubated in culture medium without amino acids for 24 hours (Fig 
2.24). ATG5 siRNA did not cause increased caspase 3/7 activity if present in amino acid 
complete medium for an equivalent period of time. 
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Direct inhibition of autophagy using ATG5 siRNA resulted in increased caspase 3/7 cleavage 
in MCF12A cells incubated in culture medium without amino acids for 24 hours (Fig 2.25). 
ATG5 siRNA did not cause increased caspase 3/7 activity if present in amino acid complete 
medium for an equivalent period of time. 
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4.6 An apparent activation of an autophagy related gene occurs during 
amino acid starvation of MDAMB231 cells 
 
 
 
 
 
 
 
 
A moderate induction of ATG5 was observed in MDAMB231 cells starved of amino acids 
(Fig 2.26). Using relative quantification based on data acquired from the Real-Time PCR 
assay, a moderate induction of ATG5 was observed at 6 and 24 hours during amino acid 
starvation of MDAMB231 cells. 
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A.
B.
 
 
 
Relative quantification based on data acquired from the Real-Time PCR assay confirmed 
silencing of ATG5 through down-regulation of ATG5 expression in both MDAMB231 and 
MCF12A cells (Fig 2.27). Western blotting illustrated that protein levels of LC3 II declined 
following ATG5 silencing. This experiment serves as a validation that ATG5 expression 
levels are blunted by ATG5 siRNA in our experimental model.  
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5 Discussion 
 
Although autophagy is known to become activated in response to metabolic stress, such as 
during times of amino acid starvation, it appears as though many cancer cell lines display high 
levels of autophagy activity even in nutrient rich conditions (Yang et al., 2011). Furthermore, 
the tumour microenvironment is prone to episodes of short term nutrient depletion due to 
poorly defined vascular systems (Tredan et al., 2007). Autophagy is initiated in these 
circumstances and is believed to confer a survival advantage during nutrient depletion. 
However, it not clear how cancer cells with already high basal autophagy levels will tolerate 
short term bouts of low nutrient levels. In addition, studies investigating the effects of acute 
amino acid deprivation in the context of breast cancer with high basal autophagy are almost 
completely absent.  
 
In general, there is a paucity of research investigating nutrient starvation in cancer, 
particularly studies considering the breast cancer setting. In fact, few studies exist for any cell 
types (cancer or otherwise) where amino acids or proteins are depleted with all other nutrients 
kept constant, and studies investigating the acute depletion of nutrients (less than 24 hours) 
are almost totally missing from the literature. In addition, data from the few studies that have 
been performed are equivocal and autophagy has been shown to either protect cells or lead to 
their death depending on the context. In a rare instance, rat hepatoma cells (H4IIE) were 
starved of amino acids with or without the autophagy inhibitor bafilomycin A1 (Wang et al., 
2009), and autophagy was monitored and found to increase rapidly following starvation. Cell 
survival was maintained in an autophagy dependent manner for the first 6 hours of amino acid 
starvation in this model, and viability was rescued by bafilomycin A1 after 12 hours of 
starvation. The authors postulated that protective autophagy occurs during the acute stages of 
amino acids starvation in these cells whereas destructive autophagy occurs at later stages. 
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Amino acid starvation was also induced during short term starvation of PC-12 cells 
(Sadasivan et al., 2006). Even though autophagy was markedly increased at six hours, various 
viability assays confirmed decreased survival during amino acid starvation. Starvation in the 
presence of the autophagy inhibitor 3-methyladenine alleviated amino acid starvation 
associated cell death leading the authors to conclude that these cells were undergoing an 
autophagy cell death (type-II) response.  
 
It has recently become clear that several cancer lines are dependent on autophagy for normal 
growth, and that human cancer with mutations in H-ras or K-ras may require autophagy for 
tumour survival (Guo et al., 2011). Some pancreatic (Yang et al., 2011) and other Ras-driven 
tumours (Lock et al., 2011) have also been shown to require autophagy for sustained growth. 
This so-called autophagy-addiction that is now thought to be characteristic of some cancers 
could represent an important avenue for development of new anticancer strategies. Although 
genetic ras mutations are infrequent in breast cancer, Ras was shown to be highly and 
abnormally activated in over 50% of tested cancers in one study (von Lintig et al., 2000). This 
increased Ras activity was attributed to the over-expression of growth factor receptors in 
many of these breast cancers. It is therefore important that breast cancer with high Ras 
activity be studied in association with autophagy. 
 
Observations from previous experiments (described in chapter 1) demonstrated that the non-
tumourogenic breast epithelial cell line MCF12A showed few detrimental effects after being 
incubated in culture medium bereft of any amino acids for 24 hours. On the other hand, the 
commonly utilized metastatic breast adenocarcinoma cell line MDAMB231 showed greater 
sensitivity to amino acid exclusion from culture media and displayed a sudden increase in cell 
death and a profile of cell cycle arrest after only 12 hours of amino acid starvation. As these 
cells are known to have high ras activation and high basal autophagy levels (Ogata et al., 
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2001), and autophagy is thought to be an important factor in tolerance to nutrient deprivation, 
the aim of this study (presented in this chapter) was to investigate if autophagy is in fact an 
important survival mechanism during short term amino acid starvation in these cells.  
 
Bafilomycin A1, a specific inhibitor of vacuolar H+ATPase (V-ATPase) (Yoshimori et al., 
1991), was used in this study. Bafilomycin is now known to rapidly and reversibly inhibit 
fusion between autophagosomes and lysosomes, if administered for short time periods 
(Klionsky et al., 2008), acting through the mechanism of inhibiting lysosomal acidification 
(Yamamoto et al., 1998). This is a similar mechanism of autophagy inhibition as the clinically 
relevant choloroquine. It is clear from the data presented in this chapter that both the 
tumourogenic cancer cell line and the non-tumourogenic cell line in our model rely on a 
process inhibited by bafilomycin A1 for survival during short term amino acid starvation. 
 
Data in this chapter illustrates that autophagy activity increases significantly above basal 
levels during the first 6 hours of amino acid starvation in MDAMB231 cells. Increased 
lysosomal acidity (Fig 2.9) and high levels of the autophagy marker LC3 II (Fig 2.14) both 
signify an increased autophagy response at this time point. Indeed, MDAMB231 cells 
displayed no signs of apoptosis (Fig 2.5 & chapter 1) or membrane impairment (Fig 2.7 & 
chapter 1) after being incubated in the absence of amino acids for 6 hours. Furthermore, cells 
appeared to have normal cell cycle progression and retained the ability to reduce MTT. The 
MCF12A cell line showed similarly high lysosomal acidity (Fig 2.10) and increasing LC3 II 
levels (Fig 2.13) after 6 hours of amino acid deprivation and no signs of cell death or cell 
cycle disruption either. On the other hand, the beclin 1 haploinsufficent (partially autophagy 
deficient) MCF7 cell line presented with  indications of decreased viability compared to cells 
incubated in amino acid complete medium (Fig 2.3) that corresponded with high levels of 
lysosomal acidity (Fig 2.11), despite having high levels of LC3 II after 6 hours of amino acid 
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starvation (Fig 2.15).  Inhibition of autophagy with 10 nM of bafilomycin A1 was able to 
reverse tolerance to amino acid deprivation at 6 hours in MDAMB231 cells. When 
bafilomycin was present in the culture medium, these cells underwent increased apoptosis 
(Fig 2.5) and had signs of increased membrane permeability (Fig 2.7). Furthermore, if 
autophagy was inhibited, amino acid starved MDAMB231 cells presented with a significantly 
decreased s-phase and appearance of a profile of g2/m cell cycle arrest (Fig 2.21). 
Interestingly, although MCF12A cells showed a decreased MTT reducing capacity (Fig 2.1) 
with bafilomycin, they did not display any increased caspase 3/7 cleavage (Fig 2.5) or 
significantly increased membrane permeability (Fig 2.8) in response to acute amino acid 
starvation. Tellingly, these cells also did not show changes in their cell cycle parameters if 
bafilomycin was present during 6 hours of amino acid starvation (Fig 2.18). As expected, 
bafilomycin also had no influence on the MCF7 cells (Fig 2.3). Together, these results 
indicate that increased autophagy activity in MDAMB231 cells after only 6 hours of amino 
acid deprivation seems to be protective and vital for tolerance to stress during these first few 
hours of amino acid depletion. Although MCF12A cells are not completely unchanged by 6 
hours of amino acid depletion, they do not experience any serious negative effects due to 
starvation, even if autophagy is inhibited with bafilomycin. Presumably this is because they 
are much slower growing and do not require access to as high concentrations of amino acids 
as the more aggressive adenocarcinoma cell line. This is further illustrated by assessment of 
the cell cycle parameters during the first 12 hours of amino acid starvation. Importantly, 
results indicate that autophagy is vital for normal cell cycle progression in MDAMB231 cells, 
but not MCF12A cells. This is a good indicator that nutrient levels have fallen too low to 
support typical growth and cellular functioning in the faster growing cancer cells. 
 
MDAMB231 cells have an existing high basal autophagy activity, even in nutrient rich 
conditions (Fig 2.12). Still, they are unable to tolerate amino acid depletion for more than a 
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few hours in our model. This is evidenced by increased cell death after only 12 hours of 
amino acid depletion (Fig 2.5c). Nonetheless, these cells do respond to acute amino acid 
starvation by increasing their autophagy activity, which appears to aid them in tolerating 
amino acid deprivation for the initial 6 hours in our model. However, without autophagy, 
MDAMB231 cells are unable to maintain survival for even a few short hours. Importantly, the 
presence of a high basal autophagy activity in MDAMB231 cells, even in nutrient rich 
conditions, could signify that they require autophagy for normal functioning. The fact that the 
addition of bafilomycin to normal (amino acid complete) medium did not decrease cell 
viability indicates that these cells are able to survive during 6 hours without autophagy, 
provided that sufficient nutrients are available. Efficient and pronounced down regulation of 
ATG5 in MDAMB231 cells and MCF12A cells (Fig 2.27) resulted in a statistically 
significant increase in caspase 3/7 activity during 24 hours of amino acid starvation in both 
cell lines (Fig 2.24 and Fig 2.25). This serves to illustrate that down-regulation of autophagy 
prior to the protective increase in autophagy at 6 hours amino acid starvation in MDAMB231 
cells leads to an increase in activation of programmed cell death pathways. 
 
The expression of the autophagy marker LC3 II clearly increased to a peak at 6 and 8 hours in 
MDAMB231 cells (Fig 2.14a). However, despite relatively decreased LC3 II levels at 12 and 
24 hours of amino acid starvation, autophagy flux was higher than at 6 hours (Fig 2.16) and 
corresponded to levels of baseline flux (Fig 2.12b). LC3 II protein levels are known to 
decrease during high autophagy flux due to its increased degradation following lysosomal 
fusion (Mizushima et al., 2010). In our model, the status of autophagy flux corresponded 
inversely to the level of lysosomal acidity in MDAMB231 cells (Fig 2.9a). It is plausible that 
higher autophagy flux results in increased lysosomal turnover and therefore a decreased level 
of acidity in MDAMB231 cells. Notably, this phenomenon was observed to occur conversely 
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for MCF12A cells, which displayed high autophagy flux levels in association with increased 
cellular acidity.  
 
It is clear that a surging autophagy response occurs at 6 hours in the MDAMB231 cells, and 
that this amplification of autophagy is necessary for the maintenance of cell survival during 
this period. Results indicate that protective autophagy is lost after 6 hours and that by 24 
hours of amino acid starvation autophagy is playing little or no role in the maintenance of 
survival, even though autophagy flux, lysosomal acidity and LC3 II protein levels are high 
(but equivalent to levels at baseline). At this point, a sudden increase in cell death and a 
profile of cell cycle arrest after only 12 hours of amino acid starvation becomes apparent. 
MCF12A cells remained remarkably tolerant to amino acid deprivation. However, after 24 
hours of starvation, MCF12A cells also had significantly increased levels of autophagy. This 
is inferred from the high autophagy flux (2.12a) and significantly increased LC3 II protein 
levels (2.13). Furthermore, lysosomal acidity was also significantly elevated in these cells at 
this point. Importantly, if autophagy was then inhibited with bafilomycin A1, these cells 
began to display indications of increased cell death (Fig 2.6) and membrane permeability (Fig 
2.8). These results are in accordance with the hypothesis that increases in autophagy are 
protective due to the enhanced generation of amino acids through lysosomal degradation. 
Importantly, as these cells are slower growing (and presumably require access to lower amino 
acid concentrations than the MDAMB231 cells) they only begin to possess an enhanced 
autophagy response at a later point of starvation (24 hours in our model). 
 
Notably, bafilomycin was added only 6 hours prior to analysis of various parameters. 
Therefore, while bafilomycin was present during the entire period of starvation for the 6 hour 
amino acid deprivation experiments, it was only administered at hour 18 for the 24 hour 
amino acid deprivation experiments. This factor is important in interpreting results in light of 
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the fact that MDAMB231 cells display a protective surge at around six hours of starvation. 
Therefore, if autophagy is inhibited during this period, then its protective effect would not be 
realised. Conversely, if autophagy is blocked after this 6 hour protective surge (such as at 
hour 18 during the 24 hour amino acid starvation experiments) then the substrates generated 
at 6 hours would presumably elicit a protective effect during the later stages of amino acid 
deprivation. 
 
LC3 II protein levels, and not autophagy flux, appear to be a more reliable indicator of the 
ability of MDAMB231 cells (with high basal autophagy) to withstand amino acid deprivation 
through autophagy. Despite a clear increase in autophagy flux of the MCF7 cell line, 
lysosomal acidity was not significantly higher until 24 hours of amino acid starvation. 
Therefore, caution should be taken when utilizing lysosomal acidity or autophagy flux 
measurements independently of other markers of autophagy to assess survival in response to 
nutrient deprivation. Also, high basal autophagy in MDAMB231 cells does not support 
survival in the face of amino acid deprivation. In fact is seems reasonable to postulate that it 
may be due to resident high autophagy activity (and constant turnover of intracellular 
material) that these cells require greater access to free amino acids. 
 
Additionally, it is conceivable that reliance on high basal autophagy necessitates that 
MDAMB231 cells cannot increase autophagy levels further for too long periods during 
metabolic stress. It is possible that a feedback mechanism prevents overstimulation of this 
process as a safeguard. This notion is supported by evidence that the autophagy promoter 
rapamycin was able to partly rescue MTT reductive capacity during 24 hours of amino acid 
depletion (Fig 2.4). These results indicate that MDAMB231 cells are still capable of 
increasing autophagy at this time point of amino acid starvation in spite of their apparent 
failure to effectively (and protectively) do so in the absence of rapamycin. This implies that 
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these cells will only be able to withstand shorter periods of stress in the abscence of 
intervention, such as that sometimes associated with the intermittent nutrient supply in cancer 
tumours. In order to investigate this possibility, expression levels of the autophagy related 
gene ATG5 were analysed (Fig 2.26). This experiment demonstrated that MDAMB231 cells 
appear to initiate autophagy in response to starvation, even at 24 hours of amino acid 
depletion. Whether autophagy activation is prevented in some other manner is unknown. The 
fact that MDAMB231 breast cancer cells are so reliant on autophagy in the way described in 
this chapter presents an interesting and novel anticancer strategy that requires further 
exploration. The recent desire to employ fasting regimes in patients receiving anticancer 
treatment (Raffaghello et al., 2010, Safdie et al., 2009, Lee and Longo, 2011) has presented a 
need for continued investigation of the effects of acute nutrient deprivation in cancer cells. 
 
5.1 Conclusions 
 
It is clear that autophagy is an important mechanism for short term tolerance to nutrient 
deprivation in MCF12A and MDAMB231 cells. However, probably due to an already high 
basal level of autophagy activity, MDAMB231 cells are unable to sustain this protection for 
more than a few hours. On the other hand, MCF12A cells remain protected by increasing 
autophagy levels. Despite indications that MCF7 cells do respond to amino acid starvation by 
increasing autophagy activity, there is no indication that this is protective in these cells. 
Autophagy is typically assessed after only at least 24 hours in many studies. If this had been 
the case in this study then conclusions would have differed and it would have been inferred 
that autophagy is protective in MCF12A cells, but that high autophagy flux levels of 
MDAMB231 cells are unable to save these cells from negative impact of nutrient deprivation. 
This indicates the importance of dynamic assessment of autophagy, something clearly lacking 
in most published findings. 
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This study provides important and original insights into how a breast cancer cell line with 
high basal autophagy is able to respond to an acute bout of nutrient deprivation. However, no 
mechanistic support is provided for how autophagy is accomplishing this protective feat. It is 
often assumed that by generating substrates from the degradation of cytoplasmic material, 
autophagy is able to buffer any losses owing to the unavailability of (or inaccessibility to) 
nutrients. However, support for this idea has only rarely been offered. Our model provides an 
opportunity to assess this hypothesis. As only amino acids have been eliminated from the cell 
medium (and thereby forcing limited cellular access) in our model, assessment of the amino 
acid content and the consequences to energy production during amino acid starvation would 
provide great insight into the mechanism whereby autophagy is able to aid in survival during 
a starvation event. 
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Autophagy is essential for the maintenance of amino acids 
and ATP levels during acute amino acid starvation in 
MDAMB231 and MCF12A cells 
 
Tumour cells are able to survive in a harsh microenvironment that is 
associated with aberrant nutrient supply. Autophagy has been frequently 
implicated as a potential survival mechanism in these tumours, based on the 
premise that the degradation products released following autophagy-
mediated breakdown of cytoplasmic material can be utilized for protein 
synthesis or as substrates for ATP production. Unfortunately, there is little 
direct evidence to support this hypothesis in cancer cells. This chapter 
presents evidence that the autophagy inhibitor bafilomycin A1 reduces 
amino acid content and ATP levels during short term amino acid starvation, 
and implicates autophagy related processes in the generation of amino acids 
and fatty acids during short term starvation of a tumourogenic cancer cell 
line with high basal autophagy. 
 
1 Introduction 
 
All cells within the body require constant access to nutrients and a means for the steady 
removal of waste. These two requirements are assured due to the close cellular proximity of 
an intricate network of blood vessels and capillaries. Solid tumours are heterogeneous and 
structurally complex, and in contrast to non-tumour tissues the neoplastic stroma is associated 
with an altered extracellular matrix and an increased number of fibroblasts that produce 
growth factors, adhesion molecules and chemokines necessary for tumour development and 
progression (Aznavoorian et al., 1990). As a solid tumour grows, some of the cells within the 
mass will inevitably become physically separated from the host tissue's native vascular 
stroma, and nutrient and oxygen delivery to those cells located farthest away become 
diffusion limited (Kerbel, 2000). Tumours must therefore rely on existing vasculature for the 
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supply of nutrients in order to survive or they must contrive to generate new blood vessels to 
facilitate their continued growth. The concept that a growing mass of tumour cells must 
recruit its own blood supply for the preservation of oxygen and other nutrient levels, called 
angiogenesis, became accepted in the 1970s (Folkman, 1971). It has since been discovered 
that tumour cells send out signals that initiate the formation of new vessels in an adaptive 
process of neoangiogenesis, which is amplified within solid tumours. 
 
1.2 Tumour angiogenesis 
 
VEGF-A is expressed in most cells under basal conditions, but as a survival cytokine in 
cancer it attracts sprouting neovessels into hypoxic regions of the tumour mass throughout the 
life of the neoplasm (Forsythe et al., 1996). The expression of VEGF relies on the fact that 
fast growing, hypovascular tumours rapidly develop local regions of hypoxia. These low 
oxygen levels result in the stabilization and activation of the hypoxic inducible factor HIF-1 
which is followed by its translocation to the nucleus where it can bind to the vegf promoter 
and lead to expression of VEGF-A (Pouyssegur et al., 2006). Angiopoietin-2 (Ang-2) is a 
receptor ligand that is limited to endothelial cells and allows vessel remodelling (Hegen et al., 
2004), and its expression is also under hypoxic control in solid tumours (Gu et al., 2006). The 
co-expression of VEGF and Ang-2 destabilizes capillaries and allows them to move out of 
their dormant state. This then initiates sprouting angiogenesis from native vessels into the 
hypoxic regions of tumours (Pouyssegur et al., 2006). In this way, hypoxia in solid tumour 
regions can directly lead to increased angiogenesis and improved access to blood. 
 
Despite neoangiogenesis, fast growing tumours quickly develop microenvironments that are 
nutrient limited. Tumours that outstrip the capacity for neovascularisation consequently 
become hypoxic and develop characteristic nutrient starved areas. Furthermore, new tumour 
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vessels show structural malformations that produce transient episodes of chaotic blood flow 
and local regions of ischemia (Tredan et al., 2007). The rapid development of new vasculature 
can leave these vessels unable to sufficiently and continuously provide needed nutrients. Also, 
the high demand of such metabolically active cells such as those within tumours could surpass 
the supply capacity of these new vessels.  Hence, tumour cells must necessarily possess or 
attain some other method of survival during these times of nutrient depression. Indeed, 
cultured cancer cells display increased levels of survival during short (48 hours) periods of 
nutrient starvation compared to non-cancer control cells of similar origin (Izuishi et al., 2000). 
In order to understand or exploit this capability for survival, researchers must appreciate how 
these cells are able to utilize various substrates during energy metabolism. 
 
 
Adapted from Brown (2000)  
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1.3 Tumour metabolism 
 
As glucose has a greater diffusion limit than that of oxygen, and many tumour cells reside in 
hypoxic microenvironments (Vaupel et al., 1989), some cancer cells must use non-oxidative 
metabolic pathways to convert sugars into energy. Glycolysis is normally inhibited in the 
presence of oxygen, allowing mitochondria to continue with pyruvate oxidation. This so-
called Pasteur effect ensures that the more efficient oxidative phosphorylation is utilized, 
generating eighteen times more ATP per mole of glucose in the process (Racker, 1974). 
However, Otto Warburg was the first to argue that the tumour cells (subjected to his analysis) 
used aerobic glycolysis with reduced mitochondrial oxidative phosphorylation for glucose 
metabolism (Warburg, 1956). He then went on to postulate (incorrectly) that cancer was a 
consequence of defects in oxidative phosphorylation in mitochondria that forced cancer cells 
to revert to glycolysis as the predominant form of energy generation. We now know that 
cancer is a result of key genetic mutations or defects occurring in proto-oncogenes or tumour 
suppressors, but even though the Warburg hypothesis has proved to be incorrect, Warburg‟s 
observation that cancers display increased aerobic glycolysis had been repeatedly verified. In 
fact, this phenomenon is used clinically in the technique of Positron-emission tomography 
imaging with 18fluorodeoxyglucose (18F-FdG PET) where a fluorodeoxyglucose (FdG) 
tracer (a glucose analogue) becomes trapped and phosphorylated by hexokinases.  The 
resultant radiolabelling is used to facilitate in the location of tissues with high rates of glucose 
uptake, in order to identify possible cancers (Pauwels et al., 2000). Various genetic and 
biochemical origins of enhanced glycolytic flux in tumour cells have now been identified 
(Hsu and Sabatini, 2008), and is now appreciated to be a bona fide hallmark of cancer 
(Hanahan and Weinberg, 2011). However, it is now believed that oxidizable substrates do in 
fact contribute significantly to ATP generation in many cancer cell types, in spite of high 
glycolysis rates. 
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The assumption of negligible oxidative phosphorylation in cancers now seems to be a tenuous 
one, and the perception that cancer cells largely utilize aerobic glycolysis for fuel equivocal. 
For example, mass balance analysis has revealed that HeLa (Reitzer et al., 1979, Rodriguez-
Enriquez et al., 2006) and MCF7 (Guppy et al., 2002) human tumour cell lines both utilize 
oxidative and non-oxidative metabolism for ATP generation, while in other breast and lung 
cancers oxidative phosphorylation can be the predominant mode of energy metabolism 
(Kallinowski et al., 1989). In fact, it seems that despite extremely high rates of glycolysis in 
fast growing tumours, the contribution of glucose to ATP generation is measured at only 
approximately 10% in some instances (Zu and Guppy, 2004). Current conjecture is that the 
distinct microenvironment produced by high levels of glycolysis might grant a survival 
advantage to cancer cells, while at the same time not necessarily being the chief source for the 
generation of energetic intermediates as previously assumed (Gillies et al., 2008, Semenza, 
2008). These recent clarifications are important in the context of autophagy research as 
oxidative phosphorylation is the principal method by which lysosomal breakdown products 
can be converted to ATP. 
  
1.4 Metabolic fate of autophagy degradation products 
 
There is a well known incongruity between cell growth and the rate of proliferation in solid 
tumours. Data from in vitro studies and analysis of cell cycle parameters in vivo reveal that 
typical tumour cells possess the capacity for extremely rapid proliferation rates (Friberg and 
Mattson, 1997). However, the time it takes for tumours to double in size is relatively 
protracted, in the order of months or even years in some cases (Rew and Wilson, 2000). It is 
possible that the sacrificing of cell contents or even whole cells by means of autophagy in 
order to utilize the constituents for continued tumour growth and survival could be occurring. 
During starvation, the organism is able to sustain itself for rather long periods through contact 
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with many different tissues that are able to sacrifice large quantities of carbohydrates, fats and 
even proteins for energy (Finn and Dice, 2006). However, those cells subjected to ischemic 
conditions or those that have impaired nutrient availability (such as cancer cells) will have 
little or no contact with the systemic nutrient pool. Blood vessels and capillaries serve as 
conduits to supply valuable nutrients, but are diffusion limited to only a few micrometers. 
During these conditions of decreased nutrient supply cells must therefore rely solely on their 
own intracellular environment (and possibly that of their close neighbours) for energy 
substrates. 
 
Experimental evidence suggests that tumour cells exist under hypoxic conditions at a distance 
of about 100 – 400 μm from blood vessels, implying that hypoxic regions are commonly 
established in tumours of only approximately 0.5 mm in diameter (Brown, 2000). 
Interestingly, increased autophagy is prominent in poorly vascularised regions of tumours but 
not those regions that have adequate access to the host blood supply (Karantza-Wadsworth et 
al., 2007), a phenomenon strongly associated with oxygen levels. Autophagy as a response to 
nutrient deficiency could be essential for survival of some cancers in these cases (Degenhardt 
et al., 2006). 
 
It seems widely accepted that, in times of need, mammalian cells survive starvation by 
utilizing the break-down products of autophagy degradation as energy sources and for 
synthesis of survival proteins, and that in this way autophagy acts as a provider that 
replenishes the cellular amino acid pool during stressful times (Kuma and Mizushima, 2010, 
Mizushima, 2007). However, little direct evidence exists to support these claims. On the other 
hand, maintenance of amino acid levels has been demonstrated to be autophagy-dependent 
during starvation (Kuma et al., 2004), and autophagy is also known to be induced in response 
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to decreases in ATP or amino acids and increased by hypoxia acting through mTOR, and 
AMPK.  
 
1.4.1 Autophagy and gluconeogenesis 
 
Global starvation will result in rapid depletion of carbohydrate provisions. It has been 
suggested that gluconeogenesis in the liver could be fuelled by lysosomal breakdown 
products, perhaps by utilizing the glucose-alanine cycle (Kuma and Mizushima, 2010). In the 
liver, selected amino acids are able to be converted into glucose or fatty acids by 
gluconeogenesis or ketogenesis respectively, but before amino acids can be used for this 
purpose they must have their amine group removed. The presence of increased lysosomal 
degradation products leads to activation of aminotransferases and the subsequent deamination 
of the amino acids. Following deamination, the resulting keto acids are thought to be used for 
energy through gluconeogenesis. Although there is little evidence to suggest this claim as yet, 
alanine liberated through autophagy could be converted into glucose in this way. Compelling 
recent data showing that blood glucose levels are lower during starvation when an autophagy 
inhibitor is present adds strength to this idea (Kanamori et al., 2009). In addition, starvation 
leads to the largest protein loss in the liver (Yin et al., 2008), and up to 40% of liver protein 
can be lost in rodent livers after 48 hours of starvation. This protein loss appears to be sourced 
mostly from cytosolic material, and cellular volume can decrease by as much as 25% after 24 
hours of starvation as a result (Mortimore and Poso, 1987). Deletion of liver specific ATG7 in 
mice leads to increased serum alanine aminotransferase and aspartate aminotransferase 
(Komatsu et al., 2005), and glycogen degradation is facilitated by autophagy during starvation 
in the muscle and liver (Kotoulas et al., 2006). Together, these findings indicate that increased 
autophagy in this organ is important for amino acid balance and homeostasis. 
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1.4.2 Autophagy and the contribution of TCA cycle intermediates 
 
Maintenance of the amino acid pool during extremely short term starvation is managed by the 
proteasome (Vabulas and Hartl, 2005), but during starvation that persists into a few hours, 
autophagy becomes the predominant amino acids supplier. Amino acids resulting from 
autophagosomal-lysosomal degradation are often cited as potential substrates for metabolism 
through the TCA cycle and eventual production of energy. Certainly, the catabolism of amino 
acids can be used to form gluconoegenic and ketogenic precursors (Owen et al., 2002). These 
can then be used in anaplerotic and cataplerotic pathways to be terminally oxidized in the 
mitochondria for use in the production of energetic intermediates. During aerobic respiration, 
energy is garnered following degradation of glucose, fatty acids and certain amino acids in the 
mitochondria in pathways associated with the TCA cycle. Here, oxidation of the acetyl group 
of acetyl coenzyme A to carbon dioxide is coupled to the reduction of electron transporting 
coenzymes. Electrons transferred from these coenzymes to oxygen through the electron 
transport chain yield energy in the form of ATP (Da Poian, 2010). Although amino acids are 
not considered a good fuel source, certain amino acids can be used to generate energy in this 
way. 
 
In order to be used for this purpose, amino acids must be catabolised by having their nitrogen 
groups removed to form their ketogenic precursors. This is accomplished by one of two 
enzymatically catalyzed processes, namely deamination and transamination. In 
transamination, amino groups are transferred to α-ketoacids by aminotransferases, while in 
deamination the amino group is lost as ammonia (Da Poian, 2010). Proteolysis and amino 
acid catabolism result in ketogenic amino acids that can be used as intermediates at various 
points in the TCA cycle directly or following conversion to pyruvate or acetyl-CoA (Image 
3.2). 
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The branched-chain amino acids in particular can be catabolised in tissues besides the liver, 
and, following deamination, their keto acids can enter the TCA cycle at various points to 
generate reducing equivalents and produce ATP through oxidative phosphorylation (Image 
3.2). In fact, there is some evidence to support the hypothesis that substrates generated by 
autophagy help to maintain the ATP steady state. The fact that the activity of the 
aminotransferase enzyme branched-chain α-ketoacid dehydrogenase is up-regulated in 
starvation is also strong evidence that autophagy is contributing to the generation of ATP by 
increasing the cellular generation of branched chain amino acids to be used for fuel (Harris et 
al., 1989). 
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Although ATP levels are rarely measured in the context of autophagy some studies have 
provided evidence that ATP is generated intracellularly in an autophagy dependent manner. 
For instance, it was demonstrated that signs of low ATP levels in ES cells lacking autophagic 
ability could be reversed by methylpyruvate, a membrane-permeable derivative of pyruvate 
that serves as a substrate for the TCA cycle (Qu et al., 2007). It was also shown that 
supplementation with methylpyruvate could rescue an autophagy-deficient variant of an IL-3 
dependent cell line from metabolic stress-induced cell death (Lum et al., 2005). Furthermore, 
starved mice present with increased autophagy and decreased myocardial ATP (Kanamori et 
al., 2009). Inclusion of the autophagy inhibitor bafilomycin A1 lead to a further decrease in 
ATP content as well as a decrease in amino acid content and cardiac function in these 
animals. Other inhibitors of autophagy have also been shown to reduce ATP content in 
glucose starved rat cardiomyoctes (Matsui et al., 2007), while the autophagy inducer 
rapamycin has been shown to attenuate this reduction (Maruyama et al., 2008). Additionally, 
shorter periods of glucose deprivation of cardiomyocytes show similar reductions in ATP in 
the presence of autophagy inhibition (Han et al., 2011). Despite a lack of data, it appears that 
cancer cells may also be able to generate ATP in a similar manner (Katayama et al., 2007, 
Cheng et al., 2010).  
 
Indirect indications of the importance of autophagy breakdown products to energy 
maintenance can also be found upon assessment of signals controlling autophagy. Increased 
autophagy due to mTOR inhibition (Brugarolas et al., 2004) and increasing AMP/ATP ratios 
(Inoki et al., 2003) is observed during hypoxia. Sensing of intracellular ATP levels is 
accomplished through the activation of AMP-activated protein kinase (AMPK). Conditions of 
hypoxia, ischemia and exercise as well as other situations that decrease circulating amino acid 
or glucose levels lead to the activation of AMPK through escalating cellular AMP and 
phosphorylation of the catalytic subunit (Tokunaga et al., 2004). AMPK activation due to low 
Stellenbosch University  http://scholar.sun.ac.za
125 
 
energy levels up-regulates catabolic processes and decreases unnecessary energy consuming 
processes (Hardie, 2007). AMPK activation owing to withdrawal of nutrients or decreases in 
oxygen levels is involved in the activation of autophagy (Liang et al., 2007). Therefore, 
AMPK promotion of autophagy occurs most likely in an effort to maintain cellular ATP 
levels. 
 
An overlooked role of autophagy is in the regulation of lipid metabolism. Autophagy 
inhibition in the liver results in increased triglyceride storage in the form of lipid droplets 
(Komatsu et al., 2005), and it is believed that macrolipophagy may be responsible for 
autophagy mediated degradation of these lipid droplets (Singh et al., 2009). During starvation, 
this form of triglyceride storage is decreased upon autophagy inhibition (Shibata et al., 2009), 
and evidence now indicates that autophagy regulation during nutrient deprivation is 
associated with hydrolysis of triglycerides to generate free fatty acids for β-oxidation (Singh 
et al., 2009). 
 
Collectively, the lysosomal mediated decomposition of organelle membranes, lipids and 
proteins, in response to metabolic stress in harsh tumour microenvironments, yields fatty 
acids and amino acids that could potentially be oxidized in the electron transport chain for 
ATP production (Image 3.3). 
 
1.5 Autophagy and protein synthesis 
 
Proteins recycled during autophagy are released from lysosomes as amino acids and are then 
available to immediately enter back into the ribosomal system to form new proteins. Although 
protein synthesis is energetically expensive, certain proteins are important during the stress 
response and must therefore be synthesised anyway. Synthesis of some proteins does 
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continue, but in cells with deficient autophagy machinery, protein synthesis is decreased 
further than in autophagy competent controls (Onodera and Ohsumi, 2005), while the 
synthesis of important starvation-induced proteins is also decreased in these autophagy 
mutants (Tsukada and Ohsumi, 1993). Additional compelling evidence that autophagy 
supports protein synthesis in post-fertilization development, was recently obtained from an 
oocyte-specific autophagy deficient mouse model (Tsukamoto et al., 2008). 
 
 
 
 
 
 
 
 
1.6 Role of autophagy in cancer energy homeostasis 
 
Prolonged cellular stress typically initiates programmed cell death, but cancer cells have been 
consistently shown to have defects in their apoptotic pathway intermediates that are thought 
to aid in tumour survival and metastasis (Nelson et al., 2004). In the absence of apoptosis, 
cells have the ability to divert to alternate cell death modes such as necrosis (Zong and 
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Thompson, 2006). However, autophagy induction has been repeatedly shown to have 
cytoprotective effects in cancer cells undergoing metabolic stress. In cells with defective 
apoptosis, activation of autophagy is implicated as a survival mechanism that also prevents 
the onset of necrotic cellular morphology (Karantza-Wadsworth et al., 2007, Mathew et al., 
2007b), whereas cells defective in both autophagy and apoptosis inevitably undergo necrosis 
in response to surmounting metabolic stress conditions (Degenhardt et al., 2006). Also, if 
metabolic stress is eventually alleviated, and autophagy levels again depressed, normal 
cellular growth and activity is promptly restored (Mathew et al., 2007a). Therefore, in cells 
undergoing stress with no means of committing to controlled cell death (such as cancer cells) 
autophagy may be a mechanism for temporary asylum from their demise. Autophagy may 
also be partly responsible for a reversible state of dormancy following a metabolic stress in 
cancer cells (Lu et al., 2008). 
 
How autophagy protects cancer cells from becoming necrotic is not precisely known. As 
inadequate energy reserves result in the loss of cellular membrane integrity and eventual cell 
permeability and death (Zong and Thompson, 2006), it seems likely that many cancers are 
able to produce substrates through increased autophagy in order to maintain ATP levels (Lum 
et al., 2005, Katayama et al., 2007, Degenhardt and White, 2006) and this could ameliorate 
metabolic stresses and delay cell death. In support of this idea, in a colorectal cancer cell line 
that displayed decreased ATP levels when incubated under hypoxia, compared to untreated 
normoxic cells, ATP levels were almost completely abolished if autophagy was inhibited 
(Frezza et al., 2011). This decrease in ATP corresponded with a similar decrease in cell 
viability following autophagy inhibition. More studies such as this are needed if the direct 
impact of autophagy on energy generation and cellular survival during metabolic stress is to 
be understood.  
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2 Hypothesis and experimental aims 
 
2.1 Research problem 
 
Throughout the literature autophagy is implicated as a survival mechanism whereby cancer 
cells are able to overcome metabolically stressful conditions and avoid cell death though its 
activation. It is presumed that autophagy mediated consumption of cellular material within 
cancer cells increases the availability of amino acids for use in protein synthesis and in ATP 
generation. Currently, data for direct measurements of amino acids in nutrient starved cancer 
cells are completely absent. Furthermore, direct assessment of ATP levels are almost never 
published, particularly in association with cancer studies. Therefore assessment of amino acid 
levels during short term starvation and correlation with ATP levels under these conditions is a 
vital next step if therapeutic interventions are to be designed on the basis that autophagy 
increases survival through generation of substrates for energy production. 
 
2.2 Hypothesis 
 
MDAMB231 cells are able to maintain amino acid levels during short term amino acid 
starvation through a mechanism that can be inhibited by bafilomycin A1 (10 nM). 
 
2.3 Experimental aims 
 
 
1. Assess the capacity of MDAMB231 cells and MCF12A cells to maintain amino acid 
levels during short term amino acid starvation by quantifying amino acid content 
during amino acid deprivation in the presence and absence of bafilomycin A1 (10 
nM). 
2. Assess ATP levels during similar conditions. 
Stellenbosch University  http://scholar.sun.ac.za
129 
 
3. Analyse glucose consumption during amino acid starvation in order to assess whether 
glucose uptake is altered. 
4. Assess the branched chain amino acid content within both cell lines during amino acid 
deprivation in the presence and absence of bafilomycin A1 (10 nM). 
5. Use BCKDH siRNA in conjunction with ATG5 siRNA to assess the accumulation of 
branched chain amino acids during starvation. 
6. Analyse the free fatty acid content of MDAMB231 cells during short term amino acid 
starvation. 
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3 Methods and materials 
The materials and methods describing the cell culture procedures utilized in this study can be 
found in previous chapters. (+)-Etomoxir sodium salt hydrate (E1905; Sigma Chemical Co., 
St Louis, MO, USA) was prepared fresh in culture medium immediately prior to 
administration. 
3.1 Study design 
 
 
0 - 24 hour amino acid depletion
10 nM bafilomycin A1
+
Amino acid quantification (MS)
MDAMB231 cells MCF12A cells
Branched chain amino acids
1.
Glucose uptake
2-deoxy-D-2[H] 
glucose uptake
2.
ATP quantification
10 nM bafilomycin A1/ ATG5 siRNA
+
Amino acid quantification (MS)
ATP quantification
10 nM bafilomycin A1/ ATG5 & BCKDH siRNA
+
3.
Free fatty acids4.
Fatty acid quantification (GLC)
ATP quantification
10 nM bafilomycin A1/ ATG5 siRNA
+
MDAMB231 cells
+ Etomoxir (200 µM)
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3.2 Determination of 2-deoxy-D-2[H] glucose uptake 
 
 
 
100 000 MCF12A cells or 80 000 MDAMB231 cells were plated into 60 mm culture dishes 
48 hours prior to treatment. 2DG uptake was measured as previously described (Donthi et al., 
2000). Cells were cultured to reach ~70% confluency prior to amino acid deprivation. Cells 
were then washed twice with an equilibrating solution which contained in mM: KCl 6, 
Na2HPO4 1, NaH2PO4 0.2,  MgSO4 1.4, NaCl 128, HEPES 10, CaCl2 1.25 and 2% free fatty 
acid BSA. Cells were then deprived of all substrates present in the culture medium for 1 hour, 
by incubation at 37˚C in a humidified atmosphere in 2 ml of this solution. After 1 hour the 
cells were incubated with 1.5 µCi/ml 2DG (PerkinElmer, Boston, USA) in a final 
concentration of 1.8 µM deoxyglucose for 30 minutes. The solution containing the 2DG was 
then aspirated. Cells were washed twice with a basic buffer that contained in mM: KCl 6, 51 
Na2HPO4 1, MgSO4 1.4, NaH2PO4 0.2, NaCl 128 and HEPES 10. Cells were lysed with 250 
µl of 1 M NaOH overnight at room temperature. The following day the cell lysates were 
vortexed and diluted in 250 µl dH2O to yield a concentration of 0.5 M NaOH.  To determine 
the cell-associated radioactivity, 100 µl of the cell lysates was mixed with 3 ml scintillation 
fluid and left in the dark for 2 hours. All measurements were prepared in duplicate. A liquid 
scintillation counter (Beckman Coulter Inc., USA) was used for counting radioactivity.  The 
remaining 200 µl of the cell lysates was used for determination of protein content with the use 
of the Lowry method (Lowry et al., 1951). 
 
 
 
 
Stellenbosch University  http://scholar.sun.ac.za
132 
 
3.3 Amino acid analysis 
 
Amino acid analysis was performed using the Waters AccQ Tag Ultra Derivatization Kit. 
100 000 MCF12A cells or 80 000 MDAMB231 cells were plated into 60 mm culture dishes 
48 hours prior to treatment. Cells were washed twice in room temperature PBS. Cells were 
then scraped in 500 µl of PBS and transferred to centrifugal filter units (Amicon Ultra; 
Millipore, MA, USA). Tubes were centrifuged for 15 min at 1400 rpm to obtain a filtrate. 
Samples were analysed at the Mass Spec lab (Department of Biochemistry, Stellenbosch) for 
amino acid quantification using the Waters API Quattro Micro. Mass Spec conditions were as 
follows: Capillary voltage:  3.5kV, Cone voltage: 1V, Source: 100 ºC, Desolvation Temp: 350 
ºC, Desolvation gas:  350 L/h, Cone gas: 50 L/h. The analysis was carried out by MS analyst 
M. Adonis. 
 
3.3.1 Sample preparation 
10 µl of the undiluted sample was added to the Waters AccQ Tag Kit constituents and placed 
in a heating block at a temperature of 55°C, for ten minutes. 
 
EZ:Faast derivatization and solid phase extraction 
EZ:Faast consists of a solid phase extraction step followed by a derivatization step and a 
liquid-liquid extraction step to get rid of interfering compounds in the matrix. In the solid 
phase extraction step the samples are pulled through a sorbent tip that binds the amino acids 
while the remaining interfering compounds flow through. The amino acids are then extruded 
and derivatized, allowing them to migrate to the organic layer, which is removed, dried, re-
dissolved and subject to LCMS analysis. In addition a stable daughter ion is formed that 
makes LCMSMS analysis possible. 
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Standards: 
Labelled Homoarginine, Methionine-D3 and homophenylalanine were included as internal 
standards, part of the EZ:Faast kit. EZ:Faast LC method (with EZ:Faast column): The method 
was used as described in the EZ:Faast user‟s guide. Injection: 5 μl. Source: ESI +. Solvents 
A1 and A2: Eluent A2 (100 ml Eluent A concentrate and 900 ml Water). Solvents B1 and B2: 
Eluent B (Supplied by AccQ Tag Kit). Column: AccQ Tag C18, 1.7um, 2.1x100 mm. 
 
 
 
Image 3.5 Print Screen of amino acid analysis.  Solvent A: 10 mM ammonium formate in 
water  
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3.4 ATP analysis 
 
ATP levels were determined using the ATP Bioluminescence detection kit (ENLITEN®, 
Promega, Madison, WI, USA). 100 000 MCF12A cells or 80 000 MDAMB231 cells were 
plated into 60 mm culture dishes 48 hours prior to treatment. Cells were detached by 
incubation with 4 ml trypsin/EDTA (Sigma Chemical Co., St Louis, MO, USA) at 37°C, with 
occasional agitation, until cells loosened completely or for a maximum of four minutes. Cells 
were then centrifuged at 4°C and 1500 rpm and the pellet washed in sterile PBS. The resulting 
suspension was centrifuged at 4°C and 1500 rpm. The pellet was then resuspended in 50 µl 
ice-cold lysis buffer (100 mM Tris-HCl and 4 mM EDTA, pH 7.75), which was immediately 
followed by the addition of 150 µl of boiling lysis buffer (Essmann  et al., 2003). Samples 
were then incubated for 2 minutes at 99°C. Lysates were centrifuged at 10 000 rpm at 4°C for 
1 minute. Supernatants were collected for ATP detection and protein determination. 50 µl of 
supernatant and 50 µl luciferase reagent were used and chemiluminescence was immediately 
acquired in a luminometer (Glomax-96 luminometer; Promega, Madison, WI, USA).  
 
3.5 Fatty acid analysis 
 
Free fatty acid and total phospholipid fatty acids were separated and analysed using Gas 
Liquid Chromatography (GLC). Analysis was performed by J. Van Wyk at the MRC 
nutritional research unit for fatty acid analysis. 100 000 MCF12A cells or 80 000 
MDAMB231 cells were plated into 60 mm culture dishes 48 hours prior to treatment. After 
treatment, cells were washed twice in room temperature saline (0.9 mM Sodium Chloride). 
Cells were then scraped in 500 µl of saline, sonicated for 10 seconds each in order to disrupt 
cell membranes, and sent for analysis. 
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3.5.1 Analysis protocol 
 
Neutral lipids were separated from phospholipids by TLC on silica gel plates (10x 10 cm). 
Lipid bands were visualised with ultraviolet light after spraying plates with chloroform 
containing BBOT (2.5-bis (5‟-tert,-butylbenzoxazolyl-[2‟]thiophene; 10 mg/100 ml). Lipids 
were incubated in 5% H2SO4/methanol at 70°C for 2 hours to induce transmethyalation. After 
cooling fatty acid methyl esters (FAME) were extracted using with 1ml water and 2ml n-
hexane. The top layer was evaporated and redissolved in CS2 and analysed by GLC (Varian 
Model 3300 equipped with flame ionization detection) using 30 m fused silica megabore DB-
225 columns of 0.53mm diameter (J & W Scientific, Folsom California, USA). Gas flow rates 
were: hydrogen 25 ml/minutes; air 250 ml/minutes and hydrogen (carrier gas) 5-8 ml/minutes. 
Temperature increases during analysis was 4 °C/minutes, initial temperature 160 °C, final 
temperature 220 °C, injector temperature 240 °C and detector temperature 250 °C. FAME 
were identified by retention time comparison to standard FAME mixture (Nu-Check-Prep 
Inc., Elysian, MI, USA). 
 
3.6 BCKHD siRNA transfection and analysis 
 
Cells were transfected using a reverse transcription protocol into 60 mm petri dishes. An 
extended protocol can be found in the materials and methods section of the previous chapter 
or in the appendix. 20 pmol of BCKDHB - branched chain keto acid dehydrogenase E1, beta 
polypeptide (HSS100949; Invitrogen™, USA) was used per petri dish. The following primers 
were selected and purchased through the Central Analytical Facility with the assistance of Dr 
Ruhan Slabbert.: 
Branched chain keto acid dehydrogenase E1, beta polypeptide precursor; 2-oxoisovalerate 
dehydrogenase beta subunit; BCKDH E1-b. PrimerBank ID 34101272a3. Amplicon size 179. 
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Primer sequence (5'3'). Forward primer (GCAGGTGGCTCATTTTACTTTCC), reverse 
(CAACAGTGCATCTAAAGACTCCA). Heat-shock 90kD protein-1, beta [Homo sapiens]. 
PrimerBank ID 2014949594a1. Amplicon size 247. Primer sequence (5'  3'). Forward 
primer (TGGTGTGGTTGACTCTGAGGA), reverse primer 
(GGAGGTATGATAGCGCAGCA). NADH dehydrogenase (ubiquinone) 1 alpha 
subcomplex. PrimerBank ID 4758770a1. Amplicon size 102. Primer sequence (5'  3'). 
Forward primer (GGACTGGCTACTGCGTACATC), reverse primer 
(GCGCCTATCTCTTTCCATCAGA). β-cytoskeletal actin [Homo sapiens]. PrimerBank ID 
4501885a1. Amplicon size 250. Primer sequence (5'  3'). Forward primer 
(CATGTACGTTGCTATCCAGGC), reverse primer (CTCCTTAATGTCACGCACGAT). 
Stealth RNAi (Invitrogen™, STEALTH RNAI NEG CTL MED GC, 12935300) was used as 
a negative control, as suggested by the manufacturer.  
 
3.7 Statistical analysis 
 
All values are presented as the mean ± standard error of the mean (SEM). Differences 
between time points and treatment groups were analysed using one or two factorial analysis of 
variance (ANOVA). Significant changes were further assessed by means of the Bonferroni 
post hoc analysis where appropriate. All statistical analyses were performed using Graphpad 
Prism version 5.01 (Graphpad Software, Inc, CA, USA). The minimum level of significance 
accepted was p < 0.05. 
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4 Results 
 
4.1 Evidence of a transient and robust generation of amino acids at 6 
hours of amino acid deprivation in MDAMB231 cells and MCF12A cells 
 
 
A. B.
 
 
The total amino acid content (Asp, Thr, Ser, Asn, Glu, Gln, Pro, Gly, Ala, Val, Cys, Met, Ile, 
Leu, Tyr, Phe, Lys, His and Arg) of MDAMB231 cells was determined after incubating these 
cells in culture medium free of any amino acids. A significant increase in the total amino acid 
content of these cells was observed between 2 and 6 hours of amino acid starvation (Fig 3.1). 
Thereafter amino acid levels decreased to a low level that was sustained at 24 hours of amino 
acid starvation. The content of „essential amino acids‟ (Thr, Val, Met, Ile, Leu, Phe, Lys, His 
and Arg) displayed a similar pattern over time (Fig 3.1). 
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A. B.
 
 
The total amino acid content of MCF12A cells also increased significantly between 2 and 6 
hours of amino acid starvation (Fig 3.2). Although total amino acid levels were observed to 
have decreased significantly by 24 hours of starvation, the total amino acid content of 
MCF12A cells remained significantly higher than those at 2 hours of amino acid starvation. 
The content of cellular essential amino acids displayed a similar pattern to that of total amino 
acids over time (Fig 3.2). 
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4.2 Amino acid starvation causes a decrease in the ATP content of 
MDAMB231 but not MCF12A cells 
 
 
The ATP content of MDAMB231 cells was measured following 0, 6, 12 and 24 hours of 
incubation in amino acid deprived culture medium that was completely free of amino acids 
(Fig 3.3). ATP levels did not change during the first 6 hours of starvation but were observed 
to have decreased significantly by 12 hours of amino acid deprivation. ATP levels remained 
low at 24 hours of starvation as well. 
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The ATP content of MCF12A cells was measured following 0, 6, and 24 hours of incubation 
in amino acid deprived culture medium (Fig 3.4). ATP levels did not change during the 
observed period of amino acid deprivation (Fig 3.4). 
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4.3 Maintenance of amino acid levels at 6 hours of amino acid depletion 
is prevented by bafilomycin A1 (10 nM)  
 
 
 
Bafilomycin A1 inhibits fusion of autophagosomes with lysosomes, effectively blocking 
autophagy, and this should theoretically prevent the degradation of proteins engulfed through 
this process. Bafilomycin A1 (10 nM) was added to culture medium 6 hours prior to analysis 
and resulted in significantly lower total amino acid content in MDAMB231 cells after 6 but 
not 24 hours of amino acid starvation (Fig 3.5). Similar results were obtained when the 
essential amino acids were analysed in the same samples. These results indicate that 
bafilomycin (10 nM) prevented maintenance of amino acid levels during 6 hours of amino 
acid starvation. 
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The addition of bafilomycin A1 (10 nM) to culture medium 6 hours prior to analysis resulted 
in significantly lower total amino acid content in MCF12A cells after both 6 and 24 hours of 
amino acid starvation (Fig 3.6). Although results for the essential amino acids showed a 
similar trend, amino acid levels were significantly lower only at 6 (and not 24) hours of amino 
acid starvation. 
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4.4 Maintenance of ATP levels at 6 hours of amino acid depletion is 
prevented by bafilomycin (10 nM) and ATG5 siRNA in MDAMB231 cells 
 
 
The addition of bafilomycin A1 (10 nM) to culture medium 6 hours prior to analysis resulted 
in a significantly lower ATP content in MDAMB231 cells after 6 hours of amino acid 
starvation (Fig 3.7). However, a similar decrease in ATP was not observed if cells were 
incubated in amino acid free medium for 24 hours with bafilomycin (10 nM). 
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The addition of bafilomycin A1 (10 nM) to culture medium 6 hours prior to analysis resulted 
in a no significant changes in ATP content in MCF12A cells after 6 or 24 hours of amino acid 
starvation (Fig 3.8).  
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To investigate if the decreases in ATP observed when bafilomycin A1 was added to culture 
medium (Fig 3.7 and 3.8) was due to decreased autophagy, MDAMB231 and MCF12A cells 
were transfected with ATG5 siRNA, prior to their incubation in amino acid free medium. 
Cells were incubated in amino acid free medium for a period of 6 hours. The ATP levels of 
cells in normal or amino acid free medium were observed to be significantly lower if the cells 
had been transfected with ATG5 siRNA. Furthermore, ATP levels were significantly 
diminished in both cell lines when they were incubated in the absence of amino acids 
compared to when they were incubated with amino acids (black bars in Fig 3.9). Both cell 
lines were reverse transfected, 48 hours prior to treatment. 
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4.5 Amino acid depletion results in increased glucose uptake in 
MDAMB231 cells but not in MCF12A cells 
 
 
 
Cancers are believed to rely principally on glucose for energy production. Therefore, 
MDAMB231 and MCF12A cells were incubated with radiolabled deoxyglucose (1.8 µM) for 
30 minutes to assess glucose uptake. The aggressive, metastatic MDAMB231 
adenocarcinoma cell line displayed a significantly higher rate of 2-deoxy-D-2[H] glucose 
uptake than non-tumourogenic MCF12A breast epithelial cells, indicating that they have a 
higher rate of basal glucose consumption during the normal proliferation phase (Fig 3.10). 
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A. B.
 
 
MDAMB231 and MCF12A cells were incubated in amino acid free medium before being 
exposed to radiolabled deoxyglucose (1.8 µM) for 30 minutes. Cells displayed an increased 
rate of 2-deoxy-D-2[H] glucose uptake that reached significance at 24 hours of starvation (Fig 
3.11).  Glucose uptake did not increase in MCF12A starved of amino acids for 6 or 24 hours 
(Fig 3.11b). 
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4.6 Amino acid depletion results in a transient generation of branched 
chain amino acids at 6 hours of amino acid deprivation in MDAMB231 cells 
and MCF12A cells  
 
 
 
 
A significant increase in the cellular content of branched chain amino acids was observed 
between 2 and 6 hours of amino acid starvation in MDAMB231 cells. However, the level of 
valine was not significantly lower at 2 hours compared to 6 hours of starvation. Levels of all 
three branched chain amino acids decreased significantly from 6 to 12 hours and remained 
low at 24 hours of amino acid starvation (Fig 3.12). 
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MCF12A cells have significantly higher levels of detectable branched chain amino acids at 6 
hours compared to 2 hours of amino acid starvation (Fig 3.13). Although the levels of all of 
the branched chain amino acids were significantly decreased at 24 hours of starvation, these 
levels remained higher than at 2 hours. In particular, there was significantly more leucine at 
24 hours than at 2 hours of amino acid starvation. 
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4.7 Maintenance of the branched chain amino acids is prevented by 
bafilomycin (10 nM) at 6 hours but not 24 hours of amino acid depletion  
 
 
 
 
 
In similar results to those shown previously (Fig 3.5), the presence of bafilomycin A1 (10 
nM) also prevented the maintenance of cellular branched chain amino acid levels during 6 
hours but not 24 hours of amino acid starvation in MDAMB231 cells (Fig 3.14). 
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The presence of bafilomycin A1 (10 nM) also prevented the maintenance of cellular branched 
chain amino acid levels during 6 hours but not 24 hours of amino acid starvation in MCF12A 
cells (Fig 3.15). 
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4.8 Silencing the branched-chain alpha-keto acid dehydrogenase (BCKDH) 
enzyme complex results in an accumulation of the branched chain amino acids 
and a corresponding decrease in ATP content at 6 but not 24 hours of amino acid 
starvation in MDAMB231 cells 
 
The branched-chain alpha-keto acid dehydrogenase (BCKDH) enzyme complex converts the 
branched chain amino acids into derivatives capable of entering the mitochondria. The 
BCKDH enzyme was silenced using siRNA towards BCKDH in this study. Validation 
experiments confirmed a prominent down-regulation of BCKDH expression in both cell lines 
(Fig 3.17), while addition of scrambled siRNA duplexes did not have any effect on expression 
of BCKDH or the cellular content of the branched chain amino acids (Fig 3.16).  
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A.
B.
  
 
 
 
BCKDH siRNA was reverse transfected into MDAMB231 cells 48 hours prior to replacement 
of culture medium with fresh medium complete of amino acids. No change in the free amino 
acid content of any of the branched chain amino acids was observed during this incubation 
period (Fig 3.18). 
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BCKDH siRNA was transfected into proliferating MDAMB231 cells 24 hours prior to 
omitting amino acids from the culture medium for 6 and 24 hours. The addition of BCKDH 
siRNA during amino acid starvation lead to a significant accumulation of the branched chain 
amino acids in MDAMB231 cells at 6 hours of amino acid starvation (Fig 3.19). An 
accumulation of valine and leucine, but not isoleucine was detected at 24 hours of starvation. 
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A similar increase of branched chain amino acid accumulation is not observed in MCF12A 
cells following silencing of BCKDH (Fig 3.20). Interestingly, MCF12A cells appear to show 
a trend towards increased accumulation of branched chain amino acids at 24 hours of 
starvation in the presence of BCKDH siRNA. 
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BCKDH siRNA lowered the ATP content in MDAMB231 cells at 6 and 24 hours of amino 
acid depletion (Fig 3.21).  
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BCKDH siRNA did not lower the ATP content in MCF12A cells at 6 or 24 hours of amino 
acid depletion (Fig 3.22).  
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If autophagy was blocked using siRNA towards ATG5 in the presence of BCKDH siRNA 
during amino acid starvation then branched chain amino acid content decreased further in 
MDAMB231 cells (Fig 3.23). This indicates that autophagy is at least partly responsible for 
generation of the branched chain amino acids during amino acid starvation.  
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Branched chain amino acid content decreased in MCF12A cells if autophagy was blocked 
using siRNA towards ATG5 in the presence of BCKDH siRNA during amino acid starvation 
(Fig 3.24). Also, there was a strong trend towards a decrease in valine levels. Branched chain 
amino acid levels were significantly lower in cells treated with ATG5 siRNA than in cells 
where only control siRNA was added (data not shown). 
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4.9 Maintenance of free fatty acid levels at 6 hours of amino acid 
depletion is prevented by bafilomycin A1 (10 nM) and ATG5 siRNA 
 
 
 
The free fatty acid content of MDAMB231 cells was higher if they were incubated for 6 hours 
in amino acid free medium (Fig 3.25). This elevated level was maintained at 24 hours of 
amino acid starvation. The quantity of the most abundant saturated fatty acid, stearic acid, 
was higher in MDAMB231 cells after 6 hours, but not after 24 hours in amino acid free 
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medium. The quantity of the most abundant unsaturated fatty acid, oleic acid, was increased 
after 6 hours and 24 hours of amino acid starvation. 
 
 
Neither bafilomycin A1 (10 nM), nor autophagy inhibition with ATG5 siRNA altered the 
fatty acid content of MDAMB231 cells incubated in amino acid complete medium (Fig 
3.26a). On the other hand, both bafilomycin A1 (10 nM) and ATG5 siRNA prevented an 
increase in fatty acid levels in MDAMB231 cells during 6 hours of amino acid starvation (Fig 
3.26b). Scrambled siRNA did not change the fatty acid content of these cells (Fig 3.26c). 
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The total phospholipid fatty acid content of MDAMB231 cells is the same in cells incubated 
in culture medium with amino acids and in cells incubated in culture medium without amino 
acids for 24 hours (Fig 3.27).  
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The fatty acid β-oxidation inhibitor etomoxir (200 µM) lowers ATP content in MDAMB231 
cells incubated in amino acid free medium for 6 hours (Fig 3.28). A similar decrease in ATP 
content is not observed if cells were incubated in amino acid free medium for 24 hours in the 
presence of etomoxir (200 µM). 
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The fatty acid β-oxidation inhibitor etomoxir (200 µM) lowers ATP content in MCF12A cells 
incubated in amino acid free medium for 24 hours (Fig 3.29). A similar decrease in ATP 
content is not observed if cells were incubated in amino acid free medium for 6 hours in the 
presence of etomoxir (200 µM). 
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5 Discussion 
 
Established tumours are known to develop regions of transient nutrient limitation and 
ischemia, and it is believed that autophagy has a potentiating role in these microenvironments, 
generally attributed to its functional capacity to generate constituents for continued 
biosynthesis and energy generation (Degenhardt et al., 2006). Additionally, autophagy within 
neoplasms might also be able to confer protection during chemotherapy (Yang and Chen, 
2011). The protective role of autophagy within these tumours, due to its homeostatic function 
within regions with limited access to blood supply, is thought to prevent so-called metabolic 
catastrophe (Jin and White, 2008). However, data for direct measures of amino acids in 
nutrient starved cancer cells are currently completely absent. Furthermore, direct assessment 
of ATP levels are almost never published, particularly in association with cancer studies. 
Therefore, assessment of amino acid levels during short term starvation and correlation with 
ATP levels under these conditions is a vital next step if therapeutic interventions are to be 
designed on the basis that autophagy increases survival through generation of substrates for 
energy production. 
 
Many of the prominent reviews describing autophagy processes in detail highlight the point 
that the degradation of cytoplasmic material through increased activation of the 
autophagosomal-lysosomal system increases the availability of amino acids, which are then 
accessible for use in the generation of energy and to buffer the systemic amino acid pool 
(Mizushima, 2007, Klionsky, 2007, Levine and Kroemer, 2008). However, little evidence 
linking these claims is presented. Although a few studies have assessed some of these 
parameters independently, the generation of amino acids by autophagy is never directly 
correlated with their utility. Moreover, even though autophagy is thought to be vital for the 
generation of these substrates in harsh cancer microenvironments, even less investigation into 
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nutrient generation in the cancer setting has been undertaken as yet. Furthermore, the drive to 
use low protein diets and autophagy inhibition in patients receiving cancer therapy 
(information from clinicaltrials.gov) necessitates increased research. 
 
5.1 Autophagy regulation of cellular amino acid levels in MDAMB231 
cells 
 
Previous experiments demonstrated that a breast cancer cell line with high basal autophagy 
(MDAMB231) is able to respond to an acute bout of nutrient deprivation by further increasing 
autophagy activity (detailed in chapter 2). The current study was undertaken in order to 
provide some mechanistic support to explain how autophagy is accomplishing this protective 
feat. It is often assumed that by generating substrates from the degradation of cytoplasmic 
material, autophagy is able to buffer any nutrient losses. However, support for this idea is 
rarely offered. Our model of dynamic autophagy assessment in cell lines with high and low 
basal autophagy provides an opportunity to assess this hypothesis. As only amino acids have 
been eliminated from the cells in this model, assessment of the amino acid content and the 
consequences to energy production during amino acid starvation would provide great insight 
into the mechanism whereby autophagy is able to aid in survival during a starvation event. 
 
Experimental data, using a model of complete amino acid starvation, provides evidence of a 
robust surge of increased amino acids at 6 hours of amino acid deprivation in MDAMB231 
cells (Fig 3.1). A significant increase in the total and essential amino acid content of these 
cells was observed between 2 and 6 hours of complete amino acid starvation. Thereafter, 
cellular free amino acid content decreased and remained significantly low between 12 and 24 
hours. Presumably, the amino acids generated in this way were utilized for functions within 
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the cells. Analysis of the supernatant medium extracted from these cells at the end of the 
treatment period indicated that there were no amino acids present in the culture medium (data 
not shown). This implies that the amino acids generated during amino acid starvation did not 
diffuse out of these cells into the incubation medium and must have been used within the cells 
for some purpose. Although a non-tumourogenic cell line (MCF12A) displayed a similar 
significant increase in amino acids at 6 hours following starvation, these levels remained 
relatively high compared to those in the cancer cell line (Fig 3.2). This demonstrates that 
these cells are able to maintain amino acid levels during starvation over this period, possibly a 
reflection of their slower rate of proliferation (and relatively inferior requirement for free 
amino acids) compared to MDAMB231 cells. Interestingly, the capacity of MDAMB231 cells 
and MCF12A cells to maintain amino acid levels at 6 and 24 hours respectively reflects their 
tolerance to amino acid deprivation and their ability to mitigate cell death during these 
conditions (chapter 1). Further investigation revealed that a bafilomycin-sensitive mechanism 
is responsible for the buffering of amino acid levels at 6 hours of amino acid deprivation in 
MDAMB231 cells (Fig 3.5). Remarkably, bafilomycin A1 (10 nM) during amino acid 
starvation completely abolished the transient surge in free intracellular total and essential 
amino acid levels at 6 hours in MDAMB231 cells. A similar bafilomycin-sensitive decrease 
in amino acid content was also noted in MCF12A cells at 6 hours (Fig 3.6). Notably, a 
significant decrease in total cellular amino content of MCF12A cells was observed at 24 hours 
as well. Taken together, it is clear that the capacity of these cell lines to successfully maintain 
amino acid levels is directly related to their respective tolerances to a starvation event of this 
type, which can be effectively blunted with bafilomycin A1 (described in chapter 1 and 
chapter 2). As bafilomycin A1 inhibits the fusion of autophagosomes with lysosomes (and 
thereby inhibits degradation of proteins and generation of amino acids by autophagy), this is 
strong support for the hypothesis that autophagy is responsible for the generation of amino 
acids during these conditions. 
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Much indirect evidence suggests that autophagy is an intracellular system of amino acid 
generation, although amino acids have also been repeatedly demonstrated to inhibit autophagy 
(Mortimore and Schworer, 1977). Liver autophagy has recently been shown to contribute to 
the maintenance of amino acid levels (Ezaki et al., 2011), but as the amino acid 
concentrations in blood are mostly unchanged during starvation (Kuma and Mizushima, 
2010), few studies have thought to directly measure amino acid changes and relate them to 
autophagy. The transient amino acid surge observed in this study has not been demonstrated 
elsewhere in the cancer context, but similar transient increases have infrequently been 
described in the literature before. During nitrogen starvation, yeast were found to transiently 
generate amino acids in a similar way, but autophagy defective cells treated in a comparable 
manner did not display a similar spike in amino acid content (Onodera and Ohsumi, 2005). 
Also, starved rat kidney cells in culture also show a rapid short lived increase in autophagy 
(Yu et al., 2010). In the seminal in vivo study describing the role of autophagy during the 
early neonatal period it was shown that, after birth, a transient increase in autophagy peaks 
after 3-6 hours before subsiding (Kuma et al., 2004), and is vital for the maintenance of 
plasma and tissue amino acid concentrations during this period. 
 
Recently it has been proposed that cancers with high basal autophagy levels may have 
evolved to require autophagy for continued progression. In particular, cancers with mutations 
in H-ras or K-ras may need autophagy for tumour survival (Guo et al., 2011), and data from 
recent studies suggests that pancreatic (Yang et al., 2011) and other Ras-driven tumours 
(Lock et al., 2011) require autophagy for sustained growth. In fact, it appears as though these 
cancers are partly reliant on a system of oxidative phosphorylation for energy production. 
Indeed, inhibition of autophagy in these cancers leads to a decrease in ATP generation (Yang 
et al., 2011). This so-called autophagy-addiction has been suggested to be a property typical 
of these Ras-driven tumours. Although genetic ras mutations are infrequent in breast cancer, 
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Ras was shown to be highly and abnormally activated in over 50% of tested cancers in one 
study (von Lintig et al., 2000), owing to the high prevalence of mutations elsewhere in this 
pathway. MDAMB231 cells are known to have high basal autophagy and high ras activation 
(Ogata et al., 2001), and therefore may also rely on autophagy for the generation of substrates 
for energy production. 
 
5.2 Autophagy regulation of ATP levels in MDAMB231 cells 
 
Bioenergetic activities are regulated by the TCA cycle in the mitochondria. Oxidizable 
substrates are provided through the electron transport chain, reducing molecular oxygen to 
water and fuelling oxidative phosphorylation for ATP production. Although generally 
considered to be poor fuel substrates, amino acids can be consumed to generate energy in this 
way. Although infrequently demonstrated experimentally, there is some precedent in the 
literature, and amino acid starvation of yeast leads to the rapid depression of ATP levels after 
just 3 hours. Also, extreme decreases in ATP levels of growth factor deprived cells after 5 
hours of incubation with 3-methyladenine can be mostly rescued by the administration of 
methylpyruvate (Lum et al., 2005). As bafilomycin A1 (10 nM) is only administered 6 hours 
prior to analysis in the current study, it allows for delineation of autophagy influence at 
specific times of interest in this model. 
 
Interestingly, the ATP content in MDAMB231 cells mirrored the changes in the capacity of 
this cell line to maintain intracellular amino acid levels (Fig 3.3). Furthermore, the ability of 
MDAMB231 cells to maintain ATP levels during the first 6 hours of amino acid starvation 
was abolished in the presence of bafilomycin A1 (10 nM) (Fig 3.7). This evidence suggests 
that either amino acids generated in a bafilomycin-sensitive manner (such as autophagy) or 
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another corresponding mechanism associated with this amino acid generation might be 
important for the maintenance of ATP in this cell line. In order to investigate if the decreases 
in ATP observed when bafilomycin A1 was added to culture medium was due to an 
autophagy related mechanism, MDAMB231 and  MCF12A cells were transfected with  
ATG5 siRNA 48 hours prior to incubation in amino acid free medium. Indeed, the ATP levels 
of cells in either the normal or amino acid free medium were observed to be significantly 
lower if the cells had been transfected with ATG5 siRNA (Fig 3.9). Furthermore, ATP levels 
were significantly diminished in both cell lines when they were incubated in the absence of 
amino acids compared to when they were incubated in the presence of amino acids (Fig 3.9). 
Collectively, this suggests that the maintenance of intracellular amino acids by autophagy (in 
a process inhibitable by bafilomycin A1) is important for the preservation of ATP levels in 
these cell lines, and that MDAMB231 cells are particularly reliant on autophagy derived 
amino acids for homeostasis during the first 6 hours of amino acid deprivation. At this point it 
is not clear how a decrease in amino acid levels leads to a decrease in cellular ATP content, 
but it is evident that the buffering capacity of autophagy is able to prevent this decline in ATP 
in both cell lines.  
 
Cancer is widely believed to rely on glycolysis for energy production. Although this 
observation remains true for some cancer types, it now appears that many cancers rely on both 
glycolysis and oxidative phosphorylation for energy production. Moreover, in many other 
cancers, oxidative phosphorylation may be the predominant and preferred form of energy 
generation. A particular strength of the model used in this study is that it does not limit 
cellular access to glucose. Therefore, any changes to energy levels following amino acid 
depletion could be correlated with glucose uptake in order to assess if a dearth in available 
amino acids impacts on the ability of these cells to take in glucose. Interestingly, the non-
malignant epithelial cell line, MCF12A, has measurable levels of GLUT 1 and HK 1, which 
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are considerably higher than other non-cancer cell lines; and these cells are able to take up 
significant amounts of a 2-deoxy-glucose analogue from a glucose free medium (Millon et al., 
2011). Although normal mammary epithelial cells rarely over-express GLUT 1 (Bos et al., 
2002) it is likely that GLUT 1 expression occurred during immortalization of these cells. For 
the purposes of this study it allowed direct measurement of 2-deoxy-glucose uptake and 
comparison with another GLUT 1 over-expressing cell line, MDAMB231 (Millon et al., 
2011). Experimental evidence presented here demonstrates that MDAMB231 cells have high 
glucose uptake at baseline compared to the non-cancer line, and that starvation leads to 
significantly increased glucose uptake after 24 hours, in the cancer cell line only (Fig 3.11). 
This indicates that molecular changes within these cells have allowed them to adapt to 
metabolic stress by increasing glucose uptake, a phenomenon that has been demonstrated in 
these cells previously (Li et al., 2009). However, despite increases in glucose uptake 
decreases in ATP levels were still observed. In fact, even though glucose uptake was shown 
to increase slightly, ATP levels dropped significantly after 24 hours of amino acid starvation.  
 
5.3 Branched chain amino acids, and possibly free fatty acids, are 
potential sources for ATP generation in MDAMB231 cells 
 
The three branched chain amino acids (leucine, isoleucine, and valine) are among the essential 
amino acids for humans. These amino acids have been postulated as a source of oxidizable 
substrates for use in energy production, and activity of the branched-chain α-ketoacid 
dehydrogenase complex (BCKDH) has been shown to be up-regulated during starvation 
(Harris et al., 1989). Still, no discernable increase in the expression levels of BCKDH were 
found during the 24 hour amino acid starvation of MDAMB231 cells in this study (data not 
shown). Activation of the BCKDH complex catalyzes the second-step in the reaction of the 
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BCAA catabolic pathway and is essential for branched chain amino acid catabolism in the 
mitochondria. Also, the preferential reduction of BCAA in neonates with Atg5−/− and Atg7 
−/− is an indication of enhanced consumption of these amino acids as an energy source 
(Kuma et al., 2004). As MDAMB231 cells do not appear to have a diminished capacity for 
glucose uptake during amino acid starvation, and a surge in the cellular free branched chain 
amino acids levels is obvious during short periods of amino acid deprivation, further 
investigation into whether this particular subset of amino acids are partly responsible for ATP 
maintenance was merited. 
 
The addition of BCKDH siRNA during amino acid starvation lead to a significant 
accumulation of the branched chain amino acids in MDAMB231 cells at 6 hours of amino 
acid starvation but no corresponding  accumulation in MCF12A cells (Fig 3.19 and Fig 3.20). 
As no accumulation is observed if BCKDH translation is blocked in cells cultured in amino 
acid complete conditions, it is plausible that a significant amount of the branched chain amino 
acids generated at 6 hours during amino acid starvation are being converted into substrates 
useable by the mitochondria, potentially for energy production in these cells. Furthermore, the 
fact that the inhibition of BCKDH expression significantly decreases ATP content in these 
cells (Fig 3.21), but not in MCF12A cells (Fig 3.22), during amino acid starvation adds 
credence to the assertion that branched chain amino acids generated during amino acid 
starvation are being used as fuel substrates for homeostasis maintenance. Importantly, if 
autophagy is simultaneously inhibited in MDAMB231 cells treated with BCKDH siRNA, 
then the accumulation of branched chain amino acids decreases (Fig 3.23), indicating that 
autophagy is an important process responsible for the generation of these amino acids for use 
as fuel substrates. Also, as branched chain amino acids are not a major fuel source during 
basal, amino acid replete, conditions (Fig 3.18), this evidence signifies that these cells may 
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have shifted their preference for substrate utilization in energy generation. More evidence is 
required to assess the plausibility of this claim. 
 
Proteins are not the only constituents of the cytoplasm that become degraded during 
autophagy. Although only scant evidence is currently available, it now appears that autophagy 
has an important role in the degradation of intracellular lipids and in the regulation of lipid 
metabolism. Since numerous organelles (including mitochondria and peroxisomes) have been 
observed in autophagosomes and autolysosomes, degradation of their membrane 
phospholipids could contribute to energy generation in times of need.  As evidence within this 
study does imply a change in substrate preference during amino acid deprivation, the fatty 
acid content within these cells was analysed during amino acid starvation. Indeed, the free 
fatty acid content of MDAMB231 cells was higher if they were incubated for 6 hours in 
amino acid free medium (Fig 3.25), and remained elevated at 24 hours of amino acid 
starvation. Importantly, the quantity of the most abundant saturated fatty acid, stearic acid, 
was higher in MDAMB231 cells after 6 hours, but not after 24 hours in amino acid free 
medium, this apparent decrease indicating its utilization within the cell. As bafilomycin (10 
nM) and ATG5 siRNA were able to prevent the increase in free fatty acids at 6 hours of 
amino acid starvation, it is likely that it is driven by a process mediated through autophagy. 
Also, inhibition of β-oxidation using etomoxir (200 µM) lowers ATP content in MDAMB231 
cells at 6 hours (Fig 3.28) and in MCF12A at 24 hours (Fig 3.29). This change correlates 
directly with previous findings that show autophagy to be important for tolerance of amino 
acid deprivation when these cell lines are deprived of amino acids for those time periods. 
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5.4 Conclusions 
 
Collectively, this study provides very compelling evidence that MDAMB231 cells are able to 
transiently degrade cytoplasmic contents in order to tolerate a short term reduction in amino 
acids. Additionally, a potential mechanism is provided here, where preferential utilization of 
autophagy-produced fuel substrates, can buffer against decreases in ATP levels during this 
short period of amino acid deprivation.  
 
The need for ATP does not always remain constant. Demand for substrates (assessed though 
demand for the universal free energy transmitter (ATP) of the cell) must be balanced with 
supply, and the increase in autophagy activity should not be separated from the processes that 
utilize its products. Currently, ignorance of the energy requirements of cancer cells and the 
possible role of autophagy necessitates continued research into this important area of 
oncology. 
 
5.5 Limitations and future recommendations 
 
Although evidence in the present study convincingly implicates autophagy, and the associated 
generation of amino acids, in tolerance to amino acid deprivation (partly through maintenance 
of ATP levels), other mechanisms for amino acid maintenance do exist. The addition of 
proteosome inhibitors and further assessment of the role of the proteosome in the maintenance 
of amino acids is important. Furthermore, this study is not able to delineate whether 
MDAMB231 cells have an altered substrate preference during amino acid starvation. Future 
assessment of oxygen consumption and the role (and relative weight) that various substrates 
have with regard to ATP generation is recommended. 
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4  
 
Changes in lysosomal acidity due to amino acid starvation 
are associated with susceptibility to doxorubicin mediated 
cell death in MDAMB231 cells and tolerance to doxorubicin 
in MCF12A cells 
 
Autophagy appears to have conflicting roles in response to cancer therapy. 
Even so, many clinical trials are beginning to assess the effectiveness of 
compounds known to regulate autophagy, in patients receiving anticancer 
therapy. Furthermore, short term starvation has shown promise in 
alleviating some of the symptoms associated with chemotherapy, posing 
questions regarding the role of autophagy in these circumstances. Short 
term, complete amino acid deprivation elicits dynamic alterations to the 
acidic compartmentalization of the tumourogenic cancer cell line 
MDAMB231 (chapter 2). We demonstrate in this chapter that decreased 
lysosomal acidity associated with amino acid starvation in MDAMB231 
cells treated with doxorubicin correlates with decreased cell survival, 
whereas sustained elevation of autophagy in MCF12A cells during similar 
treatment is associated with a relative protection from cell death. 
 
1 Introduction 
 
Solid tumours make up the majority of all human cancers. Once solid neoplasms become 
established they can partially adapt to local microenvironmental shortages in nutrient supply 
by increasing autophagy (Mathew et al., 2007a). Even though autophagy is considered to be 
an important mechanism whereby cancer cells are able to survive stressful environmental 
conditions, it has been given roles in tumour suppression (Aita et al., 1999) and the promotion 
of tumour progression and survival (Degenhardt et al., 2006) depending on context. It is now 
also known that many anti-cancer agents and therapies increase autophagy levels in treated 
cancer cells at certain doses (Wu et al., 2006, Park et al., 2008). Transient, rapid and 
unpredictable alterations in autophagy flux could modify the way that tumours respond to 
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chemotherapy and supposedly interfere with or even augment therapy outcomes in 
unexpected ways. In fact, reports vary as to whether increases in autophagy are protective 
(Park et al., 2008) or detrimental (Garcia-Escudero and Gargini, 2008) to cancer cells 
undergoing these treatments. 
  
Autophagy has recently become a popular target for opposing chemotherapy resistance, and 
measurement of autophagy and its associated markers are now also being considered for their 
prognostic relevance and value (Giatromanolaki et al., 2010, Ma et al., 2011). Furthermore, 
many patients with increased solid tumour autophagy have presented with increased 
resistance to chemotherapy. On the other hand, cancer variants with known autophagy 
deficiencies could be susceptible to agents that are able to effectively augment autophagy 
(Turcotte et al., 2008). Divergent responses and outcomes demand that the basic underlying 
systems controlling autophagy in these situations be resolved if therapeutic modulation of this 
process is to be successfully implemented in cancer patients already receiving conventional 
treatments. 
 
1.2 Clinical autophagy detection 
 
If autophagy is to be used effectively in a clinical environment, then improved methods of 
detection for the autophagy status of tumour cells, and the influence of autophagy modulating 
agents on these autophagic levels, are needed. Currently, methods for the in vivo assessment 
of autophagy are lacking but, most recently, plasma levels of clusterin protein were 
demonstrated to decrease during autophagy induction in vivo (Powolny et al., 2011), implying 
the prospect for its use as a biomarker for autophagy. Furthermore, it is believed that 
autophagy can be used as a potential prognostic marker in certain cancer cells (Pirtoli et al., 
2009). For example, cytoplasmic Beclin1 levels have been found to correlate with survival in 
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gliomas (Pirtoli et al., 2009), while morphological changes associated with increased 
autophagy predicted survival and invasiveness in melanomas (Ma et al., 2011).  Interestingly, 
there has been a suggestion that increased autophagy levels could serve as a marker to 
indicate whether some cancers will be sensitive to chemotherapy or not (Nicotra et al., 2010), 
but evidence remains inconclusive at present (Won et al., 2010). It is crucial that oncologists 
develop methods to determine which cancers are capable of autophagy induction and whether 
any increases in autophagy would confer survival advantages or bring about changes in the 
capacity of these cells for drug resistance.   
 
1.3 Role of autophagy in drug resistance 
 
Cancers are able to develop resistance to drugs in a multitude of ways. Specialized 
transporters on cell membranes can accelerate the efflux of certain chemotherapy compounds 
(Krishna and Mayer, 2000), drugs can be inactivated (Giaccone and Pinedo, 1996) and 
programmed cell death pathways evaded (Adams and Cory, 2007). It is well established that 
many cancers possess mutations in key regulators of their apoptosis machinery, and in this 
way are able to avoid programmed cell death in the face of metabolic or other stresses 
(Mathew et al., 2007a). Autophagy is important for the maintenance of homeostasis and the 
initiation of autophagy in these circumstances has been demonstrated to either protect cancer 
cells from death or lead to it through so-called autophagic cell death (type-II programmed cell 
death) (Kondo and Kondo, 2006). Cancers such as malignant gliomas possessing the active 
variant of the Bcl2 gene are resistant to many chemotherapeutic interventions (Kondo et al., 
1995), and these malignancies are known to activate autophagy, but not apoptosis, in response 
to chemotherapy or radiation treatment. Furthermore, HeLa cells over-expressing the anti-
apoptotic BCL-XL also display increased autophagy in response to anti-cancer treatments 
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(Shao et al., 2004). Targeting autophagy in circumstances when apoptosis is defective could 
result in increased efficacy of some drugs. 
 
Autophagy is often observed as a response to chemotherapy (Yang and Chen, 2011). The 
therapeutic efficacy of several antineoplastic treatments is increased if autophagy is inhibited, 
which is reliable indication that it is functioning as a mechanism of cytotoxic resistance to 
these therapies. Evidence in support of this has shown that the inhibition of autophagy 
sensitized tamoxifen-resistant breast cancer cells (Qadir et al., 2008), lymphomas (Amaravadi 
et al., 2007) and other mammalian cells (Boya et al., 2005) to apoptosis. 
 
Autophagy is able to reduce the effectiveness of some chemotherapeutics and its regulation 
could provide a useful anticancer tool. Unfortunately, too little is understood about its role 
during treatment and there is some support that increasing autophagy could even aid in 
enhancing treatment efficacy through initiation of autophagy-mediated cell death. A better 
understanding of the mechanisms underlying autophagy regulation and its consequences is 
needed. 
    
1.4 Diet, autophagy and cancer treatment 
 
Dietary habits have long been implicated in cancer risk and tumour progression (Popkin, 
2007), and one of the most potent stimulators of autophagy is cellular nutritional status. 
Several dietary factors are known to promote autophagy induction. One of the most effective 
of these is restriction of dietary calorie intake, which is thought to be one of the most 
promising strategies by which to extend lifespan (Heilbronn and Ravussin, 2005) and is 
believed to be an effective tumour suppression mechanism (Kritchevsky, 2003). Dietary 
restriction leads to reduced glucose and growth hormone levels, and a consequential 
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autophagy activation (governed by the mTOR pathway) has been implicated in a protective 
role in decreasing cancer formation and onset (Sell, 2003). Many additional bioactive 
compounds are also known to increase autophagy levels in cancer as well. For example, 
curcumin, resveratrol, tocotrienols, vitamin C and vitamin D3 increased autophagy in brain 
(Aoki et al., 2007), ovarian and lung (Opipari et al., 2004, Ohshiro et al., 2007), pancreatic 
(Rickmann et al., 2007), glial and lung (Martin et al., 2002, Ohtani et al., 2007) and head and 
neck cancers (Tavera-Mendoza et al., 2006) respectively. Even though autophagy is increased 
in these and other instances, it is difficult to identify the consequences of autophagy 
augmentation in many of these cases. Further research is needed to clarify the function and 
role of autophagy in these circumstances before use of these compounds can be sanctioned for 
clinical use. 
 
Interestingly, a clinical study using a low protein diet to „reactivate‟ autophagy is set to begin 
phase II trials shortly (table 4.1). Plans are to use a low-protein diet or treatment with the 
mitochondrial PTP inhibitor cyclosporine A in patients with Bethlem Myopathy or Ullrich 
Congenital Muscular Dystrophy. Patients will receive a diet with 0.6-0.8 grams of 
protein/kilogram body weight/day for one year and autophagy specifically monitored over 
that period (information from clinicaltrial.gov). 
 
Remarkably, the recent application of short term starvation protocols in patients receiving 
high doses of chemotherapy has proven to have great success in reducing side effects in these 
patients (Safdie et al., 2009). Although the feasibility and effect of fasting remain unknown, 
patients diagnosed with a variety of cancers, and undergoing high dose chemotherapy, 
voluntarily fasted in a protocol of Differential Stress Resistance (DSR) and all enjoyed a 
decrease of many of the negative symptoms normally associate with the treatments they were 
receiving. In a cell culture and a neuroblastoma mouse xenograft model, normal cells placed 
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on a similar starvation protocol were shown to benefit from differential protection compared 
to cancer cells during high dose chemotherapy regimens (Raffaghello et al., 2008). Mice 
starved for 48 hours had reduced chemotoxicity following high dose treatment whereas mice 
fed on ad libertum diets were 50% more likely to die while cancer cell death was not 
compromised by the starvation protocol. The underlying mechanisms responsible for this 
differential protection of non-cancer cells are not yet known, although reduction of certain 
growth hormones and up-regulation of stress resistance proteins is believed to play a role 
(Spindler and Dhahbi, 2007). As many cancers have mutations in key pathways that regulate 
cellular growth, alterations in the levels of circulating growth factors could impact non-cancer 
cells to a greater degree. Indeed, extremely low levels of circulating IGF-1 have been 
associated with chemotherapy resistance in a mouse model (Safdie et al., 2009), and lower 
IGF-1 levels during dietary restriction correlates with a dramatic reduction in the progression 
of some cancers (Dunn et al., 1997). However, it is important to note that nutrient starvation 
protocols are largely untested and there is no evidence of consistency across cancers or even 
among similar cancer variants. For instance, although nutrient deprivation protected primary 
glioma cells to chemotherapy in one study (Kim, 2010), other glioma and neuroblastoma cells 
were not protected following similar treatment. The tolerance of different cell types to 
different forms of nutrient deprivation still needs extensive investigation. 
 
1.5 Autophagy inhibition in cancer treatment 
 
Based on the premise that autophagy leads to tumour survival in apoptosis deficient cancer 
cells, it is believed that targeted and specific inhibition of autophagy could be a promising 
therapeutic avenue. Several in vitro studies have illustrated the potential of class-III PI3K 
inhibitors such as 3-methyladenine, which prevent the formation of autophagosomes, in 
cancer therapy (Kanzawa et al., 2004). However, while starvation of a cervical cancer cell line 
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did result in apoptosis in the presence of this inhibitor (Boya et al., 2005), 3-methyladinine 
prevented tamoxifen induced apoptosis in breast cancer cells elsewhere (Bursch et al., 1996). 
Agents such as bafilomycin A1, hydroxychloroquine and monensin (all of which prevent 
lysosomal fusion with autophagosomes) trigger apoptosis during nutrient depletion of HeLa 
cells (Boya et al., 2005). Also, bafilomycin A1 is able to impede the protective effect of 
autophagy in several cancer lines undergoing radiation therapy (Paglin et al., 2001). 
  
Several clinical trials, now active or in the recruiting stages, are assessing combination 
treatment of chemotherapy drugs with modulators of autophagy (table 4.1). The anti-malarial 
compound chloroquine has been in use since the 1940‟s but decreased usage has been 
reported in many countries on account of drug resistance (Savarino et al., 2006). Chloroquine 
can behave as an autophagy inhibitor due to its capacity to alkalinize lysosomes through 
proton quenching, and recent studies in mice have demonstrated that chloroquine 
administration can suppress cancer formation (Maclean et al., 2008) and diminish tumour cell 
survival (Amaravadi et al., 2007). Drugs such as choloquine and hydrochloroquine are 
especially attractive adjuvant compounds due to the fact that they have been proven safe for 
human use over many decades. One small clinical trial utilizing chloroquine in conjunction 
with standard chemotherapy in glioblastoma patients demonstrated increased survival in the 
chloroquine treated patients (Sotelo et al., 2006). Choloroquine behaved in a similar manner 
to another autophagy inhibitor, 3-methyladenine, when it reduced prostate cancer growth in 
vitro and in vivo following its administration in conjunction with an anti-cancer treatment 
(Wu et al., 2010). The autophagy inhibiting property of chloroquine was again implicated in 
imanitib associated cell death in a chronic myeloid leukaemia model (Bellodi et al., 2009). 
Another new and promising autophagy inhibitor is lucanthone. This molecule prevents 
autophagy mediated degradation and induces apoptosis in breast cancer models (Carew et al., 
2010). The use of autophagy inhibition in combination with proteosome inhibition is also 
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under investigation in a clinical setting (table 4.1). Autophagy is functionally linked to the 
ubiquitin-proteosome system and inhibition of both pathways simultaneously could prove to 
be even more lethal. Bortezomib is one such proteosome inhibitor that has proven to be 
effective in treating multiple myeloma (Roccaro et al., 2006), and it is set to continue into 
phase II trials in combination with hydroxychloroquine in the near future. 
 
 
Status Study Condition Intervention Phase
Recruiting Autophagy Inhibition Using Hydrochloroquine in Breast Cancer 
Patients
Breast Cancer
Hydrochloroquine II
Not yet 
recruiting
Low Protein Diet in Patients With Collagen VI Related Myopathies Bethlem Myopathy; Ullrich Congenital 
Muscular Dystrophy
Low protein diet II
Active, not 
recruiting
Hydroxychloroquine + Carboplatin, Paclitaxel and Bevacizumb in Non-
Small Cell Lung Cancer (NSCLC)
Non-small Cell Lung Cancer Paclitaxel Carboplatin; 
Hydroxychloroquine; 
Bevacizumab
I/II
Recruiting Hydroxychloroquine in Patients With Stage III or Stage IV Melanoma 
That Can Be Removed by Surgery
Melanoma (Skin)
 Hydroxychloroquine 0
Recruiting Chloroquine as an Anti-Autophagy Drug in Small Cell Lung Cancer 
(SCLC) Patients
Small Cell Lung Cancer Chloroquine, A-CQ 
100
I/II
Recruiting FOLFOX/Bevacizumab/Hydroxychloroquine (HCQ) in Colorectal 
Cancer
Rectal Cancer; Colon Cancer; Metastasis; 
Adenocarcinoma
Hydroxychloroquine; 
Oxaliplatin
I/II
Recruiting Study of Hydroxychloroquine Before Surgery in Patients With Primary 
Renal Cell Carcinoma
Renal Cell Carcinoma
Hydroxychloroquine I
Recruiting Characterization of the Mechanisms of Resistance to Azacitidine Myelodysplastic Syndromes or Acute 
Myeloid Leukemia With Multilineage 
Dysplasia
? ?
Recruiting Study of the Efficacy of Chloroquine in the Treatment of Ductal 
Carcinoma in Situ (The PINC Trial)
Carcinoma, Intraductal, Noninfiltrating; 
DCIS; Ductal Carcinoma In Situ
Chloroquine I/II
Recruiting Hydroxychloroquine and Temsirolimus in Treating Patients With 
Metastatic Solid Tumors That Have Not Responded to Treatment
Unspecified Adult Solid Tumor, Protocol 
Specific
Hydroxychloroquine; 
temsirolimus
I
Recruiting Hydroxychloroquine, Capecitabine, Oxaliplatin, and Bevacizumab in 
Treating Patients With Metastatic Colorectal Cancer
Colorectal Cancer Bevacizumab; XELOX 
regimen; 
Hydroxychloroquine
II
Recruiting Sirolimus or Vorinostat and Hydroxychloroquine in Advanced Cancer Advanced Cancers Drug: 
Hydroxychloroquine; 
Sirolimus; Vorinostat
I
Recruiting Hydroxychloroquine + Vorinostat in Advanced Solid Tumors Advanced Solid Tumor Hydroxychloroquine; 
Vorinostat 
(Suberoylanilide 
Hydroxamic Acid)
I
Not yet 
recruiting
Topical Vitamin D3, Diclofenac or a Combination of Both to Treat 
Basal Cell Carcinoma
Basal Cell Carcinoma  Diclofenac; Diclofenac 
+ Calcitriol; Calcitriol
III
Recruiting A Study to Evaluate the Use of Chloroquine in Combination With 
VELCADE and Cyclophosphamide in Patients With Relapsed and 
Refractory Multiple Myeloma
Multiple Myeloma
Cyclophosphamide; 
Velcade; Chloroquine
II
Recruiting Ritonavir and Its Effects on Biomarkers in Women Undergoing 
Surgery for Newly Diagnosed Breast Cancer
Breast Cancer Ritonavir; Procedure: 
therapeutic conventional 
surgery
I/II
Unknown Hydroxychloroquine and Bortezomib in Treating Patients With 
Relapsed or Refractory Multiple Myeloma
Multiple Myeloma and Plasma Cell 
Neoplasm
Bortezomib;  
Hydroxychloroquine
I/II
Recruiting Treatment With Dasatinib in Patients With Acral Lentiginous, Mucosal, 
or Chronic Sun-damaged Melanoma
Melanoma
Dasatinib II
Recruiting Study of Pre-surgery Gemcitabine + Hydroxychloroquine (GcHc) in 
Stage IIb or III Adenocarcinoma of the Pancreas
Pancreatic Cancer Hydroxychloroquine; 
Gemcitabine
I/II
Recruiting Nelfinavir Mesylate and Bortezomib in Treating Patients With 
Relapsed or Progressive Advanced Hematologic Cancer
Leukemia; Lymphoma; Mature T-cell and 
Nk-cell Neoplasms; Multiple Myeloma and 
Plasma Cell Neoplasm
Bortezomib;  nelfinavir 
mesylate
I
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1.6 Autophagy promotion during cancer therapy  
 
Many cancer treatments are known to cause increased autophagy (Yang and Chen, 2011). 
Although it has been suggested that overactive autophagy can itself be a cell death response, 
contemporary thought is that autophagy functions primarily as a survival mechanism and that 
cells die “with” rather than “by” autophagy albeit in rare circumstances (Levine and Kroemer, 
2008). However, some cells do appear to undergo cell death by autophagy, with no sign of 
apoptosis initiation. For example, a pancreatic cancer cell line showed what has been termed 
an autophagy dependent cell death, that can be abolished with 3-methyladenine (Pardo et al., 
2010). An autophagy induced cell death has also been reported in many instances for cancer 
cells undergoing radiation treatment (Paglin et al., 2001). 
 
Pharmacological agents inhibiting PI3K or Akt can activate autophagy and cell death when 
used in combination with anti-cancer treatment (Fujiwara et al., 2007). Inhibition of mTOR 
can also lead to increased cancer cytotoxicity during chemotherapy or radiation treatment 
(Yao et al., 2010), but these effects have not been linked to autophagy directly, as yet. Even 
though many of these findings contradict studies using autophagy inhibition as a means to 
enhance death of cancer cells treated with cytotoxic agents, clinical trials using rapamycin to 
inhibit mTOR activity are still going ahead (table 4.1). 
 
1.6.1 A role for autophagy in enhancing radiation treatment efficacy 
 
Strategies to increase apoptosis in cancer cells and thereby boost radiation treatment are well 
sought after and finding measures that complement radiation therapy and amplify apoptosis is 
a major focus of cancer research. Cancer cells often respond to radiation therapy by inducing 
autophagy, possibly as an alternative cell death mechanism to apoptosis resistant cells (Paglin 
Stellenbosch University  http://scholar.sun.ac.za
189 
 
et al., 2001). Inhibiting pro-apoptotic proteins can lead to the induction of autophagy and 
sensitize cancer cells to radiation treatment. siRNA against Bak/Bax increased autophagy in 
breast and lung cancer models and sensitized these cells to radiation therapy to a degree 
determined by the level of autophagy. This sensitization was augmented by the presence of 
the mTOR inhibitor, Rad001 (Kim et al., 2006b). Inhibition of the mTOR pathway by 
rapamycin has also been demonstrated to delay tumour growth in soft tissue sarcoma treated 
with radiation (Murphy et al., 2009). Impairment of apoptosis and an associated increase in 
autophagy is also thought to be responsible for the enhanced tumour cytotoxicity following 
radiation treatment in another breast and lung xenograft model (Moretti et al., 2009). 
Furthermore, induction of autophagy during caspase inhibition enhanced the anti-cancer 
effects of radiation treatment, in a lung in vitro and a mouse cancer xenograft model (Kim et 
al., 2008). 
 
1.7 Can autophagy defy chemotherapy through drug sequestration? 
 
As our understanding of autophagy broadens, it is becoming clear that the dynamics of this 
ancient and essential homeostatic mechanism are more complex than first realised. Autophagy 
has now been implicated in host defence and inflammation following exposure to toxic 
substances (Levine et al., 2011). Initially, considered as a regulated system of bulk 
degradation, it is now obvious that autophagy can engulf targets located within the cytoplasm 
of cells in a selective manner (Yu et al., 2008). 
 
Autophagy is thought to confer resistance onto apoptosis deficient tumour cells receiving anti-
cancer therapy by delaying the onset of cellular death in the form of necrosis, resulting from 
metabolic catastrophe (Mathew et al., 2007a). Although autophagy is viewed as a mechanism 
to maintain cellular energy homeostasis, its activity is frequently demonstrated to be increased 
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in response to stress. An intriguing alternative hypothesis is that autophagy could act in a 
complementary manner and ingest drugs that have entered the cell and thereby prevent cancer 
killing effects by obstructing the access of these agents to the site of their anti-cancer activity. 
In support of this assertion, the inhibition of autophagy was shown to cause increased cell 
death of Caco-2 cells following exposure to toxins released by the bacterium Vibrio cholera, 
where the engulfment and sequestration in lysosomal compartments was proposed as the 
predominant mechanism of defensive action (Gutierrez et al., 2007). Most recently, HMGB1 
(high mobility group box 1) release following chemotherapy induced damage to leukaemia 
cells caused a protective autophagy response (Liu et al., 2011a), and it has been proposed that 
the release of damage-associated molecular pattern molecules (DAMPs) during chemotherapy 
can increase autophagy to grant a defensive reaction (Liu et al., 2011b). In this way, damage 
caused by cytotoxic agents could directly result in an increased autophagy response.  
 
Alkaline chemotherapy drugs such as the anthracyclines are known to become sequestered 
and deactivated in the acidic compartments of lysosomes (Hurwitz et al., 1997). Vacuolar 
ATPases are over-expressed in many multi-drug resistant cancer cells and are associated with 
the increased sequestration of chemotherapy drugs within these lysosomes (Ma and Center, 
1992). Targeting this mechanism of drug sequestration has been proposed as a potential anti-
tumour target (Lee and Tannock, 2006). Pharmacologic and genetic inhibition of vacuolar 
ATPase activity or expression can also reverse resistance to some chemotherapy agents 
(Herlevsen et al., 2007). Also, agents that increase lysosomal pH, such as the vacuolar 
ATPase inhibitor bafilomycin A1, are known to inhibit autophagy by preventing fusion of 
autophagosomes with lysosomes (Klionsky et al., 2008). As autophagy results in bulk 
cytoplasmic engulfment and delivery of cytoplasmic cargo to acidic lysosomes, and basic 
cancer drugs that are inhibited upon entering lysosomes will be present within cytoplasmic 
regions of treated cells, then it stands to reason that increased autophagy could play a role in 
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the protection of cells from cancer agents in this way. Recent literature has shown how 
autophagy can become increased in response to chemotherapy induced damage, but, to date, 
no evidence for the engulfment and delivery of anticancer agents to lysosomes has been 
described. 
 
1.8 Doxorubicin 
 
The anthracyclines, doxorubicin and epirubicin, were first introduced in the 1960s, and they 
remain some of the most effective anticancer agents available and are important elements in 
many breast cancer chemotherapeutic treatment regimens to this day (O'Shaughnessy et al., 
2002). Unfortunately, anthracyclines are also cytotoxic and affect a wide variety of systems, 
often leading to a reduction in the quality of life of many patients, and even death in some 
cases (Barrett-Lee et al., 2009). Utility of anthracyclines such as doxorubicin is limited as the 
cardiotoxicity of this drug class is cumulative and dose-limiting. Doxorubicin is more 
cardiotoxic than epirubicin and progressive myocardial damage is one possible result of its 
cumulative and dose related effects (Swain et al., 2003). As doxorubicin is a valuable tool in 
the treatment of breast cancer, strategies to reduce doses, increase efficacy and protect non-
cancer cells from off-target cytotoxicity are desperately required. 
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2 Hypothesis and experimental aims 
 
 
2.1 Hypothesis 
 
Amino acid starvation will increase the sensitivity of MDAMB231cells, but not MCF12A 
cells, to doxorubicin (1 µM). 
 
2.2 Experimental aims 
 
 
1. Establish the relative sensitivity of MDAMB231 cells and MCF12A cells to 
doxorubicin (1 µM). 
2. Establish whether autophagy increases during doxorubicin (1 µM) treatment in these 
cell lines. 
3. Determine whether bafilomycin A1 (10 nM) alters the sensitivity of these cell lines to 
doxorubicin (1 µM). 
4. Determine whether amino acid starvation in conjunction with doxorubicin (1 µM) 
treatment alters sensitivity of these cell lines to treatment and whether this is 
associated with similar changes in lysosomal acidity. 
5. Assess how MCF7 cells respond to similar treatments.  
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3 Methods and materials 
 
 
The materials and methods describing the following procedures utilized in this study can be 
found in previous chapters: Cell culture, caspase 3/7 activity assay, trypan blue assay, LC3 
and beclin 1 western blotting, ATG5 siRNA transfection and cell cycle analysis. 
 
3.1 Hoechst nuclear staining (analysis of pyknosis and karyorrhexis) 
 
 
Differentiation between normal nuclear morphology and the nuclear condensation and 
fragmentation that is characteristic of apoptosis can be achieved by using the DNA 
intercalating dye, Hoechst. MDAMB231, MCF12A and MCF7 cells were cultured and 
maintained as described previously. 60 000 MCF12A cells or 45 000 MDAMB231 or MCF7 
cells were plated into 35 mm culture dishes containing previously sterilised coverslips, 48 
hours prior to treatment. After treatments, the cover slips were removed, placed over glass 
slides, and washed with 100 µL of ice cold PBS (phosphate buffer solution). They were then 
treated with 500 µL of ice cold acetone: methanol (1:1) and incubated at 4°C for 10 minutes. 
The fixative was then removed and cover slips again washed with 100 µL ice cold PBS. 100 
µl of Hoechst (Hoechst 33342, Sigma Chemical Co., St Louis, MO, USA) in a 1:200 dilution 
(50 µg/ml) in sterile PBS was added directly onto cover slips and incubated in the dark for 10 
minutes. Coverslips were then washed 5x with 100 µL of PBS at room temperature before 
being mounted on permanent slides. They were then viewed immediately using a Nikon E-
400 fluorescence microscope (Nikon Microscopes, Kobe, Japan). Images were acquired using 
a Nikon DM X 1200 colour digital camera (Nikon Microscopes, Kobe, Japan) using ACT-I 
software (Nikon Microscopes, Kobe, Japan) to process the images. Three independent 
experiments were conducted and four representative regions of each condition were acquired 
per experiment. At least 200 cells were analysed per region. For each image the number of 
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condensed/fragmented nuclei was counted and expressed as a percentage of total number of 
nuclei counted. In this manner the percentage apoptosis was determined for each experimental 
condition. 
 
3.2 Doxorubcin and LAMP-2A fluorescence imaging 
 
  
15 000 MCF12A cells and 10 000 MDAMB231 cells were seeded per well into 8-well 
Nunc™ chambered plates (Nalge Nunc, Rochester, NY, USA). Cell monolayers were washed 
three times with sterile 0.1 M PBS before being fixed and permeabilised with an ice-cold 1:1 
methanol/acetone mixture for 10 minutes at 4ºC. After being left to air dry for 20 minutes in 
the dark, cells were, once more, washed three times in sterile PBS. The following steps were 
conducted in a dark, humidified environment at room temperature. Non-specific binding was 
blocked by incubating in 5% donkey serum for 20 minutes. Cells were then incubated with 
anti-LAMP-2A primary antibody (Cell Signalling, MA, USA) for 90 minutes. Cells were then 
rinsed three times with sterile PBS and incubated with a FITC bound secondary antibody for 
30 minutes. Immediately thereafter, cells were washed three times in sterile PBS and enough 
Hoechst 3342 (10 mg/ml in a 1:200 dilution) was then added to cover the entire cell 
monolayer. This was left to incubate for 10 minutes at 4ºC. Finally, cells were washed five 
times in sterile PBS and images were immediately acquired with an Olympus CellˆR 
fluorescence 1 X 81 inverted microscope (Olympus Biosystems, Germany) using an F-view II 
camera (Olympus Biosystems, Germany) for image acquisition and CellˆR software, 
(Olympus Biosystems, Germany) for processing images.  
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3.3 Drug preparation 
 
 
Doxorubicin hydrochloride (D1515, Sigma Chemical Co., St Louis, MO, USA) was prepared 
in amino acid free medium in ready to use aliquots to avoid freeze thaw cycles, and was 
stored at -20°C. Bafilomycin A1 from Streptomyces griseus (B1793, Sigma Chemical Co., St 
Louis, MO, USA) was dissolved in DMSO in ready to use aliquots to avoid freeze thaw 
cycles, and was stored at -20°C. 
 
3.4 Lysotracker™ (flow cytometry) 
 
Lysotracker™ was used in conjunction with flow cytometry as described previously (chapter 
2). However, all treated samples were split 1:1 and only one half stained with the 
lysotracker™ dye. Values obtained for the unstained samples were then subtracted from those 
obtained for the stained samples. 
 
3.5 Statistical analysis 
 
All values are presented as the mean ± standard error of the mean (SEM). Differences 
between time points and treatment groups were analysed using one or two analysis of 
variance (ANOVA). Significant changes were further assessed by means of the Bonferroni 
post hoc analysis where appropriate. All statistical analyses were performed using Graphpad 
Prism version 5.01 (Graphpad Software, Inc, CA, USA). The minimum level of significance 
accepted was p < 0.05. 
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4 Results 
 
4.1 MDAMB231 cells are more resistant to a 24 hour treatment of 
doxorubicin (1 µM) than MCF12A cells  
 
 
Con
Dox (1 µM)
A. B.
C.
 
 
 
 
 
Doxorubicin (1 µM) treatment significantly increased apoptosis in MCF12A cells (Fig 4.1). 
Approximately 15% percent of MCF12A nuclei presented with morphological changes to 
their nuclei that are characteristic of apoptosis, following treatment with doxorubicin (1 µM) 
and staining with Hoechst (Fig 4.1a and Fig 4.1b). MCF12A cells also displayed significantly 
increased caspase 3/7 activity following treatment with doxorubicin (1 µM) for 24 hours (Fig 
4.1c).  
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A. B.
Con
Dox (1 µM)
C.
 
 
 
 
 
MDAMB231 cells display a relative resistance to apoptosis following treatment with 
doxorubicin (1 µM), when compared to the non-tumourogenic MCF12A cell line. A very 
small, but statistically significant percentage of MDAMB231 nuclei presented with 
morphological changes that are characteristic of apoptosis, following treatment with 
doxorubicin (1 µM) and staining with Hoechst (Fig 4.2a and Fig 4.2b). MDAMB231cells also 
displayed a more pronounced (and significant) increase in caspase 3/7 activity following 
treatment with doxorubicin (1 µM) (Fig 4.2c). 
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4.2 Depleting culture medium of amino acids during 24 hours of 
doxorubicin (1 µM) treatment protects MCF12A cells but not MDAMB231 
cells from a loss of cellular membrane integrity 
 
  
 
 
 
The trypan blue vital stain is able to traverse only those cell membranes with compromised 
integrity, and therefore functions as a marker of necrotic and late stage apoptotic cell death 
and can be used as an indicator of actual cellular impairment following an intervention. 
MCF12A cells are extremely susceptible to doxorubicin (1 µM) cytotoxicity. Approximately 
80% of these cells become trypan blue positive after a 24 hour incubation in 1 µM 
doxorubicin (Fig 4.3). Treatment with doxorubicin (1 µM) in culture medium completely 
depleted of amino acids resulted in significantly less MCF12A cells becoming trypan blue 
positive.  
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MDAMB231 cells appeared to be comparatively resistant to doxorubicin (1 µM) induced 
membrane impairment, and amino acid starvation did not change the percentage of trypan 
blue positive MDAMB231 cells following treatment with doxorubicin (1 µM) (Fig 4.4). 
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4.3 A 24 hour treatment with doxorubicin (1 µM) increases LC3 II levels 
in MCF12A and MDAMB231 cells  
 
A. C.
B.
 
 
Both MCF12A and MDAMB231 cells responded to the presence of doxorubcin (1 µM) by 
increasing LC3 II protein levels (Fig 4.5). Levels of the autophagy protein beclin 1 did not 
change during these experiments. 
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4.4 Autophagy inhibition increases caspase 3/7 activity in MDAMB231 
cells but not MCF12A cells treated with doxorubicin (1 µM) 
 
 
 
Inhibition of autophagy using ATG5 siRNA did not alter the level of caspase 3/7 activity in 
MCF12A cells treated with doxorubicin (1 µM) (Fig 4.6). 
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Inhibition of autophagy in MDAMB231 cells with ATG5 siRNA lead to a significant increase 
in measurable caspase 3/7 activity when these cells were treated with doxorubicin (1 µM) (Fig 
4.7). 
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4.5 Bafilomycin (10 nM) increases caspase 3/7 activity in MDAMB231 
cells and MCF12A cells treated with doxorubicin (1 µM) 
 
 
 
Treating MCF12A cells with 10 nM of bafilomycin 6 hours prior to analysis greatly increased 
caspase 3/7 activity when these cells were treated with doxorubicin (1 µM) (Fig 4.8). 
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As in MCF12A cells, treating MDAMB231 cells with 10 nM of bafilomycin 6 hours prior to 
analysis greatly increased caspase 3/7 activity when these cells were treated with doxorubicin 
(1 µM) (Fig 4.9). 
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4.6 Bafilomycin (10 nM) increases detectable levels of intracellular 
doxorubicin in MDAMB231 cells and MCF12A cells treated with 
doxorubicin (1 µM) 
 
Doxorubicin (1 µM)
Doxorubicin (1 µM) + 
Bafilomycin (10 nM)
DoxorubicinLAMP-2A
 
 
 
 
Cells were stained with the lysosomal associated membrane protein (LAMP-2A) during 
doxorubicin treatment (1 µM). Intracellular localization of doxorubicin was tracked by 
exploiting the autofluorescence of doxorubicin, a technique that has been utilized successfully 
in MDAMB231 and other cell lines (Li et al., 2010). MCF12A cells treated with doxorubicin 
(1 µM) displayed obvious intracellular red fluorescence associated with doxorubicin (Fig 
4.10). Notably, small localized regions of intense red fluorescence were observed in most 
doxorubicin treated (1 µM) MCF12A cells (white arrows in above images) but were 
completely absent in cells that had also been supplemented with bafilomycin (10 nM).   
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DoxorubicinLAMP-2A
Doxorubicin (1 µM)
Doxorubicin (1 µM) + 
Bafilomycin (10 nM)
 
 
MDAMB231 cells treated with doxorubicin (1 µM) displayed obvious and intense localized 
regions of intracellular red fluorescence associated with doxorubicin (Fig 4.11). This red 
fluorescence was associated with pooling of the LAMP-2A signal (white arrows in the above 
image) in doxorubicin (1 µM) treated MDAMB231 cells. Notably, LAMP-2A pooling 
disappeared if bafilomycin (10 nM) was added. Importantly, MDAMB231 cells treated with 
doxorubicin (1 µM) and bafilomycin (10 nM) had significantly more observable red 
fluorescence within the cytoplasmic regions of these cells. However, unlike MCF12A cells, 
there was no doxorubicin associated with nuclear regions of these cells. 
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4.7 Amino acid deprivation increases autophagy induction and 
autophagy flux in MCF12A cells and in MDAMB231 cells treated with 
doxorubicin (1 µM) respectively 
 
 
 
Doxorubicin (1 µM) treatment during amino acid deprivation resulted in increased induction 
of LC3 in MCF12A cells (Fig 4.12). Furthermore, decreased LC3 II protein levels following 
doxorubicin (1 µM) treatment during amino acid deprivation were shown to accumulate if 
bafilomycin (10 nM) was administered 6 hours prior to analysis. This indicates increased 
autophagy flux in MDAMB231 cells following doxorubicin (1 µM) treatment during amino 
acid starvation. 
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4.8 Amino acid deprivation during doxorubicin (1 µM) treatment causes 
lower levels of lysosomal acidity in MDAMB231 cells but not in MCF12A 
cells which correspond to increased and decreased caspase activity 
respectively 
 
 
 
In concurrence with previous experimental data (described in chapter 2), amino acid 
deprivation during a 24 hour treatment with doxorubicin (1 µM) resulted in higher, albeit non-
significant, lysosomal acidity levels in MCF12A cells (Fig 4.13). 
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In concurrence with previous experimental data (described in chapter 2), amino acid 
deprivation during a 24 hour treatment with doxorubicin (1 µM) resulted in significantly 
diminished lysosomal acidity levels, close to baseline, in MDABM231 cells (Fig 4.14). 
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Omission of amino acids from culture medium during treatment of MCF12A cells with 
doxorubicin (1 µM) resulted in decreased caspase 3/7 activity in these cells (Fig.4.15). This 
protection from increased caspase activation corresponds with the increased and sustained 
lysosomal acidity observed during amino acid starvation (described in chapter 2). 
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Incubation of MDAMB231 cells in culture medium deprived of amino acids, during treatment 
with doxorubicin (1 µM), resulted in significantly increased caspase 3/7 activity at 24 hours, 
but not 12 hours after intervention (Fig 4.16). These findings are in accordance with dynamic 
changes in lysosomal acidity levels at these times during amino acid deprivation (described in 
chapter 2). 
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4.9 Amino acid deprivation during doxorubicin (1 µM) treatment 
exacerbates g2/m cell cycle arrest associated with doxorubicin toxicity in 
MDAMB231 cells 
 
 
 
A.
B.
 
 
 
 
Doxorubicin (1 µM) treatment of MCF12A cells results in significant changes to the cell 
cycle profile in these cells. Deprivation of amino acids from culture medium during treatment 
of MCF12A cells with doxorubicin (1 µM) resulted in the percentage of cells in the g0/g1 
phase being similar to those in untreated controls (Fig 4.17). However, the percentage of cells 
in g2/m phase decreased further if amino acids were absent. 
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A.
B.
 
 
 
Doxorubicin treatment is typically associated with an increased g2/m arrest in MDAMB231 
cells (Lambert et al., 2008), a phenomenon that was also observed in our model (Fig 4.18). 
Treatment of MDAMB231 cells with doxorubicin (1 µM) in culture medium deprived of 
amino acids resulted in a further increase in the percentage of cells in the g2/m phase of the 
cell cycle.  
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4.10 Amino acid deprivation or autophagy inhibition with ATG5 siRNA 
during doxorubicin (1 µM) treatment results in increased levels of 
doxorubicin in the nuclear regions of MDAMB231 cells 
 
DoxorubicinLAMP-2A
Doxorubicin (1 µM) + 
ATG5 siRNA
Doxorubicin (1 µM) –
amino acids
Doxorubicin (1 µM)
 
 
 
Amino acid deprivation from culture medium during treatment of MCF12A cells with 
doxorubicin (1 µM) caused an apparent increase in LAMP-2A pooling in the perinuclear area 
of these cells (illustrated by the white arrow) (Fig 4.19). Furthermore, amino acid deprivation 
during treatment resulted in a prominent decrease in observable doxorubicin (red 
fluorescence). Inhibition of autophagy with ATG5 siRNA resulted in a dispersed pattern of 
LAMP-2A staining, but doxorubicin was still readily visible in these cells. 
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DoxorubicinLAMP-2A
Doxorubicin (1 µM)  
+ ATG5 siRNA
Doxorubicin (1 µM)
- amino acids
Doxorubicin (1 µM)
+ amino acids
 
 
MDAMB231 cells treated with doxorubicin (1 µM) displayed obvious cytoplasmic pooling of 
LAMP-2A and intense localized regions of intracellular red fluorescence associated with 
these regions (illustrated by the white arrow) (Fig 4.20). Amino acid deprivation during 
treatment resulted in a loss of LAMP-2A pooling and a more dispersed staining pattern for 
this marker. Furthermore, these cells displayed increased levels of nuclear doxorubicin (red 
fluorescence). Inhibition of autophagy with ATG5 siRNA resulted in a prominent increase in 
cellular doxorubicin, especially at the perinuclear zone (illustrated by the blue arrow). 
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4.11 Amino acid deprivation does not alter lysosomal acidity or apoptosis 
levels during doxorubicin (1 µM) treatment in beclin 1 haploinsufficient 
MCF7 cells 
 
 
 
MCF7 cells are autophagy incompetent due to a haploinsufficiency in the gene associated 
with the autophagy protein beclin 1. Doxorubicin (1 µM) treatment, either with or without 
amino acids, did not significantly alter lysosomal acidity in these cells (Fig 4.21). 
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A. B.
Con Dox (1 µM)
Dox (1 µM)
- aacids
+ baf (10 mM)
 
 
Doxorubicin (1 µM) treatment of MCF7 cells resulted in increased apoptosis (Fig 4.23). 
However, doxorubicin (1 µM) treatment of these cells in culture medium deprived of amino 
acids, either with or without bafilomycin (10 nM), does not significantly alter apoptosis levels 
(Fig 4.23). Notably, MCF7 cells do not possess active caspase 3 (Fig 4.22). 
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5 Discussion 
 
Many cancers are known to respond to certain chemotherapy or to radiation therapy by 
increasing autophagy activity. Although the consequences of autophagy activation in these 
circumstances are still debatable, it appears as though autophagy acts in its predominant role 
of survival mediator in many of these cases (Yang and Chen, 2011). Anthracyclins such as 
doxorubicin have also been shown to increase autophagy levels in cancer cells in some 
instances. At lower doses, doxorubicin elicits an autophagy response in breast cancer cells 
(Akar et al., 2008) as well as in sarcoma cell lines (Lambert et al., 2008). Additionally, 
increased levels of ATG2A mRNA have been observed following doxorubicin treatment 
(Levy and Thorburn, 2011), suggesting increased autophagy activation at the transcriptional 
level. 
 
 
In a recent study, 2-deoxy-glucose preserved ATP content and contributed to the 
cytoprotection of rat cardiomyocytes treated with 1 µM doxorubicin (Chen et al., 2011). This 
glucose analogue increased markers of autophagy which was posited as a potential reason for 
protection from cytotoxicity. Conversely, activation of autophagy in cultured cardiomyocytes 
following doxorubicin (1 µM) treatment mediated its cardiotoxic effect (Kobayashi et al., 
2010). Here, it was shown that autophagy inhibition resulted in decreased cell death and it 
was postulated that autophagy directly contributed to doxorubicin induced toxicity. These 
exemplify the conflicting nature of studies and reported findings relating autophagy to drug 
toxicity and illustrate the need for further research into this important topic. 
 
Autophagy activity is increased in response to stress, where it functions as an important 
mechanism whereby damaged organelles and aggregated proteins are degraded in lysosomes. 
However, there is still no clear mechanism whereby induction of autophagy could lead to 
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tolerance against chemotherapy agents. Recently it has been shown that release of damage-
associated molecular pattern molecules (DAMPs) during chemotherapy is related to 
autophagy mediated resistance to anticancer treatment in some contexts (Liu et al., 2011b), 
providing a mechanism where damage caused by drug treatment can directly result in 
increased autophagy. Elevation of high mobility group box 1 (HMGB1), released in response 
to chemotherapy induced cell damage, was also shown to increase drug resistance in 
leukaemia cells by increasing autophagy (Liu et al., 2011a). Bafilomycin A1 increased 
sensitivity of leukaemia cells to chemotherapy in the aforementioned study. Lysosomal fusion 
and throughput of autophagy depends on the low pH of lysosomal compartments (Klionsky et 
al., 2008). Increasing the lysosomal pH with pharmacological agents is an effective method of 
autophagy inhibition as disruption of the fusion event between autophagosomes and 
lysosomes prevents progression of autophagy. Some drug resistant cell lines are able to 
tolerate alkaline chemotherapy drugs such as the anthracyclines by sequestering and 
deactivating these agents in the acidic compartments of lysosomes (Hurwitz et al., 1997). 
Exposure of these compounds to environments of low pH renders them inactive and unable to 
access sites of chemotoxicity such as the nucleus.  
 
In the previous chapters (chapter 2 and chapter 3), experimental data suggested that a 
metastatic adenocarcinoma cell line with high basal autophagy (MDAMB231) is susceptible 
to amino acid starvation and relies on autophagy for survival in these circumstances. 
However, during longer periods of amino acid starvation (24 hours), increased autophagy flux 
resulted in a particular and reproducible pattern of decreased lysosomal acidity in these cancer 
cells with high basal autophagy. Importantly, it was noted that lysosomal acidity levels 
underwent dynamic changes during amino acid starvation and returned to baseline levels 
following peak acidity between 6 and 12 hours of starvation while non-cancer cells displayed 
a sustained increase in lysosomal acidic compartmentalisation. Lysosomal acidity appears to 
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be important to autophagy continuance. Therefore, it was postulated that a protective increase 
in autophagy during drug treatment could be circumvented during amino acid starvation 
therapy, were drug induced autophagy to coincide with amino acid induced lysosomal acidity 
depression (even in conditions of high autophagy flux). 
 
Data clearly indicates that a non-tumourogenic cell line (MCF12A) with low basal autophagy 
is less resistant to programmed cell death during treatment with a moderate dose of 
doxorubicin (1 µM) than a metastatic cell line with high basal autophagy (MDAMB231). 
MCF12A cells had a significantly increased appearance of morphological changes 
characteristic of apoptosis as well as significantly enhanced caspase 3/7 activity (Fig 4.1). On 
the other hand, MDAMB231 cells showed few signs of late stage apoptosis and a more 
modest increase in activation of caspase 3/7 (Fig 4.2). Interestingly, depletion of amino acids 
from the culture medium of MCF12A cells during doxorubicin treatment resulted in a 
significant protection from loss of membrane integrity (a sign of late stage cell damage), as 
assessed by the trypan blue assay (Fig 4.3). Previous experimental data revealed that amino 
acid starvation resulted in an enhanced autophagy response (chapter 2). It is suggested here 
that this increase in autophagy could be responsible, at least in part, for the tolerance to 
doxorubicin treatment seen here. On the other hand, MDAMB231 cells did not experience 
any protection if starved of amino acids during treatment. 
 
Both MCF12A and MDAMB231 cells responded to the presence of doxorubicin (1 µM) by 
increasing LC3 II protein levels (Fig 4.5), indicating an autophagy response during treatment. 
Inhibition of autophagy with ATG5 siRNA lead to a significant increase in caspase 3/7 
activity only in MDAMB231 cells (Fig 4.7), suggesting that autophagy has a protective role 
during chemotherapy of these cells. Importantly, the addition of bafilomycin (10 nM), 6 hours 
prior to analysis, greatly increased caspase 3/7 activity during doxorubicin treatment in both 
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cell lines, but had a particularly pronounced influence on the partially resistant cancer cell 
line. Agents such as bafilomycin A1, a specific inhibitor of vacuolar H+ATPase (V-ATPase) 
(Yoshimori et al., 1991), are now known to rapidly and reversibly inhibit fusion between 
autophagosomes and lysosomes, if administered for short time periods (Klionsky et al., 2008), 
through the mechanism of inhibiting lysosomal acidification (Yamamoto et al., 1998). 
Furthermore, many drug resistant cancer cells are thought to increase sequestration and 
deactivation of chemotherapy drugs within lysosomes (Hurwitz et al., 1997). The proposed 
mechanism is through increased uptake of these compounds into endosomes which eventually 
fuse with lysosomes to deliver these drugs into the acidic internal environments where they 
become deactivated (Lee and Tannock, 2006). Bafilomycin A1 and other agents that raise the 
pH of lysosomes can increase cytotoxcity by preventing fusion and delivery of drugs in this 
way. Therefore, the increased caspase activity observed here, following bafilomycin 
administration, suggests that doxorubicin is being delivered to and accumulating in lysosomes 
and is therefore unable to exert its cytotoxic effects on the cell. As autophagy inhibition also 
results in increased caspase activity here, it is possible that mass engulfment of cytoplasmic 
material (which includes doxorubicin) could facilitate delivery of this drug into lysosomal 
compartments in this cell line and thereby have a protective influence. As MDAMB231 cells 
have high basal autophagy levels, internalized doxorubicin could rapidly be delivered to 
lysosomes and deactivated, conferring a partial resistance. 
 
These assertions are further strengthened by qualitative evidence gained from fluorescence 
microscopy of MDAMB231 cells receiving doxorubicin treatment. Intracellular localization 
of doxorubicin can be tracked by exploiting the autofluorescence of doxorubicin, a technique 
that has been utilized successfully in MDAMB231 and other cell lines in the past (Li et al., 
2010). Treatment of MDAMB231 cells results in the clear accumulation of doxorubicin at 
perinuclear regions (Fig 4.11). Identification of the spatial location of lysosomes at the same 
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time, by fluorescently tagging the lysosomal associated membrane protein LAMP-2A, 
demonstrates lysosomal pooling in regions associated with doxorubicin accumulation in these 
cells. This implies that doxorubicin is located in association with lysosomes during these 
conditions.  MCF12A cells show little pooling of doxorubicin after a 24 hour treatment and 
have no discernable pooling of LAMP-2A signal (Fig 4.10).  Furthermore, the addition of 
bafilomycin A1 (10 nM), 6 hours prior to imaging, led to a vast and pronounced accumulation 
of doxorubicin within the cytoplasmic compartment of MDAMB231 cells. Intriguingly, 
pooling of LAMP-2A signal is mostly dissipated and little association between LAMP-2A 
and doxorubicin is evident after the addition of bafilomycin A1. Therefore, it appears as 
though doxorubicin is not associated with lysosomes when administered in the presence of 
vacuolar H+ATPase inhibitor bafilomycin A1. However, excessive pooling of the drug does 
suggest that it is accumulating somewhere. As bafilomycin A1 inhibits the fusion of 
autophagosomes and endosomes with lysosomes, it is possible that the observed 
accumulations of doxorubicin is due to increased cytoplasmic accumulation of 
autophagosomes and endosomes containing doxorubicin, but which are unable to fuse with 
lysosomes. Further investigation of this phenomenon is required. 
 
Autophagy flux is clearly increased in MDAMB231 cells in response to doxorubicin (1 µM) 
treatment (Fig 4.12) as well as during a short term bout of amino acid starvation (chapter 2), 
and lysosomal acidity greatly increases as a consequence of this treatment in both MCF12A 
cells (Fig 4.13) and in MDAMB231 cells (Fig 4.14). Interestingly, when these cell lines were 
treated with the anticancer agent in culture medium deprived of amino acids, lysosomal 
acidity significantly decreased in MDAMB231 cells but remained elevated in MCF12A cells. 
These findings mirrored previous observations when these cell lines were exposed to 
conditions of amino acid starvation (chapter 2). Notably, alterations in lysosomal acidity were 
associated with corresponding changes in caspase 3/7 activity in both cell lines. MDAMB231 
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cells experienced significantly greater levels of caspase 3/7 activity during conditions of 
depressed lysosomal acidity while MCF12A cells were granted a relative protection from the 
cytotoxic impact of drug treatment (Fig 4.15 and Fig 4.16). Strikingly, if MDAMB231 cells 
were analysed after 12 hours of combined doxorubicin/amino acid starvation treatment, these 
increases in apoptosis activation were not evident. Importantly, at this time point of amino 
acid starvation lysosomal acidity was confirmed to be elevated compared to baseline (chapter 
2), further supporting the premise of lysosomal acidity deprivation facilitated increases in 
caspase activity in this model. 
 
If decreased lysosomal acidity levels during amino acid starvation prevent fusion of 
autophagosomes with lysosomes then the probability of drug access to sites of cytoxic action 
would be increased. This would result in the increased apoptosis activation demonstrated 
here. Doxorubicin treatment is associated with genotoxic stress and prolonged g2/m cell cycle 
arrest (Koutsilieris et al., 1999, Lambert et al., 2008), due to intercalation of this agent with 
DNA and activation of the g2/m DNA damage checkpoint. Therefore, decreased abundance 
of doxorubicin within lysosomes during amino acid deprivation would result in an 
exacerbated accumulation of cells in the g2/m phase of the cell cycle. Our experimental data 
indicates this to be precisely the case with an approximately 6% increase in the percentage of 
MDAMB231 cells in the g2/m phase of the cell cycle if doxorubicin treated cells are 
simultaneously starved of amino acids (Fig 4.18). Additionally, the relative protection of 
MCF12A cells can be attributed to increased autophagy levels and decreased access of 
doxorubicin to the nucleus, as amino acid starvation during drug treatment resulted in a return 
of the cell cycle profile similar to that of untreated cells (Fig 4.17). Also, qualitative 
experimental evidence shows that doxorubicin treatment during amino acid starvation causes 
decreased doxorubicin accumulation and decreased LAMP-2A pooling and an increased 
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doxorubicin signal in the nuclear regions of MDAMB231 cells (Fig 4.20), whereas the 
converse is observed in MCF12A cells during similar treatment (Fig 4.19). 
 
Data presented here suggests that alterations in lysosomal acidity are the cause for increased 
apoptosis induction or protection in MDAMB231 cells and MCF12A cells respectively. 
However, the role for autophagy should not be overlooked. Inhibition of autophagy with 
ATG5 siRNA resulted in a prominent increase in levels of doxorubicin, in the nucleus and at 
the perinuclear zone (Fig 4.20), while MCF12A cells exposed to ATG5 siRNA prior to 
treatment showed signs of increased cytoplasmic doxorubicin accumulation (Fig 4.19). 
Interestingly, a cell line with decreased autophagy (MCF7), due to haploinsufficiency in the 
gene coding for beclin 1, displayed no alterations to lysosomal acidity during doxorubicin (1 
µM) treatment, in the presence or absence of amino acids (Fig 4.21). While this cell line does 
not possess active caspase 3 (Fig 4.22), it did show signs of significantly increased apoptosis 
during doxorubicin (1 µM) treatment. These levels of apoptosis did not increase if treatment 
occurred in the absence of amino acids or the presence of bafilomycin A1 (10 nM) (Fig 4.23). 
Together, these results indicate that active autophagy machinery is required for the 
accumulation of doxorubicin within lysosomes and demonstrates an important role for 
autophagy in these possesses. 
  
5.1 Conclusions 
 
It is suggested here that cancers with high basal autophagy, such as the ras-mutant 
MDAMB231 cells, possess an inherent resistance to alkaline chemotherapy agents such as 
doxorubicin that can be overcome with the pharmacologically mediated elevation of 
lysosomal pH. Furthermore, experimental evidence presented here indicates that short term 
starvation during chemotherapy is a realistic avenue for adjuvant therapy but there is need for 
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future investigation. Non-cancer cells, with low basal autophagy, able to increase autophagy 
activity in response to short term starvation could potentially benefit from protection during 
anthracycline treatment. Recent evidence of differential protection of non-cancer cells in 
human (Safdie et al., 2009) and animal studies (Raffaghello et al., 2008) during chemotherapy 
and the recent clinical interest in autophagy modulation during therapy necessitate additional 
studies such as the one presented here. Finally, this study is the first to our knowledge that 
describes a mechanism whereby autophagy can lead to the inactivation of basic cancer drugs 
by delivering these agents to acidic lysosomal compartments. 
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5  
 
Development of a novel in vivo mouse mammary cancer 
model to study autophagy in the non-cancer cell 
population of the tumour and apoptosis within the whole 
tumour 
 
Solid tumours are heterogenous masses comprised of cancer cell and 
stromal elements that collectively make up the malignant neoplasm. 
Although generally thought of as a mass of cancer cells, much of the solid 
tumour is typically made up of a variety of cell subpopulations that are 
required for continued growth and invasion. This chapter describes the 
establishment of a novel mammary tumour model in GFP-LC3 transgenic 
mice in which the influence of protein deprivation (and theoretically other 
interventions) on autophagy in the non-cancer population of tumours was 
analysed. The impact of apoptosis after protein deprivation in this model 
was also assessed. 
 
1 Introduction 
 
Solid tumours are sometimes described as being organ-like and are now known to contain 
many different cell subpopulations. Neoplasms possess a heterogenous composition, and 
contain cancer and non-cancer cells of many varieties. In fact, invading non-cancer cells and 
stromal elements are vital for the continued survival of solid tumours (Mueller and Fusenig, 
2004, Egeblad et al., 2008). Although Stephen Paget‟s well known metaphor of tumour cells 
behaving like plant seeds requiring favourable conditions and a microenvironment able to 
facilitate progression and growth is over 100 years old, the tumour microenvironment and the 
contribution of non-cancer cells within cancers has been largely ignored in the study of solid 
neoplasms (Mueller and Fusenig, 2004).  
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 In addition to tumour cells, so-called non-cancer tumour cells such as fibroblasts, 
macrophages and other myeloid cells are all present within the tumour microenvironment 
(Egeblad et al., 2008). Together with interstitial fluid and other connective tissue elements 
such as elastin, fibrin and collagen, the relative amount of stroma to malignant cells can vary 
considerably between tumours (Dvorak et al., 1983). Additionally, neoangiogenesis and the 
development of blood vessels that are derived from native vascular stroma, throughout the 
tumour mass, are vital for continued progression of tumour growth (Johann et al., 2010, 
Tredan et al., 2007) where hematopoietic cells in the tumour stroma regulate tumour 
progression (Huynh et al., 2011). Moreover, prognosis and sensitivity to chemotherapeutics 
also depend on the makeup of the tumour microenvironment (Tredan et al., 2007). 
 
All mammalian cells are believed to be able to induce autophagy in response to stress such as 
amino acid deprivation (Mizushima et al., 2004). Strategies aiming to induce cell death in 
cancer cells or protect non-cancer cells during treatments often overlook the impact of indirect 
effects on surrounding cell populations. It is vitally important that models are devised that 
take these aspects into account. 
 
1.2 In vivo assessment of autophagy using GFP-LC3 
 
Assessment of autophagy is complex and contains many pitfalls. The most common methods 
employ the use of fluorescence techniques or electron microscopy (Mizushima et al., 2010), 
but these techniques are laborious and require much experience if they are to be used 
accurately. LC3 is a mammalian homologue of yeast Atg8 and is a marker of 
autophagosomes. Frequent use of GFP (a green fluorescent protein that exhibits a green 
fluorescence when exposed to specfic wavelengths of light) fused LC3 to monitor 
incorporation of LC3 into autophagosomes, and thereby quantify autophagosome number and 
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by inference autophagy induction, is described in the literature (Mizushima et al., 2010). This 
method has been used most successfully to label autophagosomes in vivo in a number of 
organisms (Rusten et al., 2004, Melendez et al., 2003), including mammals (Mizushima et al., 
2004). However, up to now models to describe autophagy in the cancer context in vivo are 
conspicuously absent. 
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2 Research problem and aims 
 
2.1 Motivation  
 
Findings in previous studies (presented in chapter 1 to 4) showed that while amino acid 
deprivation caused increased cell death in cancer cells, it also protected non-cancer cells from 
cell death. In order to apply the concepts outlined in those studies in vivo, and investigate if 
the findings revealed there would translate in the context of a living organism, it was 
neccessary that a novel animal model be established. 
 
2.2 Research problem  
 
Cancers are heterogenous masses that rely on non-cancer tumour cells and host tissue stroma 
to survive and grow. Most cancer cells are thought to induce autophagy as a protective 
mechanism in response to stress. Therefore, if increased autophagy in non-cancer cells within 
a solid neoplasm results in protection of these cells during treatment then, hypothetically, this 
could ultimately facilitate long term tumour progression and invasion. However, models 
capable of describing these events in vivo are currently lacking. 
 
2.3 Aims  
 
1. Determine if E0771 murine mammary adenocarcinoma cells can form tumours in a 
transgenic mouse that systematically expresses GFP fused to LC3 in most tissues. 
2. Contingent to results obtained from aim 1, establish a protocol that details a method to 
reproducibly grow these tumours in vivo. 
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3. Establish a protocol and associated methods for excision and analysis of these tumours 
to determine if a GFP-LC3 signal derived from non-cancer cells is present within 
tumour tissue. 
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3 Methods, results and discussion 
 
Previous experimental data has shown that amino acid deprivation from the culture medium 
of non-cancer mammary epithelial cells (MCF12A) resulted in a relative protection of these 
cells from cytotoxicity associated with chemotherapy whereas cytotoxicity appeared to be 
enhanced in cancer cells (MDAMB231) receiving similar treatments (described in chapter 4). 
As solid tumours rely on non-cancer cells for survival, protection of non-cancer cells, within 
tumours, from cytotoxicity during short term starvation could indirectly result in prolonged 
tumour cell survival during chemotherapy. 
 
In this study a murine mammary adenocarcinoma cell line, originally isolated from an 
immunocompetent C57BL6 mouse, was utilized. This cell line is well established (Casey et 
al., 1951, Casey et al., 1952) and has a well characterized metastatic potential (Ewens et al., 
2006). Furthermore, increased recent use of these cells (Young et al., 2010, Hiratsuka et al., 
2011, McHowat et al., 2011, Sharma et al., 2008) and previous comparisons with 
MDAMB231 cells (Young et al., 2010, Li, 2009) made this cell line an attractive candidate 
for use in our model. E0771 cells are typically used in cell culture and in allografting mouse 
models in syngenic C57BL6 mice. However, these cells have also been used to establish 
mammary tumours in a transgenic knockout mouse model assessing calcium-independent 
phospholipase A2β deficiency during lung metastasis (McHowat et al., 2011). In order to 
establish a model where autophagy could be assessed in non-cancer cells within a tumour, 
transgenic mice systemically expressing GFP fused to LC3 (referred to as GFP-LC3 mice 
from here on) were used in conjunction with E0771 murine mammary adeoncarcinoma cells 
to generate tumours where the GFP signal could be related to autophagy status in the non-
cancer cell population within tumours. GFP-LC3 mice were originally generated with the 
intention of being used to assess autophagosomes in vivo (Mizushima et al., 2004), and this 
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elegantly designed model has been used successfully to analyse autophagy induction in vivo. 
Using these mice, autophagy is monitored as GFP-LC3 becomes incorporated into 
autophagosomes. Currently, methods used to quantify and monitor autophagy are limited, 
time consuming and require vast amounts of expertise (Mizushima et al., 2010). Moreover, 
methods to assess autophagy specifically in the in vivo cancer setting are absent and assessing 
intratumour, non-cancer cell populations in the context of autophagy do not exist to date. Our 
aim was to establish such a model using GFP-LC3 mice. However, chemical induction of 
cancers can be difficult to characterize and xenografts of cancer cell lines usually require the 
use of immune compromised animals (Medina, 2007). As GFP-LC3 mice are crossed with 
C57BL/6N Crj mice, it was unclear if E0771 cells could be used to successfully establish 
tumours in these animals. 
 
2.1 Sourcing and culture of E0771 mouse mammary cancer cells 
 
Experiments were performed using the murine metastatic mammary adenocarcinoma cell line 
E0771. This cell line was generously provided by Fengzhi Li (Roswell Park Cancer Institute, 
Buffalo, New York, USA). During routine maintenance, cells were grown as monolayers in 
Glutamax-DMEM (Celtic Molecular Diagnostics, Cape Town, South Africa) supplemented 
with 10% foetal bovine serum (Sigma Chemical Co., St Louis, MO, USA) at 37°C in a 
humidified atmosphere of 95% air plus 5% CO2 in T75 flasks (75cm
2 flasks, Greiner Bio 
One, Germany) until they reached 80% confluence. E0771 cells were then split 1:3. Splitting 
was accomplished by washing the cell monolayer with warm phosphate buffered saline (PBS) 
followed by incubation with 4 ml trypsin/EDTA (Sigma Chemical Co., St Louis, MO, USA) 
at 37°C, with occasional agitation, until cells loosened completely or for a maximum of four 
minutes. Experiments were performed using exponentially growing cells.  
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2.2 Tumour establishment and animal protocols 
 
The protocols in this study were carried out according to the guidelines for the care and use of 
laboratory animals implemented at Stellenbosch University. Eight week-old female C57BL6 
mice (Stellenbosch University animal facility) or GFP-LC3 mice (kindly donated by Noboru 
Mizushima, Department of Cell Biology, National Institute for Basic Biology, Okazaki, 
Japan) were used in this study. The mice were maintained on standard chow diet and tap 
water before beginning the experiment. Mice were inoculated subcutaneously on the left pad 
of the fourth mammary gland with 200 µl of 2.5x105 E0771 cells suspended in Hanks 
Balanced Salt Solution (Sigma Chemical Co., St Louis, MO, USA), using a 23-gauge needle 
(image 5.1). This protocol was adapted from Ewans et al. 2006. 
A. B.
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Tumour cell inoculum
0 12 33
Days
1st appearance of 
tumours
Tumours reach 
~200 mm2 in 
volume
14
 
 
 
Mice were injected with cell suspensions made up of E0771 cells on day 0 and small tumours 
were evident by days 12 to 14. Tumours grew to reach approximately 230 mm2 in volume by 
day 33.  
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Neoangiogenesis
Second left abdomino-
inguinal nipple
 
Established tumours displayed evidence of extensive neovascularisation (image 5.4). 
Furthermore, the second left abdomino-inguinal nipple was always obviously located on the 
tumour surface upon excision. 
2.3 E0771 cells are autophagy competent and show signs of increased 
autophagy flux during amino acid starvation 
 
E0771 cells were grown to reach 60% confluence before being incubated in culture medium 
free of amino acids (Highveld Biological, South Africa) and supplemented with 10% foetal 
bovine serum (Sigma Chemical Co., St Louis, MO, USA) for a period of 24 hours. Cells were 
then scraped in RIPA buffer (appendix) on ice before being centrifuged at 4°C and 8000 rpm 
for 10 minutes. Resulting supernatants then had their protein content determined immediately 
using the Bradford protein determination method (Bradford, 1976). Following protein 
quantification, aliquots diluted in Laemmli sample buffer were prepared for all samples, each 
containing 40 μg of protein. Electrophoresis (SDS-PAGE) using 12% gels was followed by 
western blotting using antibodies against LC3 (Cell Signalling, MA, USA) and beclin 1 (Cell 
Signalling, MA, USA). 
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A. B.
  
 
 
 
 
E0771 cells have high levels of LC3 under baseline culture conditions. Depletion of amino 
acids from growth medium results in decreased LC3 I levels and apparent increased 
conversion to LC3 II after 6 hours (Fig 5.1). E0771 cells also have detectable levels of beclin 
1. Together, these results indicate that E0771 cells are autophagy competent and are able to 
increase autophagy flux by increasing conversion of LC3 I to LC3 II during amino acid 
starvation in a pattern similar to MDAMB231 cells (chapter 2). 
 
2.3 E0771 tumours established using this protocol grow extremely 
reproducibly and lead to increased total mouse weight after 30 days 
 
Tumour size was monitored every two to three days by making measurements in two 
perpendicular dimensions parallel with the surface of the mice using digital calipers. The 
body weight of the mice was monitored twice weekly.  
Fig. 5.1 Change in protein levels of the autophagy markers LC3 and beclin 1in 
E0771cells during a 6 hour period of amino acid starvation. Bar graphs show 
densitometric representation of A) Bar graph of LC3 II/LC3 I depicting lipidation of 
LC3I and autophagy flux. B) Representative western blots showing changes in LC3 II 
protein levels at 6 hours of complete amino acid deprivation. hr = hours; AU = 
Arbitrary Units. Values are expressed as mean ± SEM. *, P < 0.05. 
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Tumours grown in GFP-LC3 mice using the protocol established in this study grow 
reproducibly. A pilot study showed that the gauge of the needle used to inject cell suspensions 
as well as the location of cell injection both influence reproducibility of tumour growth (data 
not shown). Data of tumour volumes from 24 mice demonstrated the small variance in tumour 
size at day 30 after the initial E0771 cell injection (Fig 5.2a). After day 30, the weight of 
tumour bearing animals was found to be greater than those without tumours (Fig 5.2b). This is 
presumed to be due to the increased tumour mass, as tumour bearing animals presented with 
less subcutaneous fat than those without tumours (data not shown). 
 
2.4 E0771 tumours from GFP-LC3 mice have significantly greater GFP 
signal than those from C57BL6 mice 
 
 
Tumours generated in GFP-LC3 mice and in C57BL6 mice are extremely dense (Fig 5.3a). 
Histological sections of the internal portions of these tumours show that cells are packed very 
close to one another, but still appear to have healthy nuclear features (Fig 5.3b). 
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A. B.
 
 
C57BL6
GFP-LC3
Hoechst GFP
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After treatment, excised tumours were immediately snap-frozen in tissue freezing medium 
(Leica Microsystems) in liquid nitrogen and then stored at -80°C. 8 µm thick sections of 
tumours were cut from the central fraction of the tumour mass using a rotary microtome 
(Leica Microsystems CM1850, Nussloch, Germany). 100 µl of Hoechst (Hoechst 33342, 
Sigma Chemical Co., St Louis, MO, USA) in a 1:200 dilution (50 µg/ml) in sterile PBS was 
added directly onto the tissue sections and left to incubate for 10 minutes at 4°C. Thereafter, 
sections were washed in 100 µl of PBS and viewed under an Olympus CellˆR fluorescence 1 
X 81 inverted microscope (Olympus Biosystems, Germany) using an F-view II  camera 
(Olympus Biosystems, Germany) for image acquisition and CellˆR software (Olympus 
Biosystems, Germany) for processing images. 
 
Sections of tumours excised from C57BL6 mice have significantly less visible GFP signal 
(Fig 5.4). As these mice do not possess GFP fused LC3, any green signal generated must be 
due to background autofluorescence. On the other hand, sections prepared from tumours from 
GFP-LC3 mice have pronounced GFP fluorescence (green). Some cells even display localized 
regions of green puncta under basal conditions (Fig 5.4). As E0771 cells do not possess GFP 
fused LC3, and tumours in C57Bl6 mice do not have much detectable GFP, any GFP signal 
must necessarily be derived from GFP-LC3 mice. This experiment serves as a qualitative 
illustration that autophagy competent mouse derived cells are present within E0771 tumours 
generated in this model. Furthermore, it is hypothesised that, during treatment, this LC3 
signal could be used to quantify autophagy levels of non-cancer cells present within the 
tumour mass and associated microenvironment. 
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2.5 Basal GFP signal in E0771 tumours is detectable using flow 
cytometry in this model and is lower in C57BL6 mice than in GFP-LC3 
mice 
 
A. B.
 
 
Whole excised tumours were finely minced using sharp nose scissors and immersed in a 
collagenase (10 mg/ml) (Sigma Chemical Co., St Louis, MO, USA)/trypsin-EDTA (Sigma 
Chemical Co., St Louis, MO, USA) mixture and incubated with agitation for 1 hour in the 
dark at 37°C. The resulting suspension was then centrifuged at 950 g for 3 minutes. The pellet 
was then resuspended in PBS (with vortexing) and then centrifuged at 500 g for 10 minutes. 
The resulting suspension was then passed through a tea sieve and then a 100 μm cell strainer 
before being washed in PBS and centrifuged at 500 g for 3 minutes. Samples were again 
resuspended in PBS before being filtered through a 50 µm nylon mesh into 12x75 mm tubes. 
Sample GFP fluorescence was acquired using flow cytometry (BD FACSAria I) where 
100 000 events were collected. 
 
Basal intratumour GFP signal is significantly lower in untreated C57BL6 mice than in GFP-
LC3 mice (Fig 5.5). This experiment serves to illustrate that the GFP signal is quantifiable 
using flow cytometry in our model and that this signal corresponds to qualitative evidence.  
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2.6 Protein deprivation results in a rapid autophagy response in vivo and 
a corresponding increase in intratumour GFP signal 
 
 
 
Standard mouse chow was replaced with an open source protein free diet (Research Diets, 
Inc., NJ, USA) at the start of their night cycle for a period of 6, 12, 18, 24, 48 or 72 hours. 
Control animals were placed on isocaloric diets that contained protein (Research Diets, Inc., 
Nj, USA). After treatment, excised whole right gastrocnemius muscles were immediately 
snap-frozen in liquid nitrogen and then stored at -80°C. These samples were then 
homogenized in RIPA buffer (appendix) on ice before being centrifuged at 4°C and 8000 rpm 
for 10 minutes. Resulting lysates then had their protein content determined immediately using 
the Bradford protein determination method (Bradford, 1976). Following protein 
quantification, aliquots diluted in Laemmli sample buffer were prepared for all samples, each 
containing 40 μg of protein. Electrophoresis (SDS-PAGE) using 12% gels was followed by 
western blotting using antibodies against LC3 (Cell Signalling, MA, USA) and beclin 1 (Cell 
Signalling, MA, USA). 
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Surprisingly, a prominent increase in LC3 levels in the gastrocnemius muscles of these mice 
was noted already at 6 hours of protein depletion (Fig 5.6). A corresponding increase in beclin 
1 levels was also seen after 6 hours. After 24 hours, an increase in conversion of LC3 I to 
LC3 II was evident, indicating an increased autophagy flux at this point. This increase in 
autophagy flux continued at 48 hours, but appeared diminished by 72 hours. Similar results 
were obtained from western blots of the hearts obtained from the same mice, prepared and 
analysed in the same manner (results not shown). This serves as a control to demonstrate that 
the protein free diet can rapidly increase LC3 accumulation in these mice. 
 
 
 
 
 
Flow cytometry is a rapid and well established technique for the quantitative measurement of 
fluorescence signals in cell populations. Flow cytometry and FACS can be used to monitor 
autophagy in cells containing GFP-LC3 by exploiting the fact that GFP is sensitive to acidic 
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environments, such as that of lysosomes (Martinet et al., 2006, Shvets et al., 2008). It is 
known that the GFP fluorescence disappears immediately on it entering the reduced pH 
environment of a lysosome. A reduction in GFP-LC3 therefore reflects delivery of this 
complex  into lysosomes and the degree of autophagy flux (Shvets et al., 2008), while an 
increase in GFP-LC3 would reflect increased expression of this complex due to an increase in 
autophagy induction. GFP-LC3 mice placed on a protein free diet for 24 hours displayed a 
pronounced and significant increase in GFP signal as quantified using flow cytometry (Fig 
5.7). This corresponds to the increase in LC3 levels seen in other tissues after 24 hours of 
protein starvation in this model. It is proposed here that this technique can be used to monitor 
and quantify autophagy in this model, and that when comparing treatment groups and the 
level of GFP fluorescence with flow cytometry a decrease in GFP signal would indicate an 
increase in autophagy flux. 
 
These experiments illustrate that GFP-LC3 mice placed on a diet free of proteins have a rapid 
and pronounced increase in the level of autophagy protein markers in vivo and display a 
quantifiable increase in intratumour autophagy after 24 hours. It is believed that this is a 
viable model for the study of the effects of short term protein starvation in vivo and could be 
utilized as a model to assess the effects of short term starvation on the non-cancer cell 
population within tumours induced through this model. Furthermore, this technique may serve 
as an assay to quantify autophagy in non-cancer cells within the tumour microenvironment in 
response to other treatment stimuli that may induce an autophagy response. 
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2.7 Protein deprivation results in an increase in intratumour caspase 
cleavage in GFP-LC3 E0771 tumour bearing mice 
 
A. B.
 
 
FLIVO™ (FLuorescence in vIVO) in vivo apoptosis tracers (Immunochemistry Technologies 
LLC, MN, USA) have been validated and used to assess caspase activity in various in vivo 
cancer models (Tsai et al., 2007). Upon encountering active caspases, FLIVO forms 
irreversible covalent bonds with reactive cysteines on the large subunit of the caspase 
heterodimers, thus further inhibiting enzymatic activity and labelling the location of active 
caspases. Unbound FLIVO™ probes are removed from the circulation of the animal in about 
1 hour. 100 µl of red SR FLIVO™ dye was prepared as per the manufacturer‟s protocol and 
injected i.v. into the tail vein of E0771 tumour bearing GFP-LC3 mice (Fig 5.8a) after 
appropriate treatments were completed. After 1 hour, whole tumours were excised and 
digested (described previously) and analysed using flow cytometry (BDFACSAria I). A 
significant increase in intratumour caspase activity was observed if GFP-LC3 mice were 
placed on a protein free diet for 24 hours (Fig 5.8b). 
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3 Closing remarks 
 
This successful establishment of a novel tumour model, and the validation of techniques 
associated with assessment of autophagy and apoptosis within the tumour microenvironment, 
allows future studies investigating stimuli or treatments that may induce an autophagy or 
apoptosis response. This study outlines the protocols and the corresponding procedures 
necessary for the induction of reproducible, autophagy competent solid tumours in GFP-LC3 
mice. Additionally, this model represents a unique opportunity for assessment of autophagy, 
during different treatment regimes or interventions, within the non-cancer cell population in 
solid tumours.  
 
It is believed that this is a viable model for the investigation of short term protein starvation 
during chemotherapy in vivo, and that this model could be utilized to assess the effects of 
short term starvation on the non-cancer cell population within tumours.  
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6  
 
Short term protein starvation results in increased tolerance 
to high dose chemotherapy but also increased autophagy 
flux and decreased apoptosis within tumours in vivo 
 
Short term starvation of patients receiving chemotherapy is a promising new 
strategy that has been demonstrated to differentially protect non-cancer 
cells during treatment. Previous experimental data has shown that while a 
non-cancer cell line experienced protection if starved of amino acids during 
doxorubicin treatment, a cancer cell line with high basal autophagy activity 
had increased cell death (chapter 4). A recently established model with the 
capacity to assess the impact of protein starvation on autophagy in the host 
derived stromal subpopulation within mammary tumours (chapter 5) is used 
in this study. Evidence in this chapter shows that protein deprivation of mice 
receiving a high cumulative dose of doxorubicin treatment increases 
survival, whereas intratumour caspase activity decreases. Increased 
intratumour autophagy flux in the non-cancer cell population of these 
tumours is implicated in this protection. 
 
1 Introduction 
 
Recent application of short term starvation protocols in patients receiving high doses of 
chemotherapy has showed remarkable success in reducing side effects (Safdie et al., 2009). 
Furthermore, in a cell culture and a neuroblastoma mouse xenograft model, it was shown that 
non-cancer cells placed on a similar starvation protocol benefited from differential protection 
compared to cancer cells during high dose chemotherapy regimens as well (Raffaghello et al., 
2008). Mice starved for 48 hours prior to chemotherapy in this study had reduced 
chemotoxicity following high dose treatment, whereas cancer cells and tumours did not 
benefit from a similar protection. In addition, many clinical trials are beginning to assess the 
effectiveness of compounds known to regulate autophagy, and a study using a low protein 
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diet to „reactivate‟ autophagy is set to begin phase II trials shortly (information from 
clinicaltrials.gov). 
 
Previous experimental data has shown that amino acid deprivation from the culture medium 
of non-cancer mammary epithelial cells (MCF12A) results in a relative protection of these 
cells from cytotoxicity associated with chemotherapy (described in chapter 4), while 
cytotoxicity appears to be enhanced in cancer cells (MDAMB231) receiving similar 
treatments. However, cancers are extremely heterogenous by nature and much of their volume 
can be comprised of non-cancer cells that are vital for their continued growth and 
development (Mueller and Fusenig, 2004). As solid tumours rely on non-cancer cells for 
survival, any protection of these cells from cytotoxicity during short term starvation could 
indirectly result in prolonged tumour cell survival during chemotherapy. Also, the benefits of 
fasting in cellular protection from cytotoxicity may rely partly on altered circulating hormone 
levels (Lee and Longo, 2011), which necessitates further investigation using in vivo models. 
In fact, reduced circulating IGF-I levels have been implicated in the differential protection of 
normal cells and cancer cells in response to fasting and improved chemotherapeutic index 
during doxorubicin treatment (Lee et al., 2010). 
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2 Study aims 
 
 
1. Use the previously developed tumour model (chapter 5) to assess survival in mice 
treated with a short regimen (3 days) of high dose of doxorubicin (10 mg/kg; 20 
mg/kg cumulative) treatment. 
2. Determine the effect of a short term exposure to a diet low in protein on survival in 
these animals. 
3. Use the previously developed model to assess caspase activity in the tumours in these 
mice. 
4. Use the previously developed model to assess autophagy in the non-cancer 
subpopulation in the tumours in these mice. 
5. Assess survival, caspase activity and autophagy in tumour bearing mice treated with a 
moderate dose of doxorubicin (5 mg/kg; 20 mg/kg cumulative) treatment. 
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3 Materials and methods 
 
 
The materials and methods describing the procedures utilized in this study are explained in 
detail in chapter 5 of this manuscript. 
 
3.1 Experimental procedure 
 
 
Tumour cell inoculum
0 12 33 35
Days
1st appearance of 
tumours
Intervention 1
Intervention 2
 
 
 
 
 
Further details describing deviations from and particulars of this experimental procedure are 
described in the results. 
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3.2 Drug preparation and administration 
 
Doxorubicin hydrochloride (D1515, Sigma Chemical Co., St Louis, MO, USA) and 
Rapamycin from Streptomyces hygroscopicus (R0395, Sigma Chemical Co., St Louis, MO, 
USA) were prepared immediately prior to the injection procedure. Both agents were dissolved 
in Hanks Balanced Salt Solution (Sigma Chemical Co., St Louis, MO, USA), and mixed on a 
shaker to ensure that they were completely dissolved. Volumes were prepared to reflect the 
exact concentration required per kilogram (kg) of body weight for each mouse on the day of 
injection. Mice were restrained by the scruff method and 100 µl drug suspensions were 
injected i.p. into the right caudal thigh (avoiding the femur and sciatic nerve) of each mouse 
using a 23-gauge needle. Control mice were injected with the vehicle only. 
 
3.3 Tumour measurement and animal weighing 
 
Tumour size was monitored every two to three days by making measurements in two 
perpendicular dimensions parallel with the surface of the mice using digital callipers. The 
body weight of the mice was monitored twice weekly.  
 
3.4 Statistical analysis 
 
All values are presented as the mean ± standard error of the mean (SEM). Differences 
between time points and treatment groups were analysed using one or two analysis of 
variance (ANOVA). Significant changes were further assessed by means of the Bonferroni 
post hoc analysis where appropriate. All statistical analyses were performed using Graphpad 
Prism version 5.01 (Graphpad Software, Inc, CA, USA). The minimum level of significance 
accepted was p < 0.05. 
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4 Results 
 
4.1 24 hour protein starvation during high dose doxorubicin (10 mg/kg) 
treatment results in increased survival of E0771 tumour bearing GFP-LC3 
mice  
 
 
 
GFP-LC3 mice with large tumours (>230 mm2) derived from E0771 mammary 
adenocarcinoma cells were placed on a diet free of proteins for 24 hours for two days, either 
side of a day on a standard chow diet. Mice with large tumours and placed on this diet were 
more likely to have died twelve days after the initial intervention (Fig 6.1a). Mice with similar 
tumours and administered doxorubicin at a high dose (10 mg/kg) on two days, either side of a 
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day without treatment had all died by day 12 after the initial treatment (Fig 6.1b). However, if 
tumour bearing mice were placed on a diet free of protein, immediately after i.p. injection 
with a high dose of doxorubicin (10 mg/kg), then the survival of these mice was prolonged 
compared to those fed a standard diet. Furthermore, protein starved doxorubicin treated mice 
showed less signs of reduced mobility and ruffled hair compared to mice treated with 
doxorubicin but fed isocaloric protein complete diets (data not shown). 
 
4.2 24 hour protein starvation during high dose doxorubicin (10 mg/kg) 
treatment does not influence changes in tumour volumes attributed to 
doxorubicin 
 
 
 
 
Growth rates of E0771 tumours in GFP-LC3 mice were very similar in size between groups, 
prior to the initial interventions (Fig 6.2). 
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A.
B.
 
 
Administration of two high dose doxorubicin (10 mg/kg) treatments over three days in GFP-
LC3 mice bearing large E0771 tumours (>230 mm2) resulted in significant reductions in 
tumour size by day eight after the first intervention (Fig 6.3a). If tumour bearing mice were 
placed on diets free of protein during doxorubicin treatment (10 mg/kg), reductions in tumour 
size were shown to be similar to those treated with doxorubicin but fed protein complete diets 
(Fig 6.3b). 
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4.3 24 hour protein starvation during high dose doxorubicin (10 mg/kg) 
treatment results in significantly lower caspase activity within tumours 
 
 
 
 
 
 
Administration of two high dose doxorubicin (10 mg/kg) treatments over three days in GFP-
LC3 mice bearing large E0771 induced tumours (>230 mm2) resulted in a significant increase 
in caspase activity within whole excised tumours, using a FLIVO™ (FLuorescence in vIVO) 
in vivo apoptosis tracer (Immunochemistry Technologies LLC, MN, USA) and FACS flow 
cytometry (Fig 6.4). However, if mice were placed on a protein free diet for 24 hours at the 
start of their night cycle, beginning immediately after each doxorubicin injection, then 
caspase activity was observed to be significantly lower in excised tumours than in those mice 
treated but fed on protein complete diets. 
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In order to ensure that any background autofluorescence signal generated as a consequence of 
doxorubicin injections did not interfere with measurements, GFP-LC3 mice (treated in the 
same way as those used for caspase activity analyses) were not injected with the FLIVO™ 
tracer dye and analysed using flow cytometry. Excised whole tumours from GFP-LC3 mice 
treated with doxorubicin (10 mg/kg) and placed on either a protein free diet or a protein 
complete diet were not found to generate any detectable autofluorescence in our model (Fig 
6.5). 
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4.4 24 hour protein starvation during high dose doxorubicin (10 mg/kg) 
treatment results in significantly increased intratumour autophagy flux in 
E0771 induced tumours in GFP-LC3 mice 
 
 
 
 
Flow cytometry and FACS can be used to monitor autophagy in cells containing GFP-LC3 by 
exploiting the fact that GFP is sensitive to acidic environments, such as that of lysosmes 
(Martinet et al., 2006, Shvets et al., 2008), and GFP fluorescence disappears immediately on it 
entering the reduced pH environment of a lysosome. A reduction in GFP signal therefore 
reflects delivery of the GFP-LC3 complex  into lysosomes and can be related to the degree of 
autophagy flux (Shvets et al., 2008). An increase in GFP signal indicates increased autophagy 
induction without high autophagy flux (chapter 5). Administration of two high dose 
doxorubicin (10 mg/kg) treatments over three days in GFP-LC3 mice bearing large E0771 
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induced tumours (>230 mm2) resulted in a significant increase in GFP signal. This is inferred 
to indicate an increased autophagy induction and translation of the GFP-LC3 complex (Fig 
6.6). However, if mice were placed on a protein free diet for 24 hours at the start of their night 
cycle, beginning immediately after each doxorubicin (10 mg/kg) injection, then a significant 
decrease in GFP signal indicates a significant increase in autophagy flux compared to mice 
treated but fed on protein complete diets. As only non-cancer cells contain the GFP-LC3 
complex (chapter 5), significantly increased intratumour autophagy flux implies that there is 
an increased autophagy flux in non-cancer stromal cells within the E0771 induced tumours of 
treated GFP-LC3 mice fed protein free diets compared to those fed protein complete diets. 
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4.5 24 hour protein starvation during moderate dose doxorubicin (5 
mg/kg) treatment prevents doxorubicin induced reductions in E0771 
tumour volumes in GFP-LC3 mice 
 
 
 
 
 
 
 
 
Administration of two treatment regimens one week apart of two moderate doses of 
doxorubicin (5 mg/kg) treatments over three days in GFP-LC3 mice bearing large E0771 
tumours (~200 mm2) resulted in significant reductions in tumour size by day 15 after the first 
intervention (Fig 6.7). Unlike in previous experiments, using higher doses of doxorubicin, no 
mice treated with these concentrations of doxorubicin (5 mg/kg) died during this treatment 
regime (data not shown).  If tumour bearing mice were placed on diets free of protein during 
doxorubicin (5 mg/kg) treatment, then reductions in tumour size observed in mice treated with 
doxorubicin but fed protein complete diets were abolished and tumour sizes were similar to 
those of untreated control mice (Fig 6.7). 
 
Stellenbosch University  http://scholar.sun.ac.za
266 
 
4.6 24 hour protein starvation during moderate dose doxorubicin (5 
mg/kg) treatment results in significantly lower caspase activity within 
tumours 
 
 
 
 
Administration of two treatment regimens one week apart of two moderate doses of 
doxorubicin (5 mg/kg) treatments over three days in GFP-LC3 mice bearing large E0771 
tumours (~200 mm2) resulted in a significant increase in caspase activity within whole 
excised tumours (Fig 6.8). However, if mice were placed on a protein free diet for 24 hours at 
the start of their night cycle, beginning immediately after each doxorubicin injection, then 
caspase activity was observed to be significantly lower in excised tumours than in those mice 
treated but fed on protein complete diets. 
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4.7 24 hour protein starvation during moderate dose doxorubicin (5 
mg/kg) treatment results in significantly increased intratumour autophagy 
flux in E0771 induced tumours in GFP-LC3 mice 
 
 
 
 
Administration of two treatment regimens one week apart of two moderate doses of 
doxorubicin (5 mg/kg) treatments over three days in GFP-LC3 mice bearing large E0771 
tumours (~200 mm2) resulted in a significant increase in GFP signal. This is inferred to 
indicate an increased autophagy induction and translation of the GFP-LC3 complex (Fig 6.9). 
However, if mice were placed on a protein free diet for 24 hours at the start of their night 
cycle, beginning immediately after each doxorubicin (5 mg/kg) injection, then a significant 
decrease in GFP signal indicates a significant increase in autophagy flux compared to mice 
treated but fed on protein complete diets. As only non-cancer cells contain the GFP-LC3 
complex (chapter 5), significantly increased intratumour autophagy flux implies that there is 
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an increased autophagy flux in non-cancer stromal cells within the E0771 induced tumours of 
treated GFP-LC3 mice fed protein free diets compared to those fed protein complete diets. 
However, the change in autophagy flux was noted to be smaller than is previous experiments 
using higher doses of doxorubicin. 
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4.8 Rapamycin (2 mg/kg) treatment during high dose doxorubicin (10 
mg/kg) treatment does not influence changes in tumour volumes attributed 
to doxorubicin 
 
A.
B.
 
 
 
GFP-LC3 mice bearing large E0771 tumours (>230 mm2) were administered two high dose 
doxorubicin (10 mg/kg) treatments over three days. If tumour bearing mice were injected with 
rapamycin (2 mg/kg) immediately prior to the first doxorubicin treatment (10 mg/kg), 
reductions in tumour size were shown to be similar to those treated with doxorubicin alone 
(Fig 6.3b). Rapamycin (2 mg/kg) alone had no influence on tumour volume (Fig 6.3a). 
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4.9 Rapamycin (2 mg/kg) treatment during high dose doxorubicin (10 
mg/kg) treatment results in increased survival of E0771 tumour bearing 
GFP-LC3 mice  
 
 
 
 
GFP-LC3 mice with large tumours (>230 mm2) derived from E0771 mammary 
adenocarcinoma cells were injected i.p. with rapamycin (2 mg/kg) on day 33 after the initial 
injection of E0771 cell suspension. Mice with large tumours and injected with rapamycin 
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were more likely to have died twelve days after the initial intervention (Fig 6.11a). Mice with 
similar tumours and administered doxorubicin at a high dose (10 mg/kg) on two days, either 
side of a day without treatment had all died by day 11 after the initial treatment (Fig 6.11b). 
However, if tumour bearing mice were injected with rapamycin (2 mg/kg), immediately after 
i.p. injection with a high dose of doxorubicin (10 mg/kg), then the survival of these mice was 
prolonged compared to those not receiving a rapamycin injection. 
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4 Discussion 
 
 
Although little data on the subject exists, it appears as though short term starvation prior to or 
during chemotherapy can result in a differential protection of normal and cancer cells to the 
cytoxic effects of some drugs. The remarkable success from the few cell culture, animal and 
human studies performed to date has been promising. If proven to be reproducible and safe, 
then this differential starvation therapy could be easily utilized to improve the quality of life 
and perhaps even prevent some of the more serious consequences and side effects in patients 
receiving conventional chemotherapy. No studies to date have investigated autophagy in the 
context of short term starvation therapy during anticancer treatment regimes. Previous 
experimental data (chapter 4) has demonstrated that a metastatic cancer cell line with high 
basal autophagy displays increased signs of apoptosis if cells are starved of amino acids 
during doxorubicin treatment. Furthermore, a non-tumourogenic cell line exposed to similar 
conditions and treatments displayed a relative protection to the cytotoxic effects of 
doxorubicin if simultaneously starved of amino acids. Increased autophagy levels were 
indirectly implicated in this increased tolerance to doxorubicin cytotoxicity (chapter 4). As 
cancers are heterogenous masses composed of metastatic as well as stromal cells that are vital 
for continued growth and survival of these neoplasms, protection of non-cancer cells or 
cancer cells within the tumour mass could potentially confer a survival advantage onto these 
treated cancers. Furthermore, few models exist for the analysis of autophagy in solid tumours 
during either cancer treatment or starvation interventions. 
 
As interest in modulation of autophagy during cancer treatment increases and novel strategies 
such as fasting therapy during high-dose cancer treatment are explored, it is imperative that 
studies are undertaken to understand the underlying mechanisms driving these beneficial 
observations before use in a clinical setting begins in earnest. 
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This chapter describes the first study to assess short term complete protein starvation during 
chemotherapy in a tumour model. Using a novel mammary tumour model (described in 
chapter 5), it was shown that high-dose doxorubicin treatment (10 mg/kg for a cumulative 
dose of 20 mg/kg over three days) resulted in low survival rates of rodents possessing large, 
aggressive tumours (Fig 6.1a). Remarkably, probability of survival was significantly 
improved if mice in this model were placed on protein free diets immediately after drug 
administration (Fig 6.1b). Although evidently extremely toxic to the tumour bearing mice in 
this model, the dose of doxorubicin used here was sufficient to significantly reduce tumour 
size after only 8 days. Crucially, these reductions in tumour sizes were not diminished in 
those mice starved of proteins during treatment (Fig 6.3a and Fig 6.3b). These results reflect 
previous findings from a cell culture based model (described in chapter 4). Although few 
similar studies exist, it has been proposed that changes in circulating hormone and glucose 
levels could be partly responsible for the differential protection of non-cancer cells from the 
cytotoxic impact of certain chemotherapy drugs in the in vivo setting. An aim of this study 
was to assess the role of autophagy in this apparent protection, a mechanistic aspect not yet 
explored in the literature, in this context. 
 
As protection of the non-cancer subpopulation within these tumours is an important concern, 
a novel in vivo model exploiting the design of a mouse with a systematic expression of GFP 
fused to LC3 was designed (described in chapter 5). Using this model, it was found that 
although tumour size did not appear to be influenced by protein starvation therapy during 
doxorubicin treatment, whole tumours displayed decreased caspase activity (Fig 6.4). This 
decreased caspase activity was correlated with a significant increase in autophagy flux in the 
non-cancer subpopulation of these tumours during the combined treatment regime (Fig 6.6). 
Previous experimental data has described a phenomenon and an associated mechanism 
whereby increased autophagy flux can contribute to the tolerance of doxorubicin (described in 
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chapter 1, chapter 2, chapter 3 and chapter 4). This data represents a caveat to researchers 
aiming to utilize fasting or starvation diets in combination with conventional chemotherapy, 
and illustrates that additional mechanistic data is required in order to better understand the 
indirect consequences of such treatment strategies. 
 
In order to further investigate these processes, tumour bearing mice were administered 
smaller single doses (5 mg/kg), but an equivalent cumulative dose (20 mg/kg), over a more 
prolonged treatment period (16 days). This treatment schedule was better tolerated by the 
treatment animals, and no pattern of decreased survival due to treatment was noted (data not 
shown). Importantly, although tumours in animals treated with doxorubicin displayed 
significant decreases in overall volume, mice starved of protein for 24 hours after doxorubicin 
injection did not experience similar reductions in tumour size. As in the tumours of mice 
treated with higher doses of doxorubicin (10 mg/kg), tumours from mice starved of protein 
during drug treatment displayed decreased caspase activity. Furthermore, significant increases 
in autophagy flux in the non-cancer population of these tumours were noted. It is proposed 
here that increased autophagy flux in this subpopulation of these tumours is protective and 
increases tolerance to lower doses of doxorubicin. Although this represents a promising 
avenue for differential protection from the well-documented off target consequences of 
doxorubicin treatment, caution must be taken as indirect protection of the neoplastic system 
could occur.  
 
To further assess the possible role of autophagy in protection during doxorubicin treatment, 
tumour bearing mice treated with doxorubicin (10 mg/kg) were simultaneously injected with 
the well described autophagy inducer rapamycin (2 mg/kg). Although, rapamycin did not 
influence tumour growth patterns, either in association with drug treatment or when 
administered alone (Fig 6.10), a significantly increased probability of survival during 
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doxorubicin treatment was noted (Fig 6.11). Together with previous experimental data, these 
promising findings imply a role for autophagy in the differential protection during 
doxorubicin treatment, and require further investigation. 
 
4.1 Conclusions 
  
This is the first study to assess the role of autophagy in the non-cancer cell population within 
a solid mammary tumour mass during chemotherapy. Cell culture based studies (chapter 4) 
demonstrated a promising differential protection of non-cancer cells and increased signs of 
apoptosis in cancer cells during chemotherapy when these cell lines were starved of amino 
acids. However, translation of this model in vivo has shown that although protein deprivation 
appears to increase survival rates without impacting on reductions in tumour volumes during 
high dose doxorubicin treatment, a potentially increased protection may be occurring in cells 
within these tumours. The model established here, and the related findings, have presented a 
novel and unique platform for further research into this remarkable phenomenon, and 
particularly the role of autophagy therein. 
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7  
 
Synthesis 
 
 
Novel research investigating approaches aimed specifically at targeting characteristics 
common to a broad range of malignancies are becoming increasingly necessary. However, the 
safety and effectiveness of many emerging therapeutic strategies remains poorly understood. 
Many neoplasms appear to have the ability to circumvent the deleterious consequences of a 
chaotic blood supply (due to abnormal vascularisation) and the resulting transient episodes of 
nutrient limitation. Understanding how cancer cells are able to avoid and tolerate the effects 
of a short term cessation of nutrient supply could prove vital if future anticancer strategies are 
to be successfully developed based on this premise. Indeed, current research has already 
begun to investigate these avenues, and the recent employment of controlled amino acid 
starvation of cancer patients has exposed a potentially feasible and reproducible therapeutic 
approach. In a series of studies, this manuscript presents an investigation into the ability of a 
commonly used cancer cell line (MDAMB231), in comparison to a non-tumourogenic control 
line (MCF12A), to tolerate a short term bout of amino acid restriction. Using this model, 
additional experiments were designed to provide mechanistic insight into these initial 
findings. Thereafter, using this knowledge, studies were undertaken in an attempt to exploit 
the novel anticancer potential of using amino acid starvation in conjunction with 
chemotherapy in vitro. A new and innovative cancer model was then developed to expand 
these findings into the in vivo setting. 
 
Initial experiments (presented in chapter 1) established that a fast growing, metastatic cancer 
cell line (MDAMB231) was more sensitive to a dearth of amino acids than a non-
tumourogenic line (MCF12A). It was shown that a short term deprivation of amino acids 
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resulted in increased cell death and a proliferation arrest in these cells. Most cells are known 
to possess proficient intracellular mechanisms that are able to maintain amino acid levels 
during times of starvation. The autophagosomal-lysosomal pathway is predominant among 
these and MDAMB231 cells are known to have high basal levels of autophagy, even in 
nutrient rich conditions. Recently published findings have revealed that human cancers with 
mutations in H-ras or K-ras may require autophagy for tumour survival and for sustained 
growth. Although, these mutations are not common in breast cancer, genetic modifications in 
regions coding for proteins elsewhere in the RAS pathway results in high RAS activation in a 
large percentage of  breast malignancies. As the MDAMB231 breast cancer cell line is a 
known K-ras mutant, it was speculated that autophagy is crucial for this tolerance to acute 
amino starvation. Experimental evidence (chapter 2) demonstrated that autophagy inhibition 
resulted in decreased cell survival and reduced proliferation levels during acute amino acid 
starvation in the MDAMB231 cell line. After a few hours without exposure to amino acids 
protection was lost and intracellular cell death programs initiated. Surprisingly, the slower 
growing, non-cancer cell line was more tolerant to these short term alterations in amino acid 
levels.  
 
Autophagy has been frequently implicated as a potential survival mechanism in cancerous 
tumours, based on the premise that the degradation products released following autophagy-
mediated breakdown of cytoplasmic materials can be utilized for protein synthesis or as 
substrates for ATP production. Unfortunately, there is little direct evidence to support this 
hypothesis in cancer cells. Based on evidence from previous experiments, the subsequent 
study (chapter 3) attempted to provide a rare insight into the autophagy-mediated changes in 
amino acid levels that occur during a short term starvation event and supply some 
mechanistic support to explain the finding that autophagy protects MDAMB231 and 
MCF12A cells during amino acid starvation. Unlike most existing studies into this 
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phenomenon, the model design used here allowed for the delineation of the impact of amino 
acid starvation alone (a known trigger for increased autophagy) while all other nutrients 
remained constant. It was successfully demonstrated, by inhibiting autophagy 
pharmacologically (bafilomycin A1) or biologically (ATG5 siRNA), that autophagy is a vital 
process for tolerance to amino acid deprivation. Interestingly, it was shown that both cell 
lines utilized in these studies exhibited a short lived autophagy-mediated surge in amino acid 
levels. While amino acid levels quickly decreased in the MDAMB231 cells thereafter, 
presumably due to the high metabolic and biosynthesis needs of these cells, they remained 
elevated in the slower growing MCF12A cells. As autophagy inhibition blunted this 
protective response, it was inferred that generation of amino acids by autophagy is a vital 
mechanism during adaptive tolerance to short term amino acid starvation. The discovery of 
an analogous elevation in free fatty acid levels during similar conditions (which could be 
blunted by autophagy inhibition) strengthened the hypothesis that increased autophagy 
results in the increased intracellular availability of basic protein and organelle constituents 
for reuse elsewhere in the cell. In an attempt to understand how these basic cellular building 
blocks were being utilized by the cell, changes in ATP levels were examined during 
starvation in the presence or absence of autophagy inhibition. Surprisingly, autophagy 
related processes were implicated in the maintenance of ATP levels within these cell lines 
during amino acid starvation. MDAMB231 cells were revealed to be particularly reliant on 
the ATP homeostasis conferred by increased autophagy, during the first hours of amino acid 
deprivation. Together, these three studies demonstrate how a cancer cell line that depends on 
autophagy for survival is able to avoid cell death during short term starvation by generating 
basic cellular building blocks and utilizing them for cellular processes such as ATP 
maintenance.  
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Many clinical trials are beginning to assess the effectiveness of compounds known to 
regulate autophagy in patients receiving anticancer therapy, and short term starvation has 
shown promise in alleviating some of the symptoms associated with chemotherapy in some 
studies. Previous results demonstrated that complete amino acid deprivation elicited specific 
and dynamic alterations to acidic compartmentalization in MDAMB231 cells. Using this 
data as a platform, the next study was designed to establish if lysosomal acidity levels, 
associated with amino acid starvation in these cells, correlated with cell survival during 
doxorubicin treatment (chapter 4). Interestingly, a sustained elevation of autophagy (and 
lysosomal acidity) in MCF12A cells during similar treatment was associated with a relative 
protection from cell death during doxorubicin treatment as well. 
 
 Much of the solid tumour is typically made up of a variety of cell subpopulations that are 
required for continued growth and invasion. As these heterogeneous neoplasms are 
comprised of cancer and stromal elements, it is therefore essential that in vitro studies are 
translated in vivo. The next study was successful in establishing a novel mammary tumour 
model in a GFP-LC3 transgenic mouse (chapter 5). A reproducible method to study 
autophagy in the non-cancer subpopulation of tumours was established, for the first time. 
 
As data showed that a non-cancer cell line experienced protection if starved of amino acids 
during doxorubicin treatment, but a cancer cell line with high basal autophagy activity had 
increased cell death, the final study reproduced here was undertaken in order to establish if 
tumours are protected or display decreased survival if mice are starved of proteins during 
doxorubicin treatment. Evidence in this chapter shows that while protein deprivation of mice 
receiving a high cumulative dose doxorubicin treatment increases survival it also decreases 
intratumour caspase activity. Increased intratumour autophagy flux in the non-cancer cell 
population of these tumours was implicated in this protection. 
Stellenbosch University  http://scholar.sun.ac.za
281 
 
Appendix 
 
Chapter one 
 
 
Caspase-Glo® 3/7 assay 
(MCF7/MDA-MB-231/MCF12-A cells in a 96-well format) 
 
Preparation of working reagent solution and storage: 
1. Mix the Caspase-Glo® 3/7 buffer reagent gently and allow to equilibrate at room 
temperature. 
2. Transfer the lyophilized substrate to the buffer and mix by swirling 
3. Store at -20°C. (Note that reconstituted reagent that is freeze thawed will display 
diminished signal over time – approximately 60% compared to freshly prepared reagent after 
4 weeks according to the manufacturer. However, little reduction in signal intensity was 
noticed over longer time periods of freeze thawing in our experiments.) 
 
Assay protocol: 
1. Allow the working buffer reagent to equilibrate at room temperature for at least 30 minutes. 
2. Remove plates containing cells from 37°C growing conditions to allow them to equilibrate 
at room temperature. (At least 10 minutes). 
3. Transfer 50 µl (1:1) of working reagent to each well containing cells. 
4. Mix plates on a shaker for 30 seconds. 
5. Incubate plates in the dark for 1 hour at constant room temperature. (Can incubate for up to 
3 hours). 
6. Measure the luminescence in a luminometer. 
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Cell cycle analysis (CycleTEST™ PLUS DNA Reagent Kit) 
(MCF7/MDA-MB-231/MCF12-A cells in a T25 flask format) 
 
1.  Add 3 ml Trypsin/EDTA (0.25%) to each flask and place on the cell shaker for 5 
minutes or until the cells have detached from the surface of the flask. 
2. Add 6 ml of appropriate culture medium to each flask. 
3. Transfer each resulting cell suspension to a separate, sterile 15 ml falcon tube.  
4. Centrifuge at 400 x g for 5 minutes at room temperature. 
5. Carefully decant all the supernatant, and tap off the last drop onto a tissue. 
6. Wash the pellet with sterile room temperature PBS. 
7. Centrifuge at 400 x g for 5 minutes at room temperature. 
8. Add 250 µl of trypsin buffer (Solution A) to each tube and mix by tapping. (Do not 
vortex). 
9. Allow solution A to react for 10 minutes at room temperature. 
10. Do not remove solution A. 
11. Add 200 µl of trypsin inhibitor and RNase buffer was added to each tube and mix 
gently by hand tapping. (Do not vortex). 
12. Incubate for 10 minutes at room temperature. 
13. Add 200 µl of ice cold propidium iodide stain solution was added to each tube and 
incubated on ice in the dark for a further 10 minutes. 
14. Filter samples through a 50 µm nylon mesh into 12x75 mm tubes. 
15. Analyse using flow cytometry 
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MTT activity assay 
(MCF7/MDA-MB-231/MCF12-A cells in 96-well plate format) 
 
 
1.  Prepare a 1% MTT working solution in PBS (0.01 g MTT/ml PBS).  
2.  Remove culture medium from cells. (Do not rinse cells with PBS).  
3.  Add 150 µl of warm PBS and then 50 µl of MTT working solution to each well containing 
the cell monolayer.  
4.  Incubate at 37ºC for two hours.  
5.  In the meantime, mix together a working stock of solution A and solution B in a 50:1 ratio. 
50 ml should be sufficient  
6.  Remove cells from the incubator and examine under the microscope. The solution is light 
sensitive so do not expose for too long  
7. Discard the supernatant and add 200 µl of the solution A/solution B mixture  
8.  Protect cells from light by covering with foil and shake vigorously for 5 minutes 
9.  Read the absorbance of the supernatant using a platereader (wavelength of 540  
nm). Use the solution A/solution B mixture as a blank.  
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RIPA buffer 
100 ml RIPA buffer (final concentration in bold) 
 
Add the reagents in the following order. Protect the solution from light and prepare while 
stirring on ice. 
1. Tris-HCl pH 7.4 (790 mg Tris + 900 mg NaCl) (50 mM) 
2. 10 ml of 10% NP-40 
3. 2.5 ml Na-deoxycholate (0.25%) 
4. 1 ml of 100 mM EDTA pH 7.4 (1 mM) 
5. 100 µl of 1 mg/ml Leupeptin (1 µg/ml) 
6. 80 µl of 5 mg/ml SBT1 (4 µg/ml) 
7. 100 µl of 1M Benzamadine (1 mM) 
8. 500 µl of 200 mM NaF (1 mM) Toxic! 
9. 500 ul of 200 mM Na3VO4 (1 mM) 
10. Mix briefly. 
11. Allow to incubate until the cells are ready to treat and assay. 
12. Add 1 ml of Triton X-100. Viscous! 
13. Aliquot into practical amounts to avoid freeze thawing 
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Bradford Assay 
 
 
 
1. Thaw 1 mg/ml BSA stock solution 
2. Thaw protein samples if in -80°C freezer. Keep on ice at all times 
3. Make up a working solution of 100 μl BSA:400μl dH2O. Vortex mixture 
4. Mark 7 Eppendorf tubes for the standards as well as tubes for the samples to be tested 
5. Now add BSA and water to marked Eppendorf tubes as followed: 
  
6. Vortex all the tubes for a moment 
7. Now add 900μl of Bradford reagent to each Eppendorf tube. Vortex again 
8. Let the solutions stand for ~5min (switch on the spectrophotometer in the meantime) 
9. Read absorbencies, twice each, at 595nm 
a. If sample values fall outside the range of the highest standard then dilute with 
RIPA buffer. 
10. Make use of excel to make a linear plot of absorbencies and then calculate the amount 
of each sample to be added to aliquots. 
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Sample preparation (Western blot-SDS-PAGE) 
 
 
1. Set heating block to 99°C 
a. Remember to keep protein samples on ice at this point 
2. Make up a stock solution containing 850 μl of sample buffer and 150 μl of 
mercaptoethanol 
3. Vortex the solution 
4. Calculate the number of sample sets needed, each containing one representative of 
each protein sample 
5. Add sample buffer to each aliquot. Do so under the fume hood 
6. Add a volume of sample buffer equal to 1/3 of the final volume 
7. Now add the amount of sample calculated previously to each respective Eppendorf 
tube 
8. Punch small pin size holes in each tube then place in boiling water to stand for a 
period of 5min. 
9. Spin tubes for a moment (~5sec) using the tabletop centrifuge 
10. Samples can now be stored at -80°C 
 
 
In the case that samples have been stored in the -80°C freezer: 
 
1. Start by bringing a beaker of water to the boil 
2. Remove samples from the freezer 
3. Make sure that small pin size holes have been punched in the top of each tube 
4. Place in boiling water for a period of 5min 
5. Spin down momentarily (20sec) on the tabletop centrifuge (take care not to over 
centrifuge, especially if samples have been obtained from tissue) 
6. Samples can now be used 
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SDS-PAGE -Western blotting 
 
 
1. Clean pairs of large and small glass plates with methanol and a paper towel.  
2. Place the small glass plate onto the large plate and slide these into the green assembly. 
3. Tighten the assembly by pushing the green clips outward. 
4. Place the assembly onto the rubber base, pushing down gently. 
5. Prepare two small beakers, two Pasteur pipettes and a small stirring bar. 
6. Fill one beaker with H2O and prepare isobutanol. 
7. Gel recipe for 10% 0.75mm gels: 
 
  2 gels: 4 gels: 
  μl μl 
dH2O 3850 7700 
1.5M Tris-HCl pH 8.8 2500 5000 
10% SDS (stock) 100 200 
10% APS (0.1g/ml) 20 40 
Acrylamide 40% 2500 5000 
Temed 5 10 
  
8. Mix the solution momentarily. 
9. Quickly pour the mixture between the glass plates using a Pasteur pipette leaving 
enough space for the stacking gel. 
10. Add a layer of isobutanol using a fresh Pasteur pipette. 
11. Allow to set for 45 minutes - 1 hour. 
12. In the meantime prepare running buffer in a 1:10 dilution. 
13. After 30- 45 minutes has passed begin to prepare the stacking gel (4% recipe): 
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  2 gels: 4 gels: 
  μl μl 
dH2O 3050 6100 
0.5M Tris-HCl pH 6.8 1250 2500 
10% SDS (stock) 50 100 
10% APS (0.1g/ml) 50 100 
Acrylamide 40% 500 1000 
Temed 10 10 
 
14. Once the gels are set (after ~1 hour), wash off the isobutanol and ensure the plates are 
dry. 
15. Add Temed to the stacking solution, mix quickly and add stack between the plates. 
16. Gently push combs (of the correct width) into the stacking gel. 
17. Allow to set for 30 minutes. 
18. Switch on the heating block (set to a temperature of 95°C). 
19. Retrieve prepared samples from the -80°C freezer and allow them to thaw (on ice). 
20. Ready the electrophoresis apparatus for use. 
21. Once thawed, vortex each sample briefly before denaturing on the heating block for 5 
minutes. 
22. In the mean time, carefully remove the combs from the gels and wash gently with 
dH20 being careful not to damage the wells. 
23. Vortex each sample briefly before centrifuging rapidly for a few seconds. 
24.  Take the gel plates out of the assembly stand and place them into the U-shaped 
adaptor cassette. The small plates must be facing inwards.  
25. Place the U-shaped adaptor into the loading system and push the latches closed, away 
from your body.  
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26. Carefully pour running buffer into the middle compartment between the gel plates, 
allowing the buffer to flow over into the wells. 
27. Add 10 μl of molecular weight marker into the first well on the left of each gel. 
28. Add your samples into each well using a micropipette and loading tips. Use a clean tip 
for every sample. 
29. Place the system into the outer running chamber, and add running buffer until ~1 cm 
below the wells. 
30. Place the green lid with electrical leads onto the cell system, making sure to attach the 
electrodes correctly (red to red and black to black). 
31. Perform an initial ten minute run at 100 V (constant) and 400 mA. 
32. Thereafter, perform a longer run (usually ~50 minutes) at 200 V (constant) 
33. Turn off the power and disconnect the electrodes before removing the gel plates from 
the system.  
34. Place the gel in transfer buffer two for at least 15 minutes. 
35. Electrotransfer can now be performed using the semi-dry apparatus (Bio-Rad). 
36. Cut two chromatography filter papers and one 0.2 micron PVDF membrane per gel. 
37. Soak filter papers in transfer buffer. 
38. Soak one PVDF membrane in methanol for 15 seconds and then rinse with water 
before leaving to soak in transfer buffer.  
39. Place one filter paper onto the semi-dry apparatus. 
40. Carefully place PVDF membranes onto lower filter paper. Role with a wet tube to 
remove any bubbles that may have formed. 
41. Place gels onto the membranes. Role with a wet tube to remove any bubbles. 
42. Place filter paper onto gel to complete the membrane sandwich. 
43. Close the system and run at limit 0.5 A and 15 V for ~1 hour. 
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44. Wash the membranes three times for 5 minutes in copious amounts of previously 
prepared TBS-Tween (allow foam to develop by vigorous mixing). 
45. Block the membranes in suitable blocking reagent. 
46. Prepare the primary antibody as per manufactures instructions (usually 5 μl in 5 ml 
TBS-T). 
47. Mix at 4°C overnight. 
48. Wash membranes in TBS-T with agitation. Three times for five minutes each is 
sufficient. 
49. Place the membranes in the HRP-conjugated secondary antibody (1.25 μl in 5ml 
 TBS-T). Incubate with agitation for one hour at room temperature. 
50. Exposure requires an enhanced chemi-luminescent reagent (e.g. ECL/ECL+ detection 
kit (Amersham biosciences) or LumiGLO Reserve™ CL substrate kit (KPL, Inc., 
USA).). 
51. Add 500 μl of each of the ECL cocktails provided in a ratio corresponding to the 
manufacturer‟s instructions. (Usually 1:1.) Cover a falcon tube with foiland mix for a 
few seconds. 
52. Cover the area of the membrane known to have the bands that you are looking for and 
leave to incubate for ~one minute. 
53. Expose membranes to x-ray film in a dark room. 
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Chapter two 
 
Reverse transfection protocol 
(siRNA into MCF7/MDA-MB-231/MCF12-A cells in a 60 mm
2
 petri format) 
 
For each petri dish to be transfected, prepare RNAi duplex-Lipofectamine RNAiMAX 
complexes in the following way: 
1. Prepare mastermix by diluting 20 pmol of duplex into 250 ul of transfection medium 
(medium containing no antibiotics or serum). 
2. Mix lipofectamine RNAiMAX gently and add 2 ul per 250 ul of mix. 
3. Resuspend and add 250 ul to each petri dish. 
4. Allow to incubate for 20 minutes. 
5. Split and dilute cells in growth medium (must contain no antibiotics) to have a final volume 
of 2 ml in each petri. 
6. Add 1.5 ml of diluted cell suspension to each well containing the RNAi duplex-
Lipofectamine RNAiMAX complexes. 
7. Mix gently 
8. Allow to incubate until cells are ready to treat (24-48 hours later). 
 
488 nm laser and 610LP, 616/23BP emission filters. 
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Lysotracker™ (Flow cytometry) 
(MCF7/MDA-MB-231/MCF12-A cells in a T25 flask format) 
 
1. Following completion of the treatment protocol, remove culture media and wash cells 
in 5 ml PBS. 
2. Add 3 ml Trypsin/EDTA (0.25%) to each flask and place on the cell shaker for 5 
minutes or until the cells have detached from the surface of the flask. 
3. Add 6 ml of appropriate culture medium to each flask. 
4. Transfer each resulting cell suspension to a separate, sterile 15 ml falcon tube.  
5. Centrifuge at 6000xg for 3 minutes.  
6. Pour off the media-trypsin.  
Preparation of Samples for Analysis 
7. Re-suspend each cell pellet in 0.5 ml LysoTracker™ red (Invitrogen/Molecular 
Probes) working solution (final concentration of 100 nmol/L). 
8. Incubate the suspension for 15 minutes at 37ºC 
9. Gently re-suspend cell suspension 10x directly before filtering through  into  FACS 
tube 
10. Analyse on the flow cytometer (BD FACSAria I) immediately  
11. Collect a minimum of 10000 events using 488 nm laser and 610LP, 616/23BP 
emission filters. 
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Hoescht and Lysotracker™ (Cell imaging) 
(MCF7/MDA-MB-231/MCF12-A cells in a 60 mm
2
 petri dish format) 
 
1. Prepare a warm solution of PBS/LysoTracker™ red (Invitrogen/Molecular Probes) 
working solution (final concentration of 100 nmol/L). 
2. Remove this solution from the cells and wash twice with sterile 0.1M PBS. 
3. Add cold fixative (1:1 methanol/acetone) and incubate for 10 minutes at 4°C. 
4. Remove fixative using a micropipette and leave to air dry for approximately 20 
minutes 
 Prepare a 1:200 Hoechst solution and centrifuge momentarily before use. 
5. Rinse the cell monolayer 3 times with sterile PBS. 
6. Add enough Hoechst dye (1:200) to cover the cell monolayer completely (100 µl) and 
then incubate for a further 10 minutes. 
7. Wash the cell monolayer 5 times. 
8. Cells can now be stored at -20°C for ~2 weeks. Wrap in foil to avoid exposure to UV 
radiation. 
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Chapter three 
 
Lowry protein determination 
(MDA-MB-231/MCF12-A cells in 60mm2 petri dishes) 
 
1. Prepare the working standards (albumin (0.5 g/10 ml) in 0.5 M NaOH):  
1:400 (0.5 ml 200 ml), 1:100 (1 ml 100 ml) and 1:200 (0.5 ml 100 ml) 
2. Prepare a cold NaK-Tartrate-CuSO4 solution: (49 ml 2% Na2CO3, 0.5 ml 1% 
CuSO4.5H2O and 0.5 ml 2% NaK-Tartrate). 
3. Add 1 ml of cold NaK-Tartrate-CuSO4 to the following groups in 10 second intervals:  
• 1x 50 µl 0.5 M NaOH as blank  
• 3x 50 µl working standard 1, 2 and 3  
• 2x sample lysate  
4. After 10 minutes add 100 µl cold 1:3 Folin Ciocult:dH2O solution to each sample in 
15 second intervals. 
5.  After 30 minutes the absorbencies were measured on a spectrophotometer at 750 nm.    
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ATP analysis (ENLITEN® ATP assay system) 
(MCF7/MDA-MB-231/MCF12-A cells in 60 mm2 petri dishes) 
 
Preparation of working reagent solution and storage: 
1. It is important to use clean glassware and equipment that are free of trace amounts of ATP. 
(e.g. don‟t touch the outside of gloves with skin). 
2. Transfer the rL/L lyophilized substrate to the reconstitution buffer and mix by swirling. 
(Don‟t shake the bottle.) 
3. Store in single use aliquots at -20°C. (Note that reconstituted reagent that is freeze thawed 
will display diminished signal over time – approximately 50% compared to freshly prepared 
reagent after 2 weeks according to the manufacturer.) 
 
ATP extraction: 
1. Allow the working buffer reagent to equilibrate at room temperature for at least 60 minutes. 
(Stable at room temperature for 8 hours.) 
2. Remove plates containing cells from 37°C growing conditions to allow them to equilibrate 
at room temperature. (At least 10 minutes). 
3. Detach cells using trypsin and then centrifuge at 4°C. 
4. Wash pellets in PBS. 
5. Centrifuge the cell suspension at 4°C to pellet. 
 
Assay protocol: 
1. Prepare standard solutions by performing a 10x serial dilution of the ATP standard (1x10-7 
M) assay buffer in lysis buffer(100 mM Tris-HCl and 4 mM EDTA, pH 7.75). (Four such 
dilutions will dilute the standard to 1x10-11 M – the lowest standard will have a final 
concentration of 1x10-16 mol/100 µl). 
2. Resuspsend the cell pellet in 50 µl of ice-cold lysis buffer and transfer to 1.5 ml tubes. 
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2. Add 150 µl of boiling lysis buffer to each sample. 
3. Incubate samples for 2 minutes at 99°C. 
4. Centrifuge the lysates at 10 000 rpm at 4°C for 1 minute. 
5. Transfer 50 µl of the supernatant of working reagent and sample (or blank assay buffer) to 
a luminometer plate (1:1). 
6. Measure the luminescence in a luminometer. (Delay period = 2 sec. Integrate period = 10 
sec. Replicates = 1) 
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Preparation for amino acid quantification by means of a mass spectroscopy 
based proteomics method 
(MCF7/MDA-MB-231/MCF12-A cells in a 60 mm
2
 petri format) 
 
1. Seed cells in 60 mm petri dishes and treat once they have reached 75% confluence. 
2. Scrape cells in 400 µl of saline (0.9mM Sodium Chloride) and transfer to previously 
labelled tubes. 
3. Sonicate samples for 10 seconds. 
4. Transfer 5 µl of each sample to a separate tube. (This will be used for protein 
quantification.) 
5. Following sonication, transfer each sample to a tube-centrifugal filter unit (AMICON 
ULTRA 0.5ML 10K; Millipore; UFC501024). 
6. Centrifuge the tubes for 10 minutes @ 1400 rpm. 
7. Retain the filtrate for the amino acid quantification process. 
Waters API Quattro Micro. Mass Spec (Capillary voltage: 3.5 kV, Cone voltage: 1 V, Source: 
100ºC, Desolvation Temp: 350ºC, Desolvation gas:  350 L/h, Cone gas: 50 L/h) 
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